References
1.
Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the
early management of patients with acute myocardial infarction: a
report of the American College of Cardiology/American Heart Association
Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular
Procedures (Subcommittee to Develop Guidelines for the Early Management
of Patients with Acute Myocardial Infarction) J Am Coll Cardiol
1990;16:249-92.
2.
Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the
management of patients with acute myocardial infarction: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
3.
Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines
for the management of patients with acute myocardial infarction:
a report of the American College of Cardiology/ American Heart Association
Task Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
4.
Braunwald E, Antman E, Beasley J, et al. ACC/AHA 2002 guideline
update for the management of patients with unstable angina and non–ST-segment
elevation myocardial infarction: summary article: a report of the
American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on the Management of Patients
With Unstable Angina). J Am Coll Cardiol 2002;40:1366.
5. Mehta RH, Montoye CK, Gallogly M, et al, for
the GAP Steering Committee of the American College of Cardiology.
Improving quality of care for acute myocardial infarction: the Guidelines
Applied in Practice (GAP) initiative. JAMA 2002;287:1269-76.
6.
Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered
to medicare beneficiaries, 1998-1999 to 2000-2001. JAMA 2003;289:305-12.
7.
Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the
quality of care for enrollees in medicare managed care. JAMA 2002;287:1288-94.
8.
Libby P. Current concepts of the pathogenesis of the acute coronary
syndromes. Circulation 2001;104:365-72.
9.
Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without
ST elevation: implementation of new guidelines. Lancet 2001;358:1533-8.
10.
Davies MJ. The pathophysiology of acute coronary syndromes. Heart
2000;83:361-6.
11.
Falk E. Plaque rupture with severe pre-existing stenosis precipitating
coronary thrombosis: characteristics of coronary atherosclerotic
plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.
12.
Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography
predict the site of a subsequent myocardial infarction in patients
with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-66.
13.
Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role
in atherosclerosis. JAMA 1999;282:2035-42.
14.
Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence
of a chronic systemic cause of instability of atherosclerotic plaques.
Lancet 2000;355:19-24.
15.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation 2002;105:1135-43.
16.
Dahlbäck B. Blood coagulation. Lancet 2000;355:1627-32.
17.
Rosenberg RD, Aird WC. Vascular-bed: specific hemostasis and hypercoagulable
states. N Engl J Med 1999;340:1555-64.
18.
Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon
of ischemic cell death: 1. Myocardial infarct size vs duration of
coronary occlusion in dogs. Circulation 1977;56:786-94.
19.
Hasche ET, Fernandes C, Freedman SB, Jeremy RW. Relation between
ischemia time, infarct size, and left ventricular function in humans.
Circulation 1995;92:710-9.
20.
DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary
occlusion during the early hours of transmural myocardial infarction.
N Engl J Med 1980;303:897-902.
21. de Feyter PJ, van den Brand M, Serruys PW,
Wijns W. Early angiography after myocardial infarction: what have
we learned? Am Heart J 1985;109:194-9.
22.
DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic
findings soon after non–Q-wave myocardial infarction. N Engl
J Med 1986;315:417-23.
23.
Early effects of tissue-type plasminogen activator added to conventional
therapy on the culprit coronary lesion in patients presenting with
ischemic cardiac pain at rest: results of the Thrombolysis in Myocardial
Ischemia (TIMI IIIA) trial. Circulation 1993;87:38-52.
24.
Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML.
Acute myocardial infarction. Lancet 2003;361:847-58.
25. The GUSTO investigators. An international randomized
trial comparing four thrombolytic strategies for acute myocardial
infarction. N Engl J Med 1993;329:673-82.
26.
The Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO III) Investigators. A comparison of reteplase with alteplase
for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
27.
The Continuous Infusion versus Double-Bolus Administration of Alteplase
(COBALT) Investigators. A comparison of continuous infusion of alteplase
with double-bolus administration for acute myocardial infarction.
N Engl J Med 1997;337:1124-30.
28.
Single-bolus tenecteplase compared with front-loaded alteplase in
acute myocardial infarction: the ASSENT-2 double-blind randomised
trial. Assessment of the Safety and Efficacy of a New Thrombolytic
Investigators. Lancet 1999;354:716-22.
29.
Intravenous NPA for the Treatment of Infarcting Myocardium Early;
InTIME-II, a double-blind comparison of single-bolus lanoteplase
vs accelerated alteplase for the treatment of patients with acute
myocardial infarction. Eur Heart J 2000;21:2005-13.
30.
Topol EJ, for the GUSTO V Investigators. Reperfusion therapy for
acute myocardial infarction with fibrinolytic therapy or combination
reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa
inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-14.
31.
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen
(ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab, or unfractionated heparin:
the ASSENT-3 randomised trial in acute myocardial infarction. Lancet
2001;358:605-13.
32.
Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein
IIb/IIIa receptor blockade on recovery of coronary flow and left
ventricular function after the placement of coronary-artery stents
in acute myocardial infarction. Circulation 1998;98:2695-701.
33.
White H, for the Hirulog and Early Reperfusion or Occlusion (HERO)-2
Trial Investigators. Thrombin-specific anticoagulation with bivalirudin
versus heparin in patients receiving fibrinolytic therapy for acute
myocardial infarction: the HERO-2 randomised vascutrial. Lancet
2001;358:1855-63.
34.
Brener SJ, Barr LA, Burchenal JE, et al, for the ReoPro and Primary
PTCA Organization and Randomized Trial (RAPPORT) Investigators.
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa
blockade with primary angioplasty for acute myocardial infarction.
Circulation 1998;98:734-41.
35.
Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein
IIb/IIIa receptor blockade with abciximab on clinical and angiographic
restenosis rate after the placement of coronary stents following
acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
36.
Montalescot G, Barragan P, Wittenberg O, et al, for the Abciximab
before Direct Angioplasty and Stenting in Myocardial Infarction
Regarding Acute and Long-Term Follow-up (ADMIRAL) Investigators.
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting
for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
37.
Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent
implantation compared with primary balloon angioplasty for acute
myocardial infarction: a meta-analysis of randomized clinical trials.
Am J Cardiol 2001;88:297-301.
38.
Stone GW, Grines CL, Cox DA, et al, for the Controlled Abciximab
and Device Investigation to Lower Late Angioplasty Complications
(CADILLAC) Investigators. Comparison of angioplasty with stenting,
with or without abciximab, in acute myocardial infarction. N Engl
J Med 2002;346:957-66.
39.
Direct thrombin inhibitors in acute coronary syndromes: principal
results of a meta-analysis based on individual patients’ data.
Lancet 2002;359:294-302.
40.
Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative
review of 23 randomised trials. Lancet 2003; 361:13-20.
41.
Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling
following acute myocardial infarction: mechanisms and management.
Am J Cardiol 1991;68:1D-6D.
42.
Pfeffer MA. Left ventricular remodeling after acute myocardial infarction.
Annu Rev Med 1995;46:455-66.
43.
Weisman HF, Healy B. Myocardial infarct expansion, infarct extension,
and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis
1987;30:73-110.
44. Weber KT. Aldosterone in congestive heart failure.
N Engl J Med 2001;345:1689-97.
45.
Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment
of over 1.5 million patients with myocardial infarction in the US
from 1990 through 1999: the National Registry of Myocardial Infarction
1, 2 and 3. J Am Coll Cardiol 2000;36: 2056-63.
46.
American Heart Association. Heart Disease and Stroke Statistics
— 2004 Update. Dallas, TX: American Heart Association; 2003.
Available at http://www.americanheart.org/presenter.jhtml?identifier=3000090.
Accessed November 15, 2003.
46a.Wiviott SD, Morrow DA, Giugliano RP, et al.
Performance of the thrombolysis in myocardial infarction risk index
for early acute coronary syndrome in the National Registry of Myocardial
Infarction: a simple risk index predicts mortality in both ST and
non-ST elevation myocardial infarction. J Am Coll Cardiol 2003;41:365A.
47.
Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D.
Temporal trends in event rates after Q-wave myocardial infarction:
the Framingham Heart Study. Circulation 1999;100: 2054-9.
48.
Goldberg RJ, Yarzebski J, Lessard D, Gore JM. A two-decades (1975
to 1995) long experience in the incidence, in-hospital and long-term
case-fatality rates of acute myocardial infarction: a community-wide
perspective. J Am Coll Cardiol 1999;33:1533-9.
49.
Rouleau JL, Talajic M, Sussex B, et al. Myocardial infarction patients
in the 1990s: their risk factors, stratification and survival in
Canada: the Canadian Assessment of Myocardial Infarction (CAMI)
Study. J Am Coll Cardiol 1996;27:1119-27.
50.
Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III). JAMA 2001;285:2486-97.
51.
National Kidney Foundation practice guidelines for chronic kidney
disease: evaluation, classification, and stratification. Ann Intern
Med 2003;139:137-47.
52.
National Heart, Lung, and Blood Institute. Act in Time to Heart
Attack. Available at http://www.nhlbi.nih.gov/actintime, 2003. Accessed
May 15, 2003.
53.
Wenger NK. You’ve come a long way, baby: cardiovascular health
and disease in women: problems and prospects. Circulation 2004;109:558-60.
54.
American College of Cardiology. Guidelines Applied in Practice.
Available at http://www.acc.org/gap/gap.htm, 2003. Accessed May
15, 2003.
55.
American Heart Association. Get With the Guidelines. Available at
http://www.americanheart.org/presenter.jhtml?identifier=1165, 2003.
Accessed May 15, 2003.
56.
Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic
heart disease: a call for specialized centers. Circulation 2003;107:1463-6.
57.
Califf RM, Faxon DP. Need for centers to care for patients with
acute coronary syndromes. Circulation 2003;107:1467-70.
58.
Willerson JT. Editor’s commentary: centers of excellence.
Circulation 2003;107:1471-2.
59.
National Cholesterol Education Program. Third Report of the Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). NIH Pub. No. 02-5125. Bethesda,
MD: National Heart, Lung, and Blood Institute, 2002;284 pages. Guidelines,
Related Tools, and Patient Information available at http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.
Accessed May 15, 2003.
60.
Wielgosz AT. What do we really know about secondary prevention after
myocardial infarction? Can J Cardiol 1995;11(Suppl A):31A-32A.
61. Ebrahim S, Davey Smith G. Multiple risk factor
interventions for primary prevention of coronary heart disease.
Cochrane Database Syst Rev 2000CD001561.
62.
Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin
treatment trials: a meta-analysis. Arch Intern Med 1999;159: 1793-802.
63.
Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment
of cardiovascular risk by use of multiple-risk-factor assessment
equations: a statement for healthcare professionals from the American
Heart Association and the American College of Cardiology. Circulation
1999;100:1481-92.
64.
Risk Assessment. American Heart Association. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3003499,
2004. Accessed May 15, 2003.
65.
Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary
prevention of cardiovascular disease and stroke: 2002 update: consensus
panel guide to comprehensive risk reduction for adult patients without
coronary or other atherosclerotic vascular diseases. American Heart
Association Science Advisory and Coordinating Committee. Circulation
2002;106:388-91.
66.
Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation
on mortality after myocardial infarction: meta-analysis of cohort
studies. Arch Intern Med 2000;160:939-44.
67.
Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade
after myocardial infarction: systematic review and meta regression
analysis. BMJ 1999;318:1730-7.
68.
Smith SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement:
AHA/ACC guidelines for preventing heart attack and death in patients
with atherosclerotic cardiovascular disease: 2001 update: a statement
for healthcare professionals from the American Heart Association
and the American College of Cardiology. Circulation 2001;104:1577-9.
69.
Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines
for cardiovascular disease prevention in women. Circulation 2004;109:672-93.
70.
Treating tobacco use and dependence: a clinical practice guideline.
Office of the Surgeon General. Available at http://www.surgeongeneral.gov/tobacco,
2000. Accessed May 15, 2003.
71.
Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
update for the management of patients with chronic stable angina:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (Committee to Update the 1999
Guidelines for the Management of Patients with Chronic Stable Angina).
Available at www.acc.org/clinical/guidelines/stable/stable.pdf,
2002. Accessed December 2, 2003.
72.
Chobanian AV, Bakris GL, Black HR, et al, for the National Heart,
Lung, and Blood Institute Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure, National
High Blood Pressure Education Program Coordinating Committee. The
seventh report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
JAMA 2003;289:2560-72.
73.
Pignone M, Mulrow CD. Evidence based management of hypertension:
Using cardiovascular risk profiles to individualise hypertensive
treatment. BMJ 2001;322:1164-6.
74.
Turnbull F. Blood Pressure Lowering Treatment Trialists’ Collaboration.
Effects of different blood-pressure-lowering regimens on major cardiovascular
events: results of prospectivelydesigned overviews of randomised
trials. Lancet 2003;362:1527-35.
75.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive
drug treatment in older persons with isolated systolic hypertension:
final results of the Systolic Hypertension in the Elderly Program
(SHEP). JAMA 1991;265:3255-64.
76.
Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary
prevention of cardiovascular events: a summary of the evidence for
the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
77.
U.S. Preventive Services Task Force. Aspirin for the primary prevention
of cardiovascular events: recommendation and rationale. Ann Intern
Med 2002;136:157-60.
78.
Peters RJ, Mehta SR, Fox KA, et al, for the Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) Trial Investigators. Effects
of aspirin dose when used alone or in combination with clopidogrel
in patients with acute coronary syndromes: observations from the
Clopidogrel in Unstable angina to prevent Recurrent Events (CURE)
study. Circulation 2003; 108:1682-7.
79.
Hung J. Medical Issues Committee of the National Heart Foundation
of Australia. Aspirin for cardiovascular disease prevention. Med
J Aust 2003;179:147-52.
80.
Dracup K, Alonzo AA, Atkins JM, et al. The physician’s role
in minimizing prehospital delay in patients at high risk for acute
myocardial infarction: recommendations from the National Heart Attack
Alert Program (Working Group on Educational Strategies to Prevent
Prehospital Delay in Patients at High Risk for Acute Myocardial
Infarction). Ann Intern Med 1997;126:645-51.
81.
Hedges JR, Feldman HA, Bittner V, et al, for the REACT Study Group.
Impact of community intervention to reduce patient delay time on
use of reperfusion therapy for acute myocardial infarction: Rapid
Early Action for Coronary Treatment (REACT) trial. Acad Emerg Med
2000;7:862-72.
82.
Canto JG, Zalenski RJ, Ornato JP, et al, for the National Registry
of Myocardial Infarction 2 Investigators. Use of emergency medical
services in acute myocardial infarction and subsequent quality of
care: observations from the National Registry of Myocardial Infarction
2. Circulation 2002;106:3018-23.
83.
Goldberg R, Goff D, Cooper L, et al. Age and sex differences in
presentation of symptoms among patients with acute coronary disease:
the REACT Trial. Rapid Early Action for Coronary Treatment. Coron
Artery Dis 2000;11:399-407.
84.
Hutchings CB, Mann NC, Daya M, et al. Rapid Early Action for Coronary
Treatment Study. Patients with chest pain calling 9-1-1 or self-transporting
to reach definitive care: which mode is quicker? Am Heart J 2004;147:35-41.
85.
Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during
self-transport for chest pain. Ann Emerg Med 1996;28: 612-6.
86.
Brown AL, Mann NC, Daya M, et al. Demographic, belief, and situational
factors influencing the decision to utilize emergency medical services
among chest pain patients: Rapid Early Action for Coronary Treatment
(REACT) study. Circulation 2000;102: 173-8.
87.
Goff DC, Feldman HA, McGovern PG, et al, for the Rapid Early Action
for Coronary Treatment (REACT) Study Group. Prehospital delay in
patients hospitalized with heart attack symptoms in the United States:
the REACT trial. Am Heart J 1999;138: 1046-57.
88.
Herlitz J, Karlson BW, Liljeqvist JA, Strömbom U, Holmberg
S. Early identification of acute myocardial infarction and prognosis
in relation to mode of transport to hospital. Am J Emerg Med 1992;10:406-12.
89.
Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between
onset of chest pain and seeking medical care: the effect of public
education. Ann Emerg Med 1989;18:727-31.
90.
Dracup K, Moser DK, Eisenberg M, Meischke H, Alonzo AA, Braslow
A. Causes of delay in seeking treatment for heart attack symptoms.
Soc Sci Med 1995;40:379-92.
91.
Herlitz J, Blohm M, Hartford M, et al. Follow-up of a 1-year media
campaign on delay times and ambulance use in suspected acute myocardial
infarction. Eur Heart J 1992;13:171-7.
92.
Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community
intervention on patient delay and emergency medical service use
in acute coronary heart disease: the Rapid Early Action for Coronary
Treatment (REACT) Trial. JAMA 2000;284:60-7.
93.
Wright RS, Kopecky SL, Timm M, et al, for the Wabasha Heart Attack
Team. Impact of community-based education on health care evaluation
in patients with acute chest pain syndromes: the Wabasha Heart Attack
Team (WHAT) project. Fam Pract 2001; 18:537-9.
94.
Access to Timely and Optimal Care of Patients with Acute Coronary
Syndromes - Community Planning Considerations: a report by the National
Heart Attack Alert Program. J Thromb Thrombolysis 1998;6:19-46.
95. Leslie WS, Urie A, Hooper J, Morrison CE. Delay
in calling for help during myocardial infarction: reasons for the
delay and subsequent pattern of accessing care. Heart 2000;84:137-41.
96. Simon AB, Feinleib M, Thompson HK. Components
of delay in the pre-hospital phase of acute myocardial infarction.
Am J Cardiol 1972;30:476-82.
97.
Alonzo AA. The impact of the family and lay others on care-seeking
during life-threatening episodes of suspected coronary artery disease.
Soc Sci Med 1986;22:1297-311.
98.
Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care: part 12: from science to survival: strengthening
the chain of survival in every community. The American Heart Association
in collaboration with the International Liaison Committee on Resuscitation.
Circulation 2000;102:I358-70.
99.
McDermott MM, Mandapat AL, Moates A, et al. Knowledge and attitudes
regarding cardiovascular disease risk and prevention in patients
with coronary or peripheral arterial disease. Arch Intern Med 2003;163:2157-62.
100. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence,
clinical characteristics, and mortality among patients with myocardial
infarction presenting without chest pain. JAMA 2000;283:3223-9.
101.
Faxon D, Lenfant C. Timing is everything: motivating patients to
call 9-1-1 at onset of acute myocardial infarction. Circulation
2001;104:1210-1.
102.
Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care: part 7: the era of reperfusion: section 1:
acute coronary syndromes (acute myocardial infarction). The American
Heart Association in collaboration with the International Liaison
Committee on Resuscitation. Circulation 2000;102:I172-203.
103.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3525. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
core_bk.pdf. Accessed December 16, 2002.
104.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3526. November 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
core_sp.pdf. Accessed December 16, 2002.
105.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3667. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
wallet.pdf. Accessed December 16, 2002.
106.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3669. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
act_ plan.pdf. Accessed December 16, 2002.
107. U.S. Department of Health and Human Services.
Public Health Service. National Institutes of Health. National Heart,
Lung, and Blood Institute. NIH Publication No. 01-3313. September
2001. Available at: http://www.nhlbi.nih.gov/health/prof/heart/mi/
provider.pdf. Accessed December 16, 2002.
108.
Act in Time to Heart Attack Signs: Physician Quick Reference Tool
for Palm OS. Department of Health and Human Services. Public Health
Service. National Institutes of Health. National Heart, Lung, and
Blood Institute. 2001. Available at: http://hin.nhlbi.nih.gov/haac_palm/haac_palm.htm.
Accessed Decmeber 16, 2002.
109.
U.S. Department of Health and Human Services. Public Health Service.
National Institutes of Health. National Heart, Lung, and Blood Institute.
NIH Publication No. 01-3646. September 2001. Available at: http://www.nhlbi.nih.gov/health/public/heart/mi/
poster.pdf. Accessed Decmeber 16, 2002.
110.
Deleted in press.
111.
Goff DC, Sellers DE, McGovern PG, et al. Knowledge of heart attack
symptoms in a population survey in the United States: the REACT
Trial. Rapid Early Action for Coronary Treatment. Arch Intern Med
1998;158:2329-38.
112.
Welsh RC, Ornato J, Armstrong PW. Prehospital management of acute
ST-elevation myocardial infarction: a time for reappraisal in North
America. Am Heart J 2003;145:1-8.
113.
Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated
with, delay to hospital presentation in patients with acute coronary
disease (the GRACE registry). Am J Cardiol 2002; 89:791-6.
114.
Finnegan JR, Meischke H, Zapka JG, et al. Patient delay in seeking
care for heart attack symptoms: findings from focus groups conducted
in five U.S. regions. Prev Med 2000;31:205-13.
115.
Feldman HA, Proschan MA, Murray DM, et al. Statistical design of
REACT (Rapid Early Action for Coronary Treatment), a multisite community
trial with continual data collection. Control Clin Trials 1998;19:391-403.
116.
McKinley S, Moser DK, Dracup K. Treatment-seeking behavior for acute
myocardial infarction symptoms in North America and Australia. Heart
Lung 2000;29:237-47.
117.
Rucker D, Brennan T, Burstin H. Delay in seeking emergency care.
Acad Emerg Med 2001;8:163-9.
118.
Sheifer SE, Gersh BJ, Yanez ND, Ades PA, Burke GL, Manolio TA. Prevalence,
predisposing factors, and prognosis of clinically unrecognized myocardial
infarction in the elderly. J Am Coll Cardiol 2000;35:119-26.
119.
Kannel WB. Silent myocardial ischemia and infarction: insights from
the Framingham Study. Cardiol Clin 1986;4:583-91.
120.
Rathore SS, Weinfurt KP, Gersh BJ, Oetgen WJ, Schulman KA, Solomon
AJ. Treatment of patients with myocardial infarction who present
with a paced rhythm. Ann Intern Med 2001;134:644- 51.
121.
Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from
sudden cardiac arrest: the “chain of survival” concept:
a statement for health professionals from the Advanced Cardiac Life
Support Subcommittee and the Emergency Cardiac Care Committee, American
Heart Association. Circulation 1991;83: 1832-47.
122.
Cummins RO, Eisenberg MS, Hallstrom AP, Litwin PE. Survival of out-of-hospital
cardiac arrest with early initiation of cardiopulmonary resuscitation.
Am J Emerg Med 1985;3:114-9.
123.
Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3-
phase time-sensitive model. JAMA 2002;288:3035-8.
124.
Stapczynski JS, Svenson JE, Stone CK. Population density, automated
external defibrillator use, and survival in rural cardiac arrest.
Acad Emerg Med 1997;4:552-8.
125.
Becker LB, Ostrander MP, Barrett J, Kondos GT. Outcome of CPR in
a large metropolitan area: where are the survivors? Ann Emerg Med
1991;20:355-61.
126.Lombardi
G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest
in New York City: the Pre-Hospital Arrest Survival Evaluation (PHASE)
Study. JAMA 1994;271:678-83.
127.
White RD, Asplin BR, Bugliosi TF, Hankins DG. High discharge survival
rate after out-of-hospital ventricular fibrillation with rapid defibrillation
by police and paramedics. Ann Emerg Med 1996;28:480-5.
128.
White RD, Hankins DG, Bugliosi TF. Seven years’ experience
with early defibrillation by police and paramedics in an emergency
medical services system. Resuscitation 1998;39:145-51.
129.
Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of outof-
hospital cardiac arrest after successful early defibrillation. N
Engl J Med 2003;348:2626-33.
130.
Stiell IG,Wells GA, Field BJ, et al. Improved out-of-hospital cardiac
arrest survival through the inexpensive optimization of an existing
defibrillation program: OPALS study phase II. Ontario Prehospital
Advanced Life Support. JAMA 1999;281:1175-81.
131.
Caffrey SL, Willoughby PJ, Pepe PE, Becker LB. Public use of automated
external defibrillators. N Engl J Med 2002;347:1242-7.
132.
Dracup K, Moser DK, Guzy PM, Taylor SE, Marsden C. Is cardiopulmonary
resuscitation training deleterious for family members of cardiac
patients? Am J Public Health 1994;84:116-8.
133.
Dracup K, Moser DK, Taylor SE, Guzy PM. The psychological consequences
of cardiopulmonary resuscitation training for family members of
patients at risk for sudden death. Am J Public Health 1997;87:1434-9.
134.
Chen MA, Eisenberg MS, Meischke H. Impact of in-home defibrillators
on postmyocardial infarction patients and their significant others:
an interview study. Heart Lung 2002;31:173-85.
135.
Home Automatic External Defibrillator Trial. National Heart, Lung,
and Blood Institute (NHLBI). Available at: http:// www.clinicaltrials.gov/ct/show/NCT00047411?order=46.
2004. NLM Identifier: NCT00047411. Accessed December 22, 2003.
136.
Hallstrom AP, Cobb LA, Johnson E, Copass MK. Dispatcher assisted
CPR: implementation and potential benefit: a 12-year study. Resuscitation
2003;57:123-9.
137. Cummins RO. From concept to standard-of-care?
Review of the clinical experience with automated external defibrillators.
Ann Emerg Med 1989;18:1269-75.
138.
Cummins RO, Schubach JA, Litwin PE, Hearne TR. Training lay persons
to use automatic external defibrillators: success of initial training
and one-year retention of skills. Am J Emerg Med 1989;7:143-9.
139.
Mosesso VN, Davis EA, Auble TE, Paris PM, Yealy DM. Use of automated
external defibrillators by police officers for treatment of out-of-hospital
cardiac arrest. Ann Emerg Med 1998;32:200-7.
140.
Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG.
Outcomes of rapid defibrillation by security officers after cardiac
arrest in casinos. N Engl J Med 2000;343:1206- 9.
141.
Page RL, Joglar JA, Kowal RC, et al. Use of automated external defibrillators
by a U.S. airline. N Engl J Med 2000;343:1210-6.
142.
Nichol G, Hallstrom AP, Kerber R, et al. American Heart Association
report on the second public access defibrillation conference, April
17-19, 1997. Circulation 1998;97:1309-14.
143.
Nichol G, Hallstrom AP, Ornato JP, et al. Potential cost-effectiveness
of public access defibrillation in the United States. Circulation
1998;97:1315-20.
144.
Kerber RE, Becker LB, Bourland JD, et al. Automatic external defibrillators
for public access defibrillation: recommendations for specifying
and reporting arrhythmia analysis algorithm performance, incorporating
new waveforms, and enhancing safety: statement for health professionals
from the American Heart Association Task Force on Automatic External
Defibrillation, Subcommittee on AED Safety and Efficacy. Circulation
1997;95:1677-82.
145.
Weisfeldt ML, Kerber RE, McGoldrick RP, et al, for the Automatic
Defibrillation Task Force. Public access to defibrillation. Am J
Emerg Med 1996;14:684-92.
146.
Weisfeldt ML, Kerber RE, McGoldrick RP, et al, for the Automatic
External Defibrillation Task Force. American Heart Association Report
on the Public Access Defibrillation Conference December 8-10, 1994.
Circulation 1995;92:2740-7.
147.
Weisfeldt ML, Kerber RE, McGoldrick RP, et al. Public access defibrillation:
a statement for healthcare professionals from the American Heart
Association Task Force on Automatic External Defibrillation. Circulation
1995;92:2763.
148. Deleted in press.
149.
Ornato JP, Racht EM, Fitch JJ, Berry JF. The need for ALS in urban
and suburban EMS systems. Ann Emerg Med 1990; 19:1469-70.
150.
Stout J, Pepe PE, Mosesso VN. All-advanced life support vs tiered-response
ambulance systems. Prehosp Emerg Care 2000;4:1-6.
151. Eisenberg MJ, Topol EJ. Prehospital administration
of aspirin in patients with unstable angina and acute myocardial
infarction. Arch Intern Med 1996;156:1506-10.
152.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative
Group. ISIS-4: a randomised factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium sulphate
in 58,050 patients with suspected acute myocardial infarction. Lancet
1995;345:669-85.
153.
Hutter AM, Weaver WD. 31st Bethesda Conference: emergency cardiac
care: task force 2: acute coronary syndromes: section 2A–prehospital
issues. J Am Coll Cardiol 2000;35:846-53.
154.
Lau J, Ioannidis J, Balk E, et al. Evaluation of Technologies for
Identifying Acute Cardiac Ischemia in Emergency Departments. Evidence
Report/Technology Assessment Number 26. (Prepared by the New England
Medical Center Evidence-based Practice Center under Contract No.
290-97-0019). AHRQ Publication No. 01-E006, Rockville, MD: Agency
for Healthcare Research and Quality, May 2001.
155.
Armstrong PW, Collen D, Antman E. Fibrinolysis for acute myocardial
infarction: the future is here and now. Circulation 2003;107:2533-7.
156.
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.
Indications for fibrinolytic therapy in suspected acute myocardial
infarction: collaborative overview of early mortality and major
morbidity results from all randomised trials of more than 1000 patients.
Lancet 1994;343:311-22.
157.
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto
Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment
in acute myocardial infarction. Lancet 1986;1:397-402.
158.
Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety
of tenecteplase in combination with the low-molecular-weight heparin
enoxaparin or unfractionated heparin in the prehospital setting:
the Assessment of the Safety and Efficacy of a New Thrombolytic
Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
Circulation 2003;108:135-42.
159.
Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated
vs hospital-initiated thrombolytic therapy: the Myocardial Infarction
Triage and Intervention trial. JAMA 1993;270:1211-6.
160.
Hermens WT, Willems GM, Nijssen KM, Simoons ML. Effect of thrombolytic
treatment delay on myocardial infarct size. Lancet 1992;340:1297.
161.
Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results
of clinical trials and the animal paradigm: paradoxic or predictable?
Circulation 1993;88:296-306.
162.
Newby LK, Rutsch WR, Califf RM, et al, for the GUSTO-1 Investigators.
Time from symptom onset to treatment and outcomes after thrombolytic
therapy. J Am Coll Cardiol 1996;27:1646-55.
163.
Milavetz JJ, Giebel DW, Christian TF, Schwartz RS, Holmes DR, Gibbons
RJ. Time to therapy and salvage in myocardial infarction. J Am Coll
Cardiol 1998;31:1246-51.
164.
Chareonthaitawee P, Gibbons RJ, Roberts RS, Christian TF, Burns
R, Yusuf S, for the CORE investigators (Collaborative Organisation
for RheothRx Evaluation). The impact of time to thrombolytic treatment
on outcome in patients with acute myocardial infarction. Heart 2000;84:142-8.
165.
McNeill AJ, Cunningham SR, Flannery DJ, et al. A double-blind placebo
controlled study of early and late administration of recombinant
tissue plasminogen activator in acute myocardial infarction. Br
Heart J 1989;61:316-21.
166.
Castaigne AD, Hervé C, Duval-Moulin AM, et al. Prehospital
use of APSAC: results of a placebo-controlled study. Am J Cardiol
1989;64:30A-33A; discussion.
167.
Barbash GI, Roth A, Hod H, et al. Improved survival but not left
ventricular function with early and prehospital treatment with tissue
plasminogen activator in acute myocardial infarction. Am J Cardiol
1990;66:261-6.
168.
Schofer J, Büttner J, Geng G, et al Prehospital thrombolysis
in acute myocardial infarction. Am J Cardiol 1990;66:1429-33.
169.
McAleer B, Ruane B, Burke E, et al. Prehospital thrombolysis in
a rural community: short- and long-term survival. Cardiovasc Drugs
Ther 1992;6:369-72.
170.
Grampian Region Early Anistreplase Trial (GREAT) Group. Feasibility,
safety, and efficacy of domiciliary thrombolysis by general practitioners:
BMJ 1992;305:548-53.
171.
The European Myocardial Infarction Project Group. Prehospital thrombolytic
therapy in patients with suspected acute myocardial infarction.
N Engl J Med 1993;329:383-9.
172.
Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved
by prehospital initiation of reteplase for ST-elevation myocardial
infarction: results of The Early Retavase- Thrombolysis in Myocardial
Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002;40:71-7.
173.
Bonnefoy E, Lapostolle F, Leizorovicz A, et al for the Comparison
of Angioplasty and Prehospital Thrombolysis in Acute Myocardial
Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis
in acute myocardial infarction: a randomised study. Lancet 2002;360:825-9.
174.
Spinler SA, Mikhail PA. Prehospital-initiated thrombolysis. Ann
Pharmacother 1997;31:1339-46.
175.
Karagounis L, Ipsen SK, Jessop MR, et al. Impact of field-transmitted
electrocardiography on time to in-hospital thrombolytic therapy
in acute myocardial infarction. Am J Cardiol 1990;66:786-91.
176.
Steg PG, Bonnefoy E, Chabaud S, et al. Impact of Time to Treatment
on Mortality After Prehospital Fibrinolysis or Primary Angioplasty:
data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-6.
177.
Widimský P, Budesinský T,Vorác D, et al. Long
distance transport for primary angioplasty vs immediate thrombolysis
in acute myocardial infarction: final results of the randomized
national multicentre trial-PRAGUE-2. Eur Heart J 2003;24:94-104.
178.
Deleted in press.
179.
Emergency department: rapid identification and treatment of patients
with acute myocardial infarction. National Heart Attack Alert Program
Coordinating Committee, 60 Minutes to Treatment Working Group. Ann
Emerg Med 1994;23:311-29.
180.
Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive
agent to thrombolytic therapy. J Thromb Thrombolysis 1994;1:27-34.
181.
Weaver WD, Litwin PE, Martin JS, et al, for the MITI Project Group.
Effect of age on use of thrombolytic therapy and mortality in acute
myocardial infarction. J Am Coll Cardiol 1991;18:657- 62.
182. Gibler WB, Kereiakes DJ, Dean EN, et al.
Prehospital diagnosis and treatment of acute myocardial infarction:
a north-south perspective. The Cincinnati Heart Project and the
Nashville Prehospital TPA Trial. Am Heart J 1991;121:1-11.
183. Pedley DK, Bissett K, Connolly EM, et al.
Prospective observational cohort study of time saved by prehospital
thrombolysis for ST elevation myocardial infarction delivered by
paramedics. BMJ 2003;327:22-6.
184. Hochman JS, Sleeper LA, White HD, et al,
for the Should We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock (SHOCK) Investigators. One-year survival following
early revascularization for cardiogenic shock. JAMA 2001;285:190-2.
185. Cannon CP. Time to treatment: a crucial factor
in thrombolysis and primary angioplasty. J Thromb Thrombolysis 1996;3:249-255.
186. Steg PG, Goldberg RJ, Gore JM, et al, for
the GRACE Investigators. Baseline characteristics, management practices,
and in-hospital outcomes of patients hospitalized with acute coronary
syndromes in the Global Registry of Acute Coronary Events (GRACE).
Am J Cardiol 2002;90:358-63.
187.
Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary
syndromes. Ann Emerg Med 2000;35:449-61.
188.
Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of
acute cardiac ischemia in the emergency department. N Engl J Med
2000;342:1163-70.
189.
Jesse RL, Kontos MC. Evaluation of chest pain in the emergency department.
Curr Probl Cardiol 1997;22:149-236.
190.
Karcz A, Korn R, Burke MC, et al. Malpractice claims against emergency
physicians in Massachusetts: 1975-1993. Am J Emerg Med 1996;14:341-5.
191.
Graff L. Missed MI diagnosis. Ann Emerg Med 1994;23:141-2.
192.
McCarthy BD, Beshansky JR, D’Agostino RB, Selker HP. Missed
diagnoses of acute myocardial infarction in the emergency department:
results from a multicenter study. Ann Emerg Med 1993;22:579-82.
193.
Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for
the evaluation and triage of the chest pain patient. Ann Emerg Med
1997;29:116-25.
194.
Tatum JL. Cost effective nuclear scanning in a comprehensive and
systematic approach to the evaluation of chest pain in the emergency
department. Md Med J 1997;Suppl:25-9.
195.
Ornato JP. Chest pain emergency centers: improving acute myocardial
infarction care. Clin Cardiol 1999;22:IV3-9.
196.
Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing
for risk stratification in chest pain units: the chest pain evaluation
by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study.
Circulation 2001;103:1832-7.
197.
Lateef F, Storrow AB, Gibler BW, Liu T. Heart emergency room: effective
for both geriatric and younger patients. Singapore Med J 2001;42:259-63.
198.
Lateef F, Storrow AB, Malone K, Liu T, Gibler BW. Comparison of
a 6-hour and 9-hour protocol for evaluation of moderate-to-low risk
chest pain patients in an emergency department diagnostic unit.
Singapore Med J 2001;42:052-6.
199.
Gibler WB. Chest pain units: do they make sense now? Ann Emerg Med
1997;29:168-71.
200.
Gibler WB. Evaluation of chest pain in the emergency department.
Ann Intern Med 1995;123:315; discussion 317.
201.
Gibler WB. Chest pain evaluation in the ED: beyond triage. Am J
Emerg Med 1994;12:121-2.
202.
Gibler WB. Evaluating patients with chest pain in the ED: improving
speed, efficiency, and cost-effectiveness, or teaching an old dog
new tricks. Ann Emerg Med 1994;23:381-2.
203.
Hoekstra JW, Gibler WB, Levy RC, et al. Emergency-department diagnosis
of acute myocardial infarction and ischemia: a cost analysis of
two diagnostic protocols. Acad Emerg Med 1994;1:103-10.
204.
Hoekstra JW, Hedges JR, Gibler WB, Rubison RM, Christensen RA, for
the National Cooperative CK-MB Project Group. Emergency department
CK-MB: a predictor of ischemic complications. Acad Emerg Med 1994;1:17-27.
205.
Cannon CP, Hand MH, Bahr R, et al, for the. National Heart Attack
Alert Program (NHAAP) Coordinating Committee Critical Pathways Writing
Group. Critical pathways for management of patients with acute coronary
syndromes: an assessment by the National Heart Attack Alert Program.
Am Heart J 2002;143:777- 89.
206.
Zalenski RJ, Selker HP, Cannon CP, et al. National Heart Attack
Alert Program position paper: chest pain centers and programs for
the evaluation of acute cardiac ischemia. Ann Emerg Med 2000;35:462-71.
207.
Lambrew CT,Weaver WD, Rogers WJ, Bowlby LJ, Rubison RM, French WJ.
Hospital protocols and policies that may delay early identification
and thrombolytic therapy of acute myocardial infarction patients.
J Thromb Thrombolysis 1996;3:301-306.
208.
Farkouh ME, Smars PA, Reeder GS, et al, for the Chest Pain Evaluation
in the Emergency Room (CHEER) Investigators. A clinical trial of
a chest-pain observation unit for patients with unstable angina.
N Engl J Med 1998;339:1882-8.
209.
Deleted in press.
210.
Charney P. Coronary artery disease in young women: the menstrual
cycle and other risk factors. Ann Intern Med 2001;135: 1002-4.
211.
Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Effect
of gender on outcomes of acute coronary syndromes. Am J Cardiol
2003;91:1466-9–A6.
212.
Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison
of presentation, treatment, and outcome of acute myocardial infarction
in men versus women (the Myocardial Infarction Triage and Intervention
Registry) Am J Cardiol 1996;78:9-14.
213. Goldberg RJ, McCormick D, Gurwitz JH,Yarzebski
J, Lessard D, Gore JM. Age-related trends in short- and long-term
survival after acute myocardial infarction: a 20-year population-based
perspective (1975-1995). Am J Cardiol 1998;82:1311-7.
214.
Meischke H, Dulberg EM, Schaeffer SS, Henwood DK, Larsen MP, Eisenberg
MS. ‘Call fast, Call 911’: a direct mail campaign to
reduce patient delay in acute myocardial infarction. Am J Public
Health 1997;87:1705-9.
215.
McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK,
Garvin BJ. Women’s early warning symptoms of acute myocardial
infarction. Circulation 2003;108:2619-23.
216.
Bonow RO, Mitch WE, Nesto RW, et al. Prevention Conference VI: Diabetes
and Cardiovascular Disease: Writing Group V: management of cardiovascular-renal
complications. Circulation 2002;105:e159-64.
217.
Levy DE. How transient are transient ischemic attacks? Neurology
1988;38:674-7.
218. Sloan MA, Gore JM. Ischemic stroke and intracranial
hemorrhage following thrombolytic therapy for acute myocardial infarction:
a risk-benefit analysis. Am J Cardiol 1992;69:21A-38A.
219. Hochman JH, Gersh BJ. Acute myocardial infarction.
In: Topol EJ, ed. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia,
PA: Lippincott, Williams, and Wilkins; 2002:438.
220.
Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis:
significance of PR segment and PR vector changes. Circulation 1973;48:575-80.
221.
Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12- lead
electrocardiographic diagnosis of acute myocardial infarction. Eur
Heart J 2000;21:275-83.
222.
Mauri F, Gasparini M, Barbonaglia L, et al. Prognostic significance
of the extent of myocardial injury in acute myocardial infarction
treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-5.
223.
Antman EM, Rutherford JD. Coronary care medicine: a practical approach.
Boston, MA: Martinus Nijhoff Publishing;1986:81.
224.
Effects of tissue plasminogen activator and a comparison of early
invasive and conservative strategies in unstable angina and non–Q-wave
myocardial infarction: results of the TIMI IIIB Trial. Thrombolysis
in Myocardial Ischemia. Circulation 1994;89: 1545-56.
225.
Matetzky S, Freimark D, Chouraqui P, et al. Significance of ST segment
elevations in posterior chest leads (V7 to V9) in patients with
acute inferior myocardial infarction: application for thrombolytic
therapy. J Am Coll Cardiol 1998;31:506-11.
226.
Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003
guideline update for the clinical application of echocardiography:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update
the 1997 Guidelines for the Clinical Application of Echocardiography).
American College of Cardiology Web Site. Available at: www.acc.org/clinical/guidelines/echo/index.pdf,
2003. Accessed August 4, 2003.
227.
Goldman L, Cook EF, Brand DA, et al. A computer protocol to predict
myocardial infarction in emergency department patients with chest
pain. N Engl J Med 1988;318:797-803.
228.
Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions
other than acute myocardial infarction. N Engl J Med 2003;349:2128-35.
229. Sgarbossa EB, Pinski SL, Barbagelata A, et
al, for the GUSTO-1 (Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Electrocardiographic diagnosis of evolving acute myocardial infarction
in the presence of left bundle-branch block. N Engl J Med 1996;334:481-7.
230.
Sgarbossa EB. Value of the ECG in suspected acute myocardial infarction
with left bundle-branch block. J Electrocardiol 2000;33(Suppl):87-92.
231.
Luepker RV, Apple FS, Christenson RH, et al. Case definitions for
acute coronary heart disease in epidemiology and clinical research
studies: a statement from the AHA Council on Epidemiology and Prevention;
AHA Statistics Committee; World Heart Federation Council on Epidemiology
and Prevention; the European Society of Cardiology Working Group
on Epidemiology and Prevention; Centers for Disease Control and
Prevention; and the National Heart, Lung, and Blood Institute. Circulation
2003;108:2543-9.
232.
Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial
injury: is MB creatine kinase the choice for the 1990s? Circulation
1993;88:750-63.
233.
Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction
redefined: a consensus document of the Joint European Society of
Cardiology/American College of Cardiology Committee for the redefinition
of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
234.
Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R. National
Academy of Clinical Biochemistry Standards of Laboratory Practice:
recommendations for the use of cardiac markers in coronary artery
diseases. Clin Chem 1999;45:1104-21.
235.
Ohman EM, Armstrong PW, White HD, et al for the Global Use of Strategies
To Open Occluded Coronary Arteries (GUSTO III) Investigators. Risk
stratification with a point-of-care cardiac troponin T test in acute
myocardial infarction. Am J Cardiol 1999;84:1281-6.
236.
Tanasijevic MJ, Cannon CP, Wybenga DR, et al. Myoglobin, creatine
kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis
for acute myocardial infarction: results from TIMI 10A. Am Heart
J 1997;134:622-30.
237.
Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms
of creatine kinase-MB to diagnose or rule out acute myocardial infarction.
N Engl J Med 1994;331:561-6.
238.
Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E.
Time to positivity of a rapid bedside assay for cardiac- specific
troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis
in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol
1998;31:326-30.
239.
Klocke FJ, Baird MG, Bateman TM, et al. ACC/AHA/ASNC guidelines
for the clinical use of cardiac radionuclide imaging: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the
1995 Guidelines for the Clinical Use of Radionuclide Imaging). American
College of Cardiology Web Site. Available at http://www.acc.org/clinical/
guidelines/radio/rni_fulltext.pdf, 2003. Accessed August 18, 2003.
240.
Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I Investigators.
Predictors of 30-day mortality in the era of reperfusion for acute
myocardial infarction: results from an international trial of 41,021
patients. Circulation 1995;91:1659-68.
241.
Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for
rapid initial triage of patients with ST-elevation myocardial infarction:
an InTIME II substudy. Lancet 2001;358:1571-5.
242.
Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for
ST-elevation myocardial infarction: a convenient, bedside, clinical
score for risk assessment at presentation: an intravenous nPA for
treatment of infarcting myocardium early II trial substudy. Circulation
2000;102:2031-7.
243.
Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions
of outcomes in myocardial infarction for real-time emergency use:
a thrombolytic predictive instrument. Ann Intern Med 1997;127:538-56.
244.
Selker HP, Beshansky JR, Griffith JL, for the TPI Trial Investigators.
Use of the electrocardiograph-based thrombolytic predictive instrument
to assist thrombolytic and reperfusion therapy for acute myocardial
infarction: a multicenter, randomized, controlled, clinical effectiveness
trial. Ann Intern Med 2002;137: 87-95.
245.
Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM, for the
National Registry of Myocardial Infarction 2 Participants. Sex-based
differences in early mortality after myocardial infarction. N Engl
J Med 1999;341:217-25.
246.
Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz
HM. Intracranial hemorrhage associated with thrombolytic therapy
for elderly patients with acute myocardial infarction: results from
the Cooperative Cardiovascular Project. Stroke 2000;31:1802-11.
247.
Krumholz HM, Pasternak RC, Weinstein MC, et al L. Cost effectiveness
of thrombolytic therapy with streptokinase in elderly patients with
suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.
248.
Maroko PR, Radvany P, Braunwald E, Hale SL. Reduction of infarct
size by oxygen inhalation following acute coronary occlusion. Circulation
1975;52:360-8.
249.
Madias JE, Hood WB. Reduction of precordial ST-segment elevation
in patients with anterior myocardial infarction by oxygen breathing.
Circulation 1976;53:I198-200.
250. Fillmore SJ, Shapiro M, Killip T. Arterial
oxygen tension in acute myocardial infarction: serial analysis of
clinical state and blood gas changes. Am Heart J 1970;79:620-9.
251. Aubier M, Trippenbach T, Roussos
C. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol
1981;51:499-508.
252.
Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates.
Am Heart J 1985;110:216-24.
253.
Winbury MM. Redistribution of left ventricular blood flow produced
by nitroglycerin: an example of integration of the macroand microcirculation.
Circ Res 1971;28(Suppl 1):140-7.
254.
Gorman MW, Sparks HV. Nitroglycerin causes vasodilatation within
ischaemic myocardium. Cardiovasc Res 1980;14:515-21.
255. Deleted in press.
256. Come PC, Pitt B. Nitroglycerin-induced severe
hypotension and bradycardia in patients with acute myocardial infarction.
Circulation 1976;54:624-8.
257.
Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994;330:1211-7.
258.
Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA expert consensus
document on the use of sildenafil (Viagra) in patients with cardiovascular
disease. American College of Cardiology/ American Heart Association.
J Am Coll Cardiol 1999;33:273-82.
259.
Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald
E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular
medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1251.
260.
Hochman JS, Califf RM. Acute myocardial infarction. In: Smith TW.
Cardiovascular therapeutics: a companion to Braunwald’s heart
disease, 2nd ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:235-291.
261. ISIS-2 (Second International Study of Infarct
Survival) Collaborative Group. Randomised trial of intravenous streptokinase,
oral aspirin, both, or neither among 17,187 cases of suspected acute
myocardial infarction: ISIS-2. Lancet 1988;2:349- 60.
262.
Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary
reocclusion and recurrent ischemia after thrombolysis: a metaanalysis.
J Am Coll Cardiol 1992;19:671-7.
263.
Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis
of randomised trials of antiplatelet therapy for prevention of death,
myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
264.
Sagar KA, Smyth MR. A comparative bioavailability study of different
aspirin formulations using on-line multidimensional chromatography.
J Pharm Biomed Anal 1999;21:383-92.
265.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during
and after myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis 1985;27:335-71.
266.
Randomised trial of intravenous atenolol among 16 027 cases of suspected
acute myocardial infarction: ISIS-1. First International Study of
Infarct Survival Collaborative Group. Lancet 1986;2:57- 66.
267.
The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction:
patient population. Am J Cardiol 1985;56:10G- 14G.
268.
The TIMI Study Group. Comparison of invasive and conservative strategies
after treatment with intravenous tissue plasminogen activator in
acute myocardial infarction: results of the thrombolysis in myocardial
infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
269.
Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred
beta-blockade following thrombolytic therapy in patients with acute
myocardial infarction: results of the Thrombolysis in Myocardial
Infarction (TIMI) II-B Study. Circulation 1991;83: 422-37.
270.
Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects
of early intravenous treatment with a beta-adrenergic blocking agent
or a specific bradycardiac agent in patients with acute myocardial
infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993;22:407-16.
271.
Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical
outcomes after thrombolysis for acute myocardial infarction: the
GUSTO-I experience. Global Utilization of Streptokinase and TPA
(alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998;32:634-40.
272.
Kloner RA, Hale S. Unraveling the complex effects of cocaine on
the heart. Circulation 1993;87:1046-7.
273. Dargie HJ. Effect of carvedilol on outcome
after myocardial infarction in patients with left-ventricular dysfunction:
the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
274.
De Luca G, Suryapranata H, Zijlstra F, et al, for the ZWOLLE Myocardial
Infarction Study Group. Symptom-onset-to-balloon time and mortality
in patients with acute myocardial infarction treated by primary
angioplasty. J Am Coll Cardiol 2003;42:991-7.
275.
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay
to treatment and mortality in primary angioplasty for acute myocardial
infarction: every minute of delay counts. Circulation 2004;109:1223-5.
275a.Williams DO. Treatment delayed is treatment
denied. Circulation 2004;109:1806-8.
276.
Davies CH, Ormerod OJ. Failed coronary thrombolysis. Lancet 1998;351:1191-6.
277.
Ito H, Okamura A, Iwakura K, Masuyama T, et al. Myocardial perfusion
patterns related to thrombolysis in myocardial infarction perfusion
grades after coronary angioplasty in patients with acute anterior
wall myocardial infarction. Circulation 1996;93: 1993-9.
278.
Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular
obstruction by magnetic resonance imaging in patients with acute
myocardial infarction. Circulation 1998;97: 765-72.
279.
Zeymer U, Tebbe U, Essen R, Haarmann W, Neuhaus KL, for the ALKK-Study
Group. Influence of time to treatment on early infarct-related artery
patency after different thrombolytic regimens. Am Heart J 1999;137:34-8.
280.
Gibson CM. Has my patient achieved adequate myocardial reperfusion?
Circulation 2003;108:504-7.
281.
Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon
J, for the GRACE Investigators. Practice variation and missed opportunities
for reperfusion in ST-segment-elevation myocardial infarction: findings
from the Global Registry of Acute Coronary Events (GRACE). Lancet
2002;359:373-7.
282.
Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary
angioplasty and intravenous thrombolytic therapy for acute myocardial
infarction: a quantitative review. JAMA 1997; 278:2093-8.
283.
Hasdai D, Behar S,Wallentin L, et al. A prospective survey of the
characteristics, treatments and outcomes of patients with acute
coronary syndromes in Europe and the Mediterranean basin. The Euro
Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS).
Eur Heart J 2002;23:1190-201.
284.
Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment
in acute myocardial infarction: reappraisal of the golden hour.
Lancet 1996;348:771-5.
285.
Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality
and prehospital thrombolysis for acute myocardial infarction: a
meta-analysis. JAMA 2000;283:2686-92.
286.
Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting
ischemic myocardium: results of the NHLBI Cooperative Study: comparison
of unconscious and conscious dog models. Circ Res 1985;56:651-65.
287.
Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size
in reperfusion therapy for acute myocardial infarction. Circulation
1992;86:81-90.
288.
Huber KC, Bresnahan JF, Bresnahan DR, Pellikka PA, Behrenbeck T,
Gibbons RJ. Measurement of myocardium at risk by technetium-99m
sestamibi: correlation with coronary angiography. J Am Coll Cardiol
1992;19:67-73.
289. Klarich KW, Christian TF, Higano ST, Gibbons
RJ. Variability of myocardium at risk for acute myocardial infarction.
Am J Cardiol 1999;83:1191-5.
290.
Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion
for 30-day and late survival and recovery of left ventricular function
after primary angioplasty for acute myocardial infarction. J Am
Coll Cardiol 1998;32:1312-9.
291.
Brodie BR, Stone GW, Morice MC, et al, for the Stent Primary Angioplasty
in Myocardial Infarction Study Group. Importance of time to reperfusion
on outcomes with primary coronary angioplasty for acute myocardial
infarction (results from the Stent Primary Angioplasty in Myocardial
Infarction Trial). Am J Cardiol 2001;88:1085-90.
292.
Brodie BR, Stuckey TD, Muncy DB, et al. Importance of time-toreperfusion
in patients with acute myocardial infarction with and without cardiogenic
shock treated with primary percutaneous coronary intervention. Am
Heart J 2003;145:708-15.
293.
Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to
treatment and mortality in patients with acute myocardial infarction
undergoing primary coronary angioplasty. Am J Cardiol 2002;89:1248-52.
294.
Berger PB, Ellis SG, Holmes DR, et al. Relationship between delay
in performing direct coronary angioplasty and early clinical outcome
in patients with acute myocardial infarction: results from the global
use of strategies to open occluded arteries in Acute Coronary Syndromes
(GUSTO-IIb) trial. Circulation 1999;100: 14-20.
295.
Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon
time and door-to-balloon time with mortality in patients undergoing
angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
296. Zijlstra F, Patel A, Jones M, et al. Clinical
characteristics and outcome of patients with early (less than 2
h), intermediate (2-4 h) and late (greater than 4 h) presentation
treated by primary coronary angioplasty or thrombolytic therapy
for acute myocardial infarction. Eur Heart J 2002;23:550-7.
297.
Van de Werf F, Ardissino D, Betriu A, et al, for the Task Force
on the Management of Acute Myocardial Infarction of the European
Society of Cardiology. Management of acute myocardial infarction
in patients presenting with ST-segment elevation. The Task Force
on the Management of Acute Myocardial Infarction of the European
Society of Cardiology. Eur Heart J 2003;24:28-66.
298.
Krumholz HM, Chen J, Wang Y, Radford MJ, Chen YT, Marciniak TA.
Comparing AMI mortality among hospitals in patients 65 years of
age and older: evaluating methods of risk adjustment. Circulation
1999;99:2986-92.
299.
Granger CB, Goldberg RJ, Dabbous O, et al, for the Global Registry
of Acute Coronary Events Investigators. Predictors of hospital mortality
in the global registry of acute coronary events. Arch Intern Med
2003;163:2345-53.
300. Kent DM, Schmid CH, Lau J, Selker HP. Is
primary angioplasty for some as good as primary angioplasty for
all? J Gen Intern Med 2002;17:887-94.
301.
Hochman JS, Sleeper LA, Webb JG, et al, for the Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK)
Investigators. Early revascularization in acute myocardial infarction
complicated by cardiogenic shock. N Engl J Med 1999;341:625-34.
302.
Wu AH, Parsons L, Every NR, Bates ER, for the Second National Registry
of Myocardial Infarction. Hospital outcomes in patients presenting
with congestive heart failure complicating acute myocardial infarction:
a report from the Second National Registry of Myocardial Infarction
(NRMI-2). J Am Coll Cardiol 2002; 40:1389-94.
303.
Magid DJ, Calonge BN, Rumsfeld JS, et al, for the National Registry
of Myocardial Infarction 2 and 3 Investigators. Relation between
hospital primary angioplasty volume and mortality for patients with
acute MI treated with primary angioplasty vs thrombolytic therapy.
JAMA 2000;284:3131-8.
304.
Canto JG, Every NR, Magid DJ, et al, for the National Registry of
Myocardial Infarction 2 Investigators. The volume of primary angioplasty
procedures and survival after acute myocardial infarction. N Engl
J Med 2000;342:1573-80.
305.
Nallamothu BK, Bates ER. Percutaneous coronary intervention versus
fibrinolytic therapy in acute myocardial infarction: is timing (almost)
everything? Am J Cardiol 2003;92:824-6.
306.
Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI- 2 Investigators.
A comparison of coronary angioplasty with fibrinolytic therapy in
acute myocardial infarction. N Engl J Med 2003;349:733-42.
307.
Aversano T, Aversano LT, Passamani E, et al, for the Atlantic Cardiovascular
Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs
primary percutaneous coronary intervention for myocardial infarction
in patients presenting to hospitals without on-site cardiac surgery:
a randomized controlled trial. JAMA 2002;287:1943-51.
308.
Angeja BG, Gibson CM, Chin R, et al, for the Participants in the
National Registry of Myocardial Infarction 2-3. Predictors of door-to-balloon
delay in primary angioplasty. Am J Cardiol 2002;89:1156-61.
309.
Henriques JP, Haasdijk AP, Zijlstra F, for the Zwolle Myocardial
Infarction Study Group. Outcome of primary angioplasty for acute
myocardial infarction during routine duty hours versus during off-hours.
J Am Coll Cardiol 2003;41:2138-42.
310.
Spencer FA, Becker RC. Circadian variations in acute myocardial
infarction: patients or health care delivery? J Am Coll Cardiol
2003;41:2143-6.
311.
Armstrong PW, Antman EM. Coronary angioplasty versus fibrinolytic
therapy in acute myocardial infarction. N Engl J Med 2003;349:2167-9;
author reply.
312.
Herrick JB. Landmark article (JAMA 1912): clinical features of sudden
obstruction of the coronary arteries. JAMA 1983;250: 1757-65.
313.
Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda
MI. [Intracoronary administration of fibrinolysin in acute myocardial
infarct.] Ter Arkh 1976;48:8-19.
314.
Aylward PE, Wilcox RG, Horgan JH, et al, for the GUSTO-I Investigators.
Relation of increased arterial blood pressure to mortality and stroke
in the context of contemporary thrombolytic therapy for acute myocardial
infarction: a randomized trial. Ann Intern Med 1996;125:891-900.
315.
Antman EM. General hospital management. In: Julian DG, Braunwald
E, eds. Management of acute myocardial infarction. London, England:
WB Saunders Co Ltd;1994:42-44.
316.
Goldberger AL. Hyperacute T waves revisited. Am Heart J 1982;104:888-90.
317.
Boden WE, Kleiger RE, Gibson RS, et al. Electrocardiographic evolution
of posterior acute myocardial infarction: importance of early precordial
ST-segment depression. Am J Cardiol 1987;59: 782-7.
318.
Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute
myocardial infarction. N Engl J Med 2003;348:933-40.
319.
Zehender M, Kasper W, Kauder E, et al. Eligibility for and benefit
of thrombolytic therapy in inferior myocardial infarction: focus
on the prognostic importance of right ventricular infarction. J
Am Coll Cardiol 1994;24:362-9.
320.
Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral
infarction, and subdural hematoma after acute myocardial infarction
and thrombolytic therapy in the Thrombolysis in Myocardial Infarction
Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and
clinical trial. Circulation 1991; 83:448-59.
321.
Thrombolytic therapy in thrombosis: a National Institutes of Health
consensus development conference. Ann Intern Med 1980; 93:141-4.
322.
Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis:
mortality and functional outcomes in the GUSTO-I trial. Global Use
of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-8.
323.
White HD, Aylward PE, Frey MJ, et al, for the Hirulog Early Reperfusion/Occlusion
(HERO) Trial Investigators. Randomized, double-blind comparison
of hirulog versus heparin in patients receiving streptokinase and
aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-61.
324.
Randomised, double-blind comparison of reteplase double-bolus administration
with streptokinase in acute myocardial infarction (INJECT): trial
to investigate equivalence. International Joint Efficacy Comparison
of Thrombolytics. Lancet 1995;346:329-36.
325.
Giugliano RP, McCabe CH, Antman EM, et al. Lower-dose heparin with
fibrinolysis is associated with lower rates of intracranial hemorrhage.
Am Heart J 2001;141:742-50.
326.
Wienbergen H, Schiele R, Gitt AK, et al, for the Myocardial Infarction
Registry (MIR) and Maximal Individual Therapy in Acute Myocardial
Infarction (MITRA) Study Groups. Incidence, risk factors, and clinical
outcome of stroke after acute myocardial infarction in clinical
practice. Am J Cardiol 2001;87:782-5, A8.
327.
Kandzari DE, Granger CB, Simoons ML, et al, for the Global Utilization
of Streptokinase and tPA for Occluded Arteries-I (GUSTO-I) Investigators.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke
after fibrinolytic therapy (from the GUSTO-I trial). Am J Cardiol
2004;93:458-61.
328.
Gurwitz JH, Gore JM, Goldberg RJ, et al, for the Participants in
the National Registry of Myocardial Infarction 2. Risk for intracranial
hemorrhage after tissue plasminogen activator treatment for acute
myocardial infarction. Ann Intern Med 1998; 129:597-604.
329.
Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment
for intracranial haemorrhage during thrombolytic therapy. Lancet
1993;342:1523-8.
330.
Sloan MA, Guigliano RP, Thompson SL. Prediction of intracranial
hemorrhage in the InTIME-II trial. J Am Coll Cardiol 2001; 37:372A.
331.
Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton
JR. Trial of tissue plasminogen activator for mortality reduction
in acute myocardial infarction. Anglo-Scandinavian Study of Early
Thrombolysis (ASSET). Lancet 1988;2:525-30.
332.
AIMS Trial Study Group. Long-term effects of intravenous anistreplase
in acute myocardial infarction: final report of the AIMS study.
Lancet 1990;335:427-31.
333.
Lamas GA, Flaker GC, Mitchell G, et al, for the Survival and Ventricular
Enlargement Investigators. Effect of infarct artery patency on prognosis
after acute myocardial infarction. Circulation 1995;92:1101-9.
334.
Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, for
the ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. ISIS-2: 10-year survival among patients with suspected acute
myocardial infarction in randomised comparison of intravenous streptokinase,
oral aspirin, both, or neither. BMJ 1998;316:1337-43.
335.
Franzosi MG, Santoro E, De Vita C, et al, for the GISSI Investigators.
Ten-year follow-up of the first megatrial testing thrombolytic therapy
in patients with acute myocardial infarction: results of the Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto-1
study. Circulation 1998;98:2659-65.
336.
Van de Werf F. Thrombolysis for acute myocardial infarction: why
is there no extra benefit after hospital discharge? Circulation
1995;91:2862-4.
337.
Deleted in press.
338.
Gillium BS, Graves EJ, Wood E. National hospital discharge survey:
data from the National Health Survey. Vital and Health Statistics
1998;13:1-51.
339.
White HD. Thrombolytic therapy in the elderly. Lancet 2000; 356:2028-30.
340.
Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe
NR. Lack of benefit for intravenous thrombolysis in patients with
myocardial infarction who are older than 75 years. Circulation 2000;101:2239-46.
341.
Berger AK, Radford MJ, Wang Y, Krumholz HM. Thrombolytic therapy
in older patients. J Am Coll Cardiol 2000;36:366-74.
342.
Stenestrand U, Wallentin L. Fibrinolytic therapy in patients 75
years and older with ST-segment-elevation myocardial infarction:
one-year follow-up of a large prospective cohort. Arch Intern Med
2003;163:965-71.
343.
Ross AM, Coyne KS, Moreyra E, et al, for the GUSTO-I Angiographic
Investigators. Extended mortality benefit of early postinfarction
reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries Trial. Circulation 1998;97:1549-56.
344.
Ross AM, Lundergan CF, Rohrbeck SC, et al, for the GUSTO-1 Angiographic
Investigators. Rescue angioplasty after failed thrombolysis: technical
and clinical outcomes in a large thrombolysis trial. Global Utilization
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries. J Am Coll Cardiol 1998;31:1511-7.
345.
Clements IP, Christian TF, Higano ST, Gibbons RJ, Gersh BJ. Residual
flow to the infarct zone as a determinant of infarct size after
direct angioplasty. Circulation 1993;88:1527-33.
346.
Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical
reperfusion therapy is an independent determinant of survival in
acute myocardial infarction: analysis from the primary angioplasty
in myocardial infarction trials. Circulation 2001; 104:636-41.
347.
Laster SB, O’Keefe JH, Gibbons RJ. Incidence and importance
of thrombolysis in myocardial infarction grade 3 flow after primary
percutaneous transluminal coronary angioplasty for acute myocardial
infarction. Am J Cardiol 1996;78:623-6.
348.
Stone GW, Peterson MA, Lansky AJ, Dangas G, Mehran R, Leon MB. Impact
of normalized myocardial perfusion after successful angioplasty
in acute myocardial infarction. J Am Coll Cardiol 2002;39:591-7.
349.
Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion
grade and ST segment resolution: association with infarct size as
assessed by single photon emission computed tomography imaging.
Circulation 2002;105:282-5.
350.
Gibbons RJ, Miller DD, Liu P, Guo P, Brooks MM, Schwaiger M. Similarity
of ventricular function in patients alive 5 years after randomization
to surgery or angioplasty in the BARI trial. Circulation 2001;103:1076-82.
351.
Rovelli F, De Vita C, Feruglio GA, Lotto A, Selvini A, Tognoni G,
for the Gruppo Italiano per la Sperimentazione della Streptochinasi
nell’Infarto Miocardico. GISSI trial: early results and late
follow-up. J Am Coll Cardiol 1987;10:33B-39B.
352.
Maggioni AP, Franzosi MG, Farina ML, et al, for the Gruppo Italiano
per lo Studio della Streptochinasi nell’Infarto Miocardico
(GISSI). Cerebrovascular events after myocardial infarction: analysis
of the GISSI trial. BMJ 1991;302:1428-31.
353.
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico. GISSI-2: a factorial randomised trial of alteplase versus
streptokinase and heparin versus no heparin among 12,490 patients
with acute myocardial infarction. Lancet 1990;336:65- 71.
354.
The International Study Group. In-hospital mortality and clinical
course of 20,891 patients with suspected acute myocardial infarction
randomised between alteplase and streptokinase with or without heparin.
Lancet 1990;336:71-5.
355.
Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni
G, for the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico II (GISSI-2) and the International Study Group. The risk
of stroke in patients with acute myocardial infarction after thrombolytic
and antithrombotic treatment. N Engl J Med 1992;327:1-6.
356.
De Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage
in association with thrombolytic therapy: incidence and clinical
predictive factors. J Am Coll Cardiol 1992;19:289-94.
357.
ISIS-3 (Third International Study of Infarct Survival) Collaborative
Group. ISIS-3: a randomised comparison of streptokinase vs tissue
plasminogen activator vs anistreplase and of aspirin plus heparin
vs aspirin alone among 41,299 cases of suspected acute myocardial
infarction. Lancet 1992;339:753-70.
358.
Estudio Multicéntrico Estreptoquinasa Repúblicas de
América del Sur (EMERAS) Collaborative Group. Randomised
trial of late thrombolysis in patients with suspected acute myocardial
infarction. Lancet 1993;342:767-72.
359.
The Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO) IIa Investigators. Randomized trial of intravenous heparin
versus recombinant hirudin for acute coronary syndromes. Circulation
1994;90:1631-7.
360.
Sloan MA, Price TR, Terrin ML, et al. Ischemic cerebral infarction
after rt-PA and heparin therapy for acute myocardial infarction:
the TIMI-II pilot and randomized clinical trial combined experience.
Stroke 1997;28:1107-14.
361.
Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton
JR. Effects of alteplase in acute myocardial infarction: 6-month
results from the ASSET study. Anglo-Scandinavian Study of Early
Thrombolysis. Lancet 1990;335:1175-8.
362.
O’Connor CM, Califf RM, Massey EW, et al. Stroke and acute
myocardial infarction in the thrombolytic era: clinical correlates
and long-term prognosis. J Am Coll Cardiol 1990;16:533-40.
363.
Kase CS, Pessin MS, Zivin JA, et al. Intracranial hemorrhage after
coronary thrombolysis with tissue plasminogen activator. Am J Med
1992;92:384-90.
364.
Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis
of intracerebral hemorrhage after rt-PA and heparin therapy for
acute myocardial infarction: the Thrombolysis in Myocardial Infarction
(TIMI) II Pilot and Randomized Clinical Trial combined experience.
Neurology 1995;45:649-58.
365.
Longstreth WT, Litwin PE, Weaver WD, for the MITI Project Group.
Myocardial infarction, thrombolytic therapy, and stroke: a community-based
study. Stroke 1993;24:587-90.
366.
Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase
6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
367.
Vermeer F, Bösl I, Meyer J, et al. Saruplase is a safe and
effective thrombolytic agent; observations in 1,698 patients: results
of the PASS study. Practical Applications of Saruplase Study. J
Thromb Thrombolysis 1999;8:143-50.
368.
Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from
the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis
(HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer
Krankenhausärzte (ALKK) Circulation 1994;90:1638-42.
369.
Antman EM, Giugliano RP, Gibson CM, et al, for the TIMI 14 Investigators.
Abciximab facilitates the rate and extent of thrombolysis: results
of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation
1999;99:2720-32.
370.
The National Institute of Neurological Disorders and Stroke (NINDS)
rt-PA Stroke Study Group. A systems approach to immediate evaluation
and management of hyperacute stroke: experience at eight centers
and implications for community practice and patient care. Stroke
1997;28:1530-40.
371.
Broderick JP, Adams HP, Barsan W, et al. Guidelines for the management
of spontaneous intracerebral hemorrhage: a statement for healthcare
professionals from a special writing group of the Stroke Council,
American Heart Association. Stroke 1999;30:905- 15.
372.
Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial
hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1
trial with clinical correlation. Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Stroke 1998;29:563-9.
373.
Gebel JM, Sila CA, Sloan MA, et al. Comparison of the ABC/2 estimation
technique to computer-assisted volumetric analysis of intraparenchymal
and subdural hematomas complicating the GUSTO-1 trial. Stroke 1998;29:1799-801.
374.
Sane DC, Califf RM, Topol EJ, Stump DC, Mark DB, Greenberg CS. Bleeding
during thrombolytic therapy for acute myocardial infarction: mechanisms
and management. Ann Intern Med 1989; 111:1010-22.
375.
Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation
of intracranial hemorrhage after thrombolytic therapy for acute
myocardial infarction: experience from the GUSTO-I trial. Global
Utilization of Streptokinase and tissue-plasminogen activator (tPA)
for Occluded Coronary Arteries. Am Heart J 1999;138:493-9.
376.
Sloan MA. Neurologic complications of thrombolytic therapy. In:
Biller J, ed. Iatrogenic neurology. Boston, MA: Butterworth Heinemann;
1997:335-78.
377.
Sloan MA, Sila CA, Mahaffey KW, et al. Prediction of 30-day mortality
among patients with thrombolysis-related intracranial hemorrhage.
Circulation 1998;98:1376-82.
378.
The thrombolytic agent. In: Sherry S, ed. Fibrinolysis, thrombosis,
and hemostasis: concepts, perspectives, and clinical applications.
Philadelphia, PA: Lea & Febiger; 1992:119-60.
379.
Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction:
current status and new horizons for pharmacological reperfusion,
part 1. Circulation 2001;103:2862-6.
380.
Cannon CP, Gibson CM, McCabe CH, et al, for the Thrombolysis in
Myocardial Infarction (TIMI) 10B Investigators. TNK-tissue plasminogen
activator compared with front-loaded alteplase in acute myocardial
infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-14.
381.
Mosby’s Drug Consult 2004 Internet Subscription, 8th ed. Elsevier,
2003. Available at http://www.mosbysdrugconsult.com. Accessed February
27, 2004.
382.
Antman EM. Hirudin in acute myocardial infarction: Thrombolysis
and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
Circulation 1996;94:911-21.
383.
The Global Use of Strategies to Open Occluded Coronary Arteries
(GUSTO) IIb investigators. A comparison of recombinant hirudin with
heparin for the treatment of acute coronary syndromes. N Engl J
Med 1996;335:775-82.
384.
Martin GV, Kennedy JW. Choice of thrombolytic agent. In: Julian
DG, Braunwald E, eds. Management of acute myocardial infarction.
London, England: WB Saunders Co Ltd; 1994:71-105.
385.
Fuster V. Coronary thrombolysis: a perspective for the practicing
physician. N Engl J Med 1993;329:723-5.
386.
Simoons ML, Arnold AE. Tailored thrombolytic therapy: a perspective.
Circulation 1993;88:2556-64.
387. White HD. Selecting a thrombolytic agent.
Cardiol Clin 1995; 13:347-54.
388.
French JK,Williams BF, Hart HH, et al. Prospective evaluation of
eligibility for thrombolytic therapy in acute myocardial infarction.
BMJ 1996;312:1637-41.
389.
Hillis LD, Forman S, Braunwald E, for the Thrombolysis in Myocardial
Infarction (TIMI) Phase II Co-Investigators. Risk stratification
before thrombolytic therapy in patients with acute myocardial infarction.
J Am Coll Cardiol 1990;16:313-5.
390.
Normand ST, Glickman ME, Sharma RG, McNeil BJ. Using admission characteristics
to predict short-term mortality from myocardial infarction in elderly
patients: results from the Cooperative Cardiovascular Project. JAMA
1996;275:1322-8.
391.
Becker RC, Burns M, Gore JM, et al, for the National Registry of
Myocardial Infarction (NRMI-2) Participants. Early assessment and
in-hospital management of patients with acute myocardial infarction
at increased risk for adverse outcomes: a nationwide perspective
of current clinical practice. Am Heart J 1998;135:786- 96.
392.
Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development
and validation of the Ontario acute myocardial infarction mortality
prediction rules. J Am Coll Cardiol 2001; 37:992-7.
393.
Jacobs DR, Kroenke C, Crow R, et al. PREDICT: a simple risk score
for clinical severity and long-term prognosis after hospitalization
for acute myocardial infarction or unstable angina: the Minnesota
heart survey. Circulation 1999;100:599-607.
394.
Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI
risk score for ST-elevation MI in the National Registry of Myocardial
Infarction 3. JAMA 2001;286:1356-9.
395.
Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial
perfusion grade to mortality after administration of thrombolytic
drugs. Circulation 2000;101:125-30.
395a.
Holper EM, Giugliano RP, Antman EM. Glycoprotein IIb/IIIa inhibitors
in acute ST-segment myocardial infarction. Coron Artery Dis 1999;10:567-73.
396.
Strategies for Patency Enhancement in the Emergency Department (SPEED)
Group. Trial of abciximab with and without low-dose reteplase for
acute myocardial infarction. Circulation 2000;101:2788-94.
397.
Brener SJ, Zeymer U, Adgey AA, et al. Eptifibatide and low-dose
tissue plasminogen activator in acute myocardial infarction: the
integrilin and low-dose thrombolysis in acute myocardial infarction
(INTRO AMI) trial. J Am Coll Cardiol 2002;39:377-86.
398.
Savonitto S, Armstrong PW, Lincoff AM, et al. Risk of intracranial
haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa
inhibitor therapy in acute myocardial infarction: dichotomous response
as a function of age in the GUSTO V trial. Eur Heart J 2003;24:1807-14.
399.
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa
inhibition and reduced-dose fibrinolytic therapy vs conventional
fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized
trial. JAMA 2002;288:2130-5.
400.
Antman EM, Gibson CM, de Lemos JA, et al, for the Thrombolysis in
Myocardial Infarction (TIMI) 14 Investigators. Combination reperfusion
therapy with abciximab and reduced dose reteplase: results from
TIMI 14. Eur Heart J 2000;21:1944- 53.
401.
Primary coronary angioplasty compared with intravenous thrombolytic
therapy for acute myocardial infarction: six-month follow up and
analysis of individual patient data from randomized trials. Am Heart
J 2003;145:47-57.
402.
Wilson SH, Bell MR, Rihal CS, Bailey KR, Holmes DR, Berger PB. Infarct
artery reocclusion after primary angioplasty, stent placement, and
thrombolytic therapy for acute myocardial infarction. Am Heart J
2001;141:704-10.
403.
Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of
immediate revascularization of acute ST-segment elevation myocardial
infarction in patients with contraindications to thrombolytic therapy:
a propensity analysis. JAMA 2003;290:1891-8.
404.
Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata
H. A comparison of immediate coronary angioplasty with intravenous
streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-4.
405.
Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct
coronary angioplasty versus intravenous streptokinase in acute myocardial
infarction. J Am Coll Cardiol 1993;22:376-80.
406.
Grinfeld L, Berrocal D, Bellardi J, et al. Fibrinolytics versus
pri-mary angioplasty in acute myocardial infarction (FAP): a randomized
trial in a community hospital in Argentina. J Am Coll Cardiol 1996;27:A222.
407.
Zijlstra F, Beukema WP, van’t Hof AW, et al. Randomized comparison
of primary coronary angioplasty with thrombolytic therapy in low
risk patients with acute myocardial infarction. J Am Coll Cardiol
1997;29:908-12.
408. Widimský P, Groch L, Zelízko
M, Aschermann M, Bednár F, Suryapranata H. Multicentre randomized
trial comparing transport to primary angioplasty vs immediate thrombolysis
vs combined strategy for patients with acute myocardial infarction
presenting to a community hospital without a catheterization laboratory.
The PRAGUE study. Eur Heart J 2000;21:823-31.
409.
de Boer MJ, Ottervanger JP, van’t Hof AW, Hoorntje JC, Suryapranata
H, Zijlstra F, for the Zwolle Myocardial Infarction Study Group.
Reperfusion therapy in elderly patients with acute myocardial infarction:
a randomized comparison of primary angioplasty and thrombolytic
therapy. J Am Coll Cardiol 2002;39:1723-8.
410. Akhras F, Ousa AA, Swann G, et al . Primary
coronary angioplasty or intravenous thrombolysis for patients with
acute myocardial infarction? Acute and late follow-up results in
a new cardiac unit [abstr]. J Am Coll Cardiol 1997;29:A235-6.
411.
Deleted in press.
412.
Grines CL, Browne KF, Marco J, et al, for the Primary Angioplasty
in Myocardial Infarction Study Group. A comparison of immediate
angioplasty with thrombolytic therapy for acute myocardial infarction.
N Engl J Med 1993;328:673-9.
413.
Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh
BJ, for the Mayo Coronary Care Unit and Catheterization Laboratory
Groups. Immediate angioplasty compared with the administration of
a thrombolytic agent followed by conservative treatment for myocardial
infarction. N Engl J Med 1993;328:685-91.
414.
Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic
therapy and primary coronary angioplasty with liberal stenting for
inferior myocardial infarction with precordial STsegment depression:
immediate and long-term results of a randomized study. J Am Coll
Cardiol 1998;32:1687-94.
415.
García E, Elízaga J, Pérez-Castellano N, et
al. Primary angioplasty versus systemic thrombolysis in anterior
myocardial infarction. J Am Coll Cardiol 1999;33:605-11.
416.
The Global Use of Strategies to Open Occluded Coronary Arteries
in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators.
A clinical trial comparing primary coronary angioplasty with tissue
plasminogen activator for acute myocardial infarction. N Engl J
Med 1997;336:1621-8.
417.
Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis
in acute myocardial infarction trial (STAT). J Am Coll Cardiol 2001;37:985-91.
418.
Schömig A, Kastrati A, Dirschinger J, et al, for the Stent
versus Thrombolysis for Occluded Coronary Arteries in Patients with
Acute Myocardial Infarction Study Investigators. Coronary stenting
plus platelet glycoprotein IIb/IIIa blockade compared with tissue
plasminogen activator in acute myocardial infarction. N Engl J Med
2000;343:385-91.
419.
Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised
comparison between thrombolysis, rescue PTCA, and primary PTCA in
patients with extensive myocardial infarction admitted to a hospital
without PTCA facilities: a safety and feasibility study. Heart 1999;82:426-31.
420.
Myocardial salvage after coronary stenting plus abciximab versus
fibrinolysis plus abciximab in patients with acute myocardial infarction:
a randomised trial. Lancet 2002;359:920-5.
421.
Grines CL, Westerhausen DR Jr, Grines LL,, et al, for the Air PAMI
Study Group. A randomized trial of transfer for primary angioplasty
versus on-site thrombolysis in patients with high-risk myocardial
infarction: the Air Primary Angioplasty in Myocardial Infarction
study. J Am Coll Cardiol 2002;39:1713-9.
421a.Melandri
G. The obsession with primary angioplasty. Circulation 2003;108:e162.
422.
Rogers WJ, Dean LS, Moore PB, Wool KJ, Burgard SL, Bradley EL, for
the Alabama Registry of Myocardial Ischemia Investigators. Comparison
of primary angioplasty versus thrombolytic therapy for acute myocardial
infarction. Am J Cardiol 1994;74:111-8.
423. Every NR, Parsons LS, Hlatky M, Martin JS,Weaver
WD, for the Myocardial Infarction Triage and Intervention Investigators.
A comparison of thrombolytic therapy with primary coronary angioplasty
for acute myocardial infarction. N Engl J Med 1996;335: 1253-60.
424.
Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical
experience with primary percutaneous transluminal coronary angioplasty
compared with alteplase (recombinant tissuetype plasminogen activator)
in patients with acute myocardial infarction: a report from the
Second National Registry of Myocardial Infarction (NRMI-2). J Am
Coll Cardiol 1998;31: 1240-5.
425.
Danchin N, Vaur L, Genès N, et al. Treatment of acute myocardial
infarction by primary coronary angioplasty or intravenous thrombolysis
in the “real world”: one-year results from a nationwide
French survey. Circulation 1999;99:2639-44.
426.
Stone GW, Grines CL, Browne KF, et al. Influence of acute myocardial
infarction location on in-hospital and late outcome after primary
percutaneous transluminal coronary angioplasty versus tissue plasminogen
activator therapy. Am J Cardiol 1996;78:19-25.
427.
van’t Hof AW, Henriques J, Ottervanger J-P, et al. No mortality
benefit of primary angioplasty over thrombolytic therapy in patients
with nonanterior myocardial infarction at long-term follow- up:
results of the Zwolle trial [abstr]. J Am Coll Cardiol 2003;41:369A.
428.
Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion
before intervention on outcomes after primary angioplasty for acute
myocardial infarction. Am J Cardiol 2000;85:13- 8.
429.
Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality
of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis
In Myocardial Infarction (TIMI) time. Am J Cardiol 2003;91:1401-5.
430.
Ellis S. Elective coronary intervention: approach, technique, and
complications. In: Topol EJ, ed. Textbook of interventional cardiology,
4th ed., Philadelphia, PA:WB Saunders Co Ltd; 2003:163- 181.
431. Levine GN, Kern MJ, Berger PB, et al, for
the American Heart Association Diagnostic and Interventional Catheterization
Committee and Council on Clinical Cardiology. Management of patients
undergoing percutaneous coronary revascularization. Ann Intern Med
2003;139:123-36.
432.
Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous
coronary intervention (revision of the 1993 PTCA guidelines): a
report of the American College of Cardiology/ American Heart Association
Task Force on Practice Guidelines (Committee to Revise the 1993
Guidelines for Percutaneous Transluminal Coronary Angioplasty).
Available at http://www.acc.org/clinical/guidelines/percutaneous/dirIndex.ht,
2001. Accessed December 16, 2003.
433.
Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with
acute myocardial infarction who are ineligible for thrombolytic
therapy. Ann Intern Med 1991;115:173-7.
434.
Brodie BR,Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary
angioplasty for acute myocardial infarction in candidates and non-candidates
for thrombolytic therapy. Am J Cardiol 1991;67:7-12.
435. Himbert D, Juliard JM, Steg PG, et al. Primary
coronary angioplasty for acute myocardial infarction with contraindication
to thrombolysis. Am J Cardiol 1993;71:377-81.
436. Zahn R, Schuster S, Schiele R, et al, for
the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA)
Study Group. Comparison of primary angioplasty with conservative
therapy in patients with acute myocardial infarction and contraindications
for thrombolytic therapy. Catheter Cardiovasc Interv 1999;46:127-33.
437.
Iannone LA, Anderson SM, Phillips SJ. Coronary angioplasty for acute
myocardial infarction in a hospital without cardiac surgery. Tex
Heart Inst J 1993;20:99-104.
438.
Weaver WD, Litwin PE, Martin JS, for the Myocardial Infarction,
Triage, and Intervention Project Investigators. Use of direct angioplasty
for treatment of patients with acute myocardial infarction in hospitals
with and without on-site cardiac surgery. Circulation 1993;88:2067-75.
439.
Weaver WD, Parsons L, Every N, for the MITI project investigators.
Primary coronary angioplasty in hospitals with and without surgery
backup. J Invasive Cardiol 1995;7:34F-39F.
440.
Brush JE, Thompson S, Ciuffo AA, et al. Retrospective comparison
of a strategy of primary coronary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction in a community
hospital without cardiac surgical backup. J Invasive Cardiol 1996;8:91-98.
441.
Moquet B, Huguet RG, Cami G, et al. [Primary angioplasty in acute
myocardial infarction: a one-year experience in a small urban community.]
Arch Mal Coeur Vaiss 1997;90:11-5.
442. Smyth DW, Richards AM, Elliott JM. Direct
angioplasty for myocardial infarction: one-year experience in a
center with surgical back-up 220 miles away. J Invasive Cardiol
1997;9:324-332.
443.
Ribichini F. Experiences with primary angioplasty without on site-cardiac
surgery. Semin Interv Cardiol 1999;4:47-53.
444.
Primary Angioplasty in Acute Myocardial Infarction at Hospitals
With No Surgery On-Site (the PAMI-No SOS study) versus transfer
to surgical centers for primary angioplasty. J Am Coll Cardiol 2004;43:1943-50.
445.
Wharton TP, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk
EJ. Primary angioplasty for the treatment of acute myocardial infarction:
experience at two community hospitals without cardiac surgery. J
Am Coll Cardiol 1999;33:1257-65.
446.
Singh M, Garratt KN, Lennon RJ, et al. Emergent angioplasty for
acute myocardial infarction at a community hospital without onsite
cardiac surgery [abstr]. J Am Coll Cardiol 2002;39:40A.
447. Sanborn TA, Jacobs AK, Frederick PD, Every
NR, French WJ. Nationwide emergent coronary interventions (primary
PCI) in patients with acute myocardial infarction in hospitals with
and without on-site cardiac surgery: a report from the National
Registry of Myocardial Infarction (NRMI) [abstr]. Circulation 2002;106:II-333.
448. Aversano T. Primary angioplasty at hospitals
without cardiac surgery: C-PORT Registry outcomes [abstr]. Circulation
2003;108:IV-613.
449.
Singh M, Ting HH, Berger PB, Garratt KN, Holmes DR, Gersh BJ. Rationale
for on-site cardiac surgery for primary angioplasty: a time for
reappraisal. J Am Coll Cardiol 2002;39:1881-9.
450.
Kutcher MA, Klein LW, Wharton TP, et al. Clinical outcomes coronary
angioplasty centers with off-site versus on-site cardiac surgery
capabilities: a preliminary report from the American College of
Cardiology—National Cardiovascular Data Registry [abstr].
J Am Coll Cardiol 2004;43:96a.
451.
Deleted in press.
452.
Lotfi M, Mackie K, Dzavik V, Seidelin PH. Impact of delays cardiac
surgery after failed angioplasty and stenting. J Am Coll Cardiol
2004;43:337-42.
453.
Dehmer GJ, Gantt DS. Coronary intervention at hospitals without
on-site cardiac surgery: are we pushing the envelope too far? J
Am Coll Cardiol 2004;43:343-5.
454.
Zijlstra F, van’t Hof AW, Liem AL, Hoorntje JC, Suryapranata
de Boer MJ. Transferring patients for primary angioplasty: a retrospective
analysis of 104 selected high-risk patients with acute myocardial
infarction. Heart 1997;78:333-6.
455.
Zahn R, Schiele R, Seidl K, et al. Primary angioplasty in acute
myocardial infarction: differences between referred patients and
those treated in hospitals with on-site facilities? J Invasive Cardiol
1999;11:213-219.
456.
Straumann E, Yoon S, Naegeli B, et al. Hospital transfer for primary
coronary angioplasty in high-risk patients with acute myocardial
infarction. Heart 1999;82:415-9.
457.
Liem AL, van ‘t Hof AW, Hoorntje JC, de Boer MJ, Suryapranata
H, Zijlstra F. Influence of treatment delay on infarct size and
clinical outcome in patients with acute myocardial infarction treated
with primary angioplasty. J Am Coll Cardiol 1998;32:629-33.
458.
NRMI-4 Investigators: The National Registry of Myocardial Infarction-4
Quarterly Report. Genentech, South San Francisco, CA, March 2003:2.
459. Deleted in press.
460.
Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini
PF. A clinical trial comparing primary stenting of the infarct-related
artery with optimal primary angioplasty for acute myocardial infarction:
results from the Florence Randomized Elective Stenting in Acute
Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-9.
461.
Rodríguez A, Bernardi V, Fernández M, et al. In-hospital
and late results of coronary stents versus conventional balloon
angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin
in Acute Myocardial Infarction. Am J Cardiol 1998;81:1286-91.
462. Suryapranata H, Ottervanger JP, Nibbering
E, et al. Long term outcome and cost-effectiveness of stenting versus
balloon angioplasty for acute myocardial infarction. Heart 2001;85:667-71.
463.
Saito S, Hosokawa G, Tanaka S, Nakamura S, for the PASTA Trial Investigators.
Primary stent implantation is superior to balloon angioplasty in
acute myocardial infarction: final results of the primary angioplasty
versus stent implantation in acute myocardial infarction (PASTA)
trial. Catheter Cardiovasc Interv 1999; 48:262-8.
464.
Grines CL, Cox DA, Stone GW, et al, for the Stent Primary Angioplasty
in Myocardial Infarction Study Group. Coronary angioplasty with
or without stent implantation for acute myocardial infarction. N
Engl J Med 1999;341:1949-56.
465.
Kawashima A, Ueda K, Nishida Y, et al. Quantitative angiographic
analysis of restenosis of primary stenting using Wiktor stent for
acute myocardial infarction: results from a multicenter randomised
PRISAM study [abstr]. Circulation 1999;100:I-856.
466.
Maillard L, Hamon M, Khalife K, et al, for the STENTIM-2 Investigators.
A comparison of systematic stenting and conventional balloon angioplasty
during primary percutaneous transluminal coronary angioplasty for
acute myocardial infarction. J Am Coll Cardiol 2000;35:1729-36.
467.
Scheller B, Hennen B, Severin-Kneib S, Ozbek C, Schieffer H, Markwirth
T. Long-term follow-up of a randomized study of primary stenting
versus angioplasty in acute myocardial infarction. Am J Med 2001;110:1-6.
468. Lemos PA, Saia F, Hofma SH, et al. Short-
and long-term clinical benefit of sirolimus-eluting stents compared
to conventional bare stents for patients with acute myocardial infarction.
J Am Coll Cardiol 2004;43:704-8.
469. Gibson CM. A union in reperfusion: the concept
of facilitated percutaneous coronary intervention. J Am Coll Cardiol
2000;36: 1497-9.
470.
Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early
percutaneous coronary intervention after reteplase with or without
abciximab in acute myocardial infarction: results from the SPEED
(GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489- 96.
471.
Ross AM, Coyne KS, Reiner JS, et al, for the Plasminogen-activator
Angioplasty Compatibility Trial (PACT) investigators. A randomized
trial comparing primary angioplasty with a strategy of short-acting
thrombolysis and immediate planned rescue angioplasty in acute myocardial
infarction: the PACT trial. J Am Coll Cardiol 1999;34:1954-62.
472.
Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Prospective
randomized trial comparing a routine invasive strategy within 24
hours to thrombolysis versus an ischemia-guided conservative approach
to acute myocardial infarction with ST-segment elevation: the Gracia-1
trial. Lancet. In press. 473. Kastrati A, Mehilli J, Schlotterbeck
K, et al, for the Bavarian Reperfusion Alternatives Evaluation (BRAVE)
Study Investigators. Early administration of reteplase plus abciximab
vs abciximab alone in patients with acute myocardial infarction
referred for percutaneous coronary intervention: a randomized controlled
trial. JAMA. 2004;291:947-54.
473a.
Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous
coronary intervention versus primary percutaneous coronary intervention:
design and rationale of the Facilitated Intervention with Enhanced
Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 2004;147:E16.
474.
Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis
of coronary arterial patency and left ventricular function after
intravenous thrombolysis for acute myocardial infarction. Am J Cardiol
1994;74:1220-8.
475.
Lange RA, Cigarroa RG, Wells PJ, Kremers MS, Hills LD. Influence
of anterograde flow in the infarct artery on the incidence of late
potentials after acute myocardial infarction. Am J Cardiol 1990;65:554-8.
476.
Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial
infarction in patients with and without residual anterograde coronary
blood flow. Am J Cardiol 1989;64:155-60.
477. Ellis SG, da Silva ER, Heyndrickx G, et al.
Randomized comparison of rescue angioplasty with conservative management
of patients with early failure of thrombolysis for acute anterior
myocardial infarction. Circulation 1994;90:2280-4.
478. Goldman LE, Eisenberg MJ. Identification
and management of patients with failed thrombolysis after acute
myocardial infarction. Ann Intern Med 2000;132:556-65.
479.
The TIMI Research Group. Immediate vs delayed catheterization and
angioplasty following thrombolytic therapy for acute myocardial
infarction: TIMI II A results. JAMA 1988;260:2849-58.
480. Topol EJ, Califf RM, George BS, et al. A
randomized trial of immediate versus delayed elective angioplasty
after intravenous tissue plasminogen activator in acute myocardial
infarction. N Engl J Med 1987;317:581-8.
481.
Califf RM, Topol EJ, Stack RS, et al, for the TAMI Study Group.
Evaluation of combination thrombolytic therapy and timing of cardiac
catheterization in acute myocardial infarction: results of thrombolysis
and angioplasty in myocardial infarction: phase 5 randomized trial.
Circulation 1991;83:1543-56.
482.
Califf RM, Topol EJ, George BS, et al. Characteristics and outcome
of patients in whom reperfusion with intravenous tissuetype plasminogen
activator fails: results of the Thrombolysis and Angioplasty in
Myocardial Infarction (TAMI) I trial. Circulation 1988;77:1090-9.
483.
Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O’Neill WW.
Percutaneous transluminal coronary angioplasty improves survival
in acute myocardial infarction complicated by cardiogenic shock.
Circulation 1988;78:1345-51.
484.
Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF, Harris PJ. Infarct
artery perfusion and changes in left ventricular volume in the month
after acute myocardial infarction. J Am Coll Cardiol 1987;9:989-95.
485.
Kersschot IE, Brugada P, Ramentol M, et al. Effects of early reperfusion
in acute myocardial infarction on arrhythmias induced by programmed
stimulation: a prospective, randomized study. J Am Coll Cardiol
1986;7:1234-42.
486.
Stadius ML, Davis K, Maynard C, Ritchie JL, Kennedy JW. Risk stratification
for 1-year survival based on characteristics identified in the early
hours of acute myocardial infarction. The Western Washington Intracoronary
Streptokinase Trial. Circulation 1986;74:703-11.
487.
Topol EJ, Califf RM, Vandormael M, et al, for the Thrombolysis and
Angioplasty in Myocardial Infarction-6 Study Group. A randomized
trial of late reperfusion therapy for acute myocardial infarction.
Circulation 1992;85:2090-9.
488.
Dzavik V, Beanlands DS, Davies RF, et al. Effects of late percutaneous
transluminal coronary angioplasty of an occluded infarctrelated
coronary artery on left ventricular function in patients with a
recent (less than 6 weeks) Q-wave acute myocardial infarction (Total
Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]:
a pilot study). Am J Cardiol 1994;73:856-61.
489.
Zeymer U, Uebis R, Vogt A, et al, for the ALKK-Study Group. Randomized
comparison of percutaneous transluminal coronary angioplasty and
medical therapy in stable survivors of acute myocardial infarction
with single vessel disease: a study of the Arbeitsgemeinschaft Leitende
Kardiologische Krankenhausärzte. Circulation 2003;108:1324-8.
490.
Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect
of late reperfusion for acute anterior myocardial infarction with
percutaneous transluminal coronary angioplasty. Circulation 1998;98:2377-82.
491.
Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention
after anterior myocardial infarction: effects on left ventricular
size, function, quality of life, and exercise tolerance: results
of the Open Artery Trial (TOAT Study). J Am Coll Cardiol 2002;40:869-76.
492.
Deleted in press.
493.
Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis:
a decade later. Am Heart J 2001;142:411-21.
494. Hochman JS, Boland J, Sleeper LA, et al,
for the SHOCK Registry Investigators. Current spectrum of cardiogenic
shock and effect of early revascularization on mortality: results
of an international registry. Circulation 1995;91:873-81.
495.
Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of
early revascularization to treat shock complicating acute myocardial
infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH.
Eur Heart J 1999;20:1030-8.
496.
Dzavik V, Sleeper LA, Cocke TP, et al, for the SHOCK Investigators.
Early revascularization is associated with improved survival in
elderly patients with acute myocardial infarction complicated by
cardiogenic shock: a report from the SHOCK trial registry. Eur Heart
J 2003;24:828-37.
497.
Dauerman HL, Goldberg RJ, Malinski M,Yarzebski J, Lessard D, Gore
JM. Outcomes and early revascularization for patients greater than
or equal to 65 years of age with cardiogenic shock. Am J Cardiol
2001;87:844-8.
498. Dauerman HL, Ryan TJ, Piper WD, et al. Outcomes
of percutaneous coronary intervention among elderly patients in
cardiogenic shock: a multicenter, decade-long experience. J Invasive
Cardiol 2003;15:380-4.
499.
Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term
mortality benefit with the combination of stents and abciximab for
cardiogenic shock complicating acute myocardial infarction. Am J
Cardiol 2002;89:132-6.
500.
Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous
transluminal coronary angioplasty plus abciximab with or without
stenting for acute myocardial infarction complicated by cardiogenic
shock. Am J Cardiol 2002;89:126-31.
501.
Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy
improves survival in patients with acute myocardial infarction complicated
by early cardiogenic shock undergoing coronary artery stent implantation.
Am J Cardiol 2002;90:353-7.
502.
Hochman JS. Cardiogenic shock complicating acute myocardial infarction:
expanding the paradigm. Circulation 2003;107:2998- 3002.
503.
Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue
plasminogen activator in acute myocardial infarction: no additional
benefit from immediate percutaneous coronary angioplasty. Lancet
1988;1:197-203.
504. Scheller B, Hennen B, Hammer B, et al, for
the SIAM III Study Group. Beneficial effects of immediate stenting
after thrombolysis in acute myocardial infarction. J Am Coll Cardiol
2003; 42:634-41.
505.
Should We Intervene Following Thrombolysis? (SWIFT) Trial Study
Group. SWIFT trial of delayed elective intervention vs conservative
treatment after thrombolysis with anistreplase in acute myocardial
infarction. BMJ 1991;302:555-60.
506.
Williams DO, Braunwald E, Knatterud G, et al. One-year results of
the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase
II Trial. Circulation 1992;85:533-42.
507.
Terrin ML,Williams DO, Kleiman NS, et al. Two- and three-year results
of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical
trial. J Am Coll Cardiol 1993;22:1763-72.
508.
Stenestrand U, Wallentin L. Early revascularisation and 1-year survival
in 14-day survivors of acute myocardial infarction: a prospective
cohort study. Lancet 2002;359:1805-11.
509.
Alter DA, Tu JV, Austin PC, Naylor CD. Waiting times, revascularization
modality, and outcomes after acute myocardial infarction at hospitals
with and without on-site revascularization facilities in Canada.
J Am Coll Cardiol 2003;42:410-9.
510.
Zeymer U, Uebis R, Vogt A, et al, for the ALKK-Study Group. Randomized
comparison of percutaneous transluminal coronary angioplasty and
medical therapy in stable survivors of acute myocardial infarction
with single-vessel disease: a study of the Arbeitsgemeinschaft Leitende
Kardiologische Krankenhausärzte. Circulation 2003;108:1324-8.
511.
Gupta M, Chang WC, Van de Werf F, et al, for the ASSENT II Investigators.
International differences in in-hospital revascularization and outcomes
following acute myocardial infarction: a multilevel analysis of
patients in ASSENT-2. Eur Heart J 2003; 24:1640-50.
512. Gibson CM, Karha J, Murphy SA, et al, for
the TIMI Study Group. Early and long-term clinical outcomes associated
with reinfarction following fibrinolytic administration in the thrombolysis
in myocardial infarction trials. J Am Coll Cardiol 2003;42:7- 16.
513.
Deleted in press.
514.
Deleted in press.
515.
Madsen JK, Grande P, Saunamäki K, et al. Danish multicenter
randomized study of invasive versus conservative treatment in patients
with inducible ischemia after thrombolysis in acute myocardial infarction
(DANAMI). DANish trial in Acute Myocardial Infarction. Circulation
1997;96:748-55.
516.
Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of
late in-hospital angiography and angioplasty versus conservative
management after treatment with recombinant tissue-type plasminogen
activator in acute myocardial infarction. Am J Cardiol 1990;66:538-45.
517.
Ellis SG, Mooney MR, George BS, et al, for the Treatment of Post-Thrombolytic
Stenoses (TOPS) Study Group. Randomized trial of late elective angioplasty
versus conservative management for patients with residual stenoses
after thrombolytic treatment of myocardial infarction. Circulation
1992;86:1400-6.
518.
Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update
for coronary artery bypass graft surgery: a report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee to Revise the 1999 Guidelines for Coronary
Artery Bypass Graft Surgery). J Am Coll Cardiol In press.
519.
Deleted in press.
520.
Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical
and medical group survival in patients with left main coronary artery
disease: long-term CASS experience. Circulation 1995;91:2325-34.
521.
Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison
of 15-year survival for men and women after initial medical or surgical
treatment for coronary artery disease: a CASS registry study. Coronary
Artery Surgery Study. J Am Coll Cardiol 1995;25:1000-9.
522.
Stone GW, Brodie BR, Griffin JJ, et al. Role of cardiac surgery
in the hospital phase management of patients treated with primary
angioplasty for acute myocardial infarction. Am J Cardiol 2000;85:1292-6.
523.
Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating
acute myocardial infarction: etiologies, management and outcome:
a report from the SHOCK Trial Registry. SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000;36:1063-70.
524.
Hochman JS, Gersh B. Acute myocardial infarction. In: Topol EJ,
ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven
Publishers; 1998:421-62.
525.
DeBusk RF. Specialized testing after recent acute myocardial infarction.
Ann Intern Med 1989;110:470-81.
526.
Holmes DR, Bates ER, Kleiman NS, et al, for the Global Utilization
of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-I) Investigators. Contemporary reperfusion therapy
for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol
1995;26:668-74.
527.
de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing
the efficacy of reperfusion therapy. J Am Coll Cardiol 2001;38:1283-94.
528. Matetzky S, Novikov M, Gruberg L, et al.
The significance of persistent ST elevation versus early resolution
of ST segment elevation after primary PTCA. J Am Coll Cardiol 1999;34:1932-8.
529. Schröder R, Dissmann R, Brüggemann
T, et al. Extent of early ST segment elevation resolution: a simple
but strong predictor of outcome in patients with acute myocardial
infarction. J Am Coll Cardiol 1994;24:384-91.
530.
Fu Y, Goodman S, Chang WC, Van De Werf F, Granger CB, Armstrong
PW. Time to treatment influences the impact of STsegment resolution
on one-year prognosis: insights from the assessment of the safety
and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation
2001;104:2653-9.
531.
de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both
epicardial flow and myocardial reperfusion in STelevation myocardial
infarction: observations from the TIMI 14 trial. Circulation 2000;101:239-43.
532.
Santoro GM, Antoniucci D, Valenti R, et al. Rapid reduction of ST-segment
elevation after successful direct angioplasty in acute myocardial
infarction. Am J Cardiol 1997;80:685-9.
533.
Antman EM. The search for replacements for unfractionated heparin.
Circulation 2001;103:2310-4.
534. Eisenberg PR. Role of heparin in coronary
thrombolysis. Chest 1992;101:131S-139S.
535.
Rao AK, Pratt C, Berke A, Jaffe A, et al. Thrombolysis in Myocardial
Infarction (TIMI) Trial: phase I–hemorrhagic manifestations
and changes in plasma fibrinogen and the fibrinolytic system in
patients treated with recombinant tissue plasminogen activator and
streptokinase. J Am Coll Cardiol 1988;11:1-11.
536.
Popma JJ, Califf RM, Ellis SG, et al. Mechanism of benefit of combination
thrombolytic therapy for acute myocardial infarction: a quantitative
angiographic and hematologic study. J Am Coll Cardiol 1992;20:1305-12.
537.
Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic
therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847-60.
538.
The GUSTO Angiographic Investigators. The effects of tissue plasminogen
activator, streptokinase, or both on coronary-artery patency, ventricular
function, and survival after acute myocardial infarction. N Engl
J Med 1993;329:1615-22.
539.
Col J, Decoster O, Hanique G, Deligne B, Boland J, Pirenne B. Infusion
of heparin conjunct to streptokinase accelerates reperfusion of
acute myocardial infarction: results of a double-blind randomized
study (OSIRIS). Circulation 1992;86:259.
540.
Melandri G, Branzi A, Semprini F, Cervi V, Galiè N, Magnani
B. Enhanced thrombolytic efficacy and reduction of infarct size
by simultaneous infusion of streptokinase and heparin. Br Heart
J 1990;64:118-20.
541.
White HD,Yusuf S. Issues regarding the use of heparin following
streptokinase therapy. J Thromb Thrombolysis 1995;2:5-10.
542.
Simoons M, Krzeminska-Pakula M, Alonso A, et al, for the AMISK Investigators.
Improved reperfusion and clinical outcome with enoxaparin as an
adjunct to streptokinase thrombolysis in acute myocardial infarction:
the AMI-SK study. Eur Heart J 2002;23:1282-90.
543.
Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman
SL. Effect of heparin on coronary arterial patency after thrombolysis
with tissue plasminogen activator in acute myocardial infarction.
Am J Cardiol 1990;66:1412-7.
544. de Bono DP, Simoons ML, Tijssen J, et al.
Effect of early intravenous heparin on coronary patency, infarct
size, and bleeding complications after alteplase thrombolysis: results
of a randomised double-blind European Cooperative Study Group trial.
Br Heart J 1992;67:122-8.
545.
Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM,
for the Heparin-Aspirin Reperfusion Trial (HART) Investigators.
A comparison between heparin and low-dose aspirin as adjunctive
therapy with tissue plasminogen activator for acute myocardial infarction.
N Engl J Med 1990;323:1433-7.
546.
Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized
trials of intravenous heparin in patients with acute myocardial
infarction treated with thrombolytic therapy. Am J Cardiol 1996;77:551-6.
547.
Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization
during PTCA: assessment using activated clotting times. Cathet Cardiovasc
Diagn 1989;18:206-9.
548. Narins CR, Hillegass WB, Nelson CL, et al.
Relation between activated clotting time during angioplasty and
abrupt closure. Circulation 1996;93:667-71.
549.
Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin
time and outcome after thrombolytic therapy for acute myocardial
infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8.
550.
Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS. New heparin
dosing recommendations for patients with acute coronary syndromes.
Am J Med 2001;110:641-50.
551.
Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary
embolism: a statement for healthcare professionals. Council on Thrombosis
(in consultation with the Council on Cardiovascular Radiology),
American Heart Association. Circulation 1996;93:2212-45.
552.
Granger CB, Becker R, Tracy RP, et al, for the Global Utilization
of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I)
Hemostasis Substudy Group. Thrombin generation, inhibition and clinical
outcomes in patients with acute myocardial infarction treated with
thrombolytic therapy and heparin: results from the GUSTO-I Trial.
J Am Coll Cardiol 1998;31:497-505.
553.
Antman EM. Hirudin in acute myocardial infarction: a safety report
from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction
(TIMI) 9A trial. Circulation 1994;90:1624- 30.
554.
Thompson PL, Aylward PE, Federman J, et al, for the National Heart
Foundation of Australia Coronary Thrombolysis Group. A randomized
comparison of intravenous heparin with oral aspirin and dipyridamole
24 hours after recombinant tissue-type plasminogen activator for
acute myocardial infarction. Circulation 1991;83:1534-42.
555.
Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin
generation and activity after cessation of intravenous heparin in
patients with acute coronary syndromes. Circulation 1995;91:1929-35.
556.
Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation
of unstable angina after the discontinuation of heparin. N Engl
J Med 1992;327:141-5.
557.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia
in patients treated with low-molecular-weight heparin or unfractionated
heparin. N Engl J Med 1995;332:1330- 5.
558.
Harrington RA, Sane DC, Califf RM, et al, for the Thrombolysis and
Angioplasty in Myocardial Infarction Study Group. Clinical importance
of thrombocytopenia occurring in the hospital phase after administration
of thrombolytic therapy for acute myocardial infarction. J Am Coll
Cardiol 1994;23:891-8.
559.
Ross AM, Molhoek P, Lundergan C, et al, for the HART Investigators.
Randomized comparison of enoxaparin, a low molecular-weight heparin,
with unfractionated heparin adjunctive to recombinant tissue plasminogen
activator thrombolysis and aspirin: second trial of Heparin and
Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-52.
560.
Baird SH, Menown IB, Mcbride SJ, Trouton TG, Wilson C. Randomized
comparison of enoxaparin with unfractionated heparin following fibrinolytic
therapy for acute myocardial infarction. Eur Heart J 2002;23:627-32.
561.
Tatu-Chitoiu G, Teodorescu C, Capraru M, et al. Accelerated streptokinase
and enoxaparin in ST-segment elevation acute myocardial infarction
(the ASENOX study) Polish J Cardiology 2004;60:441-6.
562. Antman EM, Louwerenburg HW, Baars HF, et
al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation
myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial
Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-9.
563.
Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight
heparin (dalteparin) compared to unfractionated heparin as an adjunct
to rt-PA (alteplase) for improvement of coronary artery patency
in acute myocardial infarction-the ASSENT Plus study. Eur Heart
J 2003;24:897-908.
564.
Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of
low molecular weight heparin (dalteparin) in prevention of left
ventricular thrombus formation and arterial embolism after acute
anterior myocardial infarction: the Fragmin in Acute Myocardial
Infarction (FRAMI) study. J Am Coll Cardiol 1997;30:962-9.
565.
Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight
heparin (dalteparin) as adjuvant treatment of thrombolysis in acute
myocardial infarction: a pilot study: biochemical markers in acute
coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33:627-33.
566.
Cohen M, Gensini GF, Maritz F, et al, for the TETAMI Investigators.
The safety and efficacy of subcutaneous enoxaparin versus intravenous
unfractionated heparin and tirofiban versus placebo in the treatment
of acute ST-segment elevation myocardial infarction patients ineligible
for reperfusion (TETAMI): randomized trial. J Am Coll Cardiol 2003;42:1348-56.
567.
Kakkar VV, Iyengar SS, De Lorenzo F, Hargreaves JR, Kadziola ZA,
for the FAMI Investigator Group. Low molecular weight heparin for
treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin
sodium) in acute myocardial infarction. Indian Heart J 52:533-9.
568. Wong GC, Giugliano RP, Antman EM. Use of
low-molecularweight heparins in the management of acute coronary
artery syndromes and percutaneous coronary intervention. JAMA 2003;289:331-42.
569.
Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant
desulfatohirudin compared with heparin in conjunction with tissue-type
plasminogen activator and aspirin for acute myocardial infarction:
results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
J Am Coll Cardiol 1994;23:993-1003.
570.
Lidón RM, Théroux P, Lespérance J, et al. A
pilot, early angiographic patency study using a direct thrombin
inhibitor as adjunctive therapy to streptokinase in acute myocardial
infarction. Circulation 1994;89:1567-72.
571.
Théroux P, Pérez-Villa F, Waters D, Lespérance
J, Shabani F, Bonan R. Randomized double-blind comparison of two
doses of Hirulog with heparin as adjunctive therapy to streptokinase
to promote early patency of the infarct-related artery in acute
myocardial infarction. Circulation 1995;91:2132-9.
572.
Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin)
for the improvement of thrombolysis with streptokinase in patients
with acute myocardial infarction: results of the HIT-4 trial. J
Am Coll Cardiol 1999;34:966-73.
573.
Fung AY, Lorch G, Cambier PA, et al, for the ESCALAT Investigators.
Efegatran sulfate as an adjunct to streptokinase versus heparin
as an adjunct to tissue plasminogen activator in patients with acute
myocardial infarction. Am Heart J 1999; 138:696-704.
574.
Angiomax (bivalirudin) for injection. Package Insert. The Medicine
Company, Parsippany, NJ. Available at http://www. angiomax.com/%7Eproducts_content/PN1002.REV.5.mcR4.pdf,
2003. Accessed December 5, 2003.
575.
Coussement PK, Bassand JP, Convens C, et al, for the PENTALYSE investigators.
A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct
to fibrinolysis in acute myocardial infarction. The PENTALYSE study.
Eur Heart 2001;22:1716-24.
576. Bertrand ME, Rupprecht HJ, Urban P, Gershlick
AH, for the Investigators FT. Double-blind study of the safety of
clopidogrel with and without a loading dose in combination with
aspirin compared with ticlopidine in combination with aspirin after
coronary stenting: the clopidogrel aspirin stent international cooperative
study (CLASSICS). Circulation 2000;102:624-9.
577.
Mehta SR, Yusuf S, Peters RJ, et al, for the Clopidogrel in Unstable
angina to prevent Recurrent Events trial (CURE) Investigators. Effects
of pretreatment with clopidogrel and aspirin followed by long-term
therapy in patients undergoing percutaneous coronary intervention:
the PCI-CURE study. Lancet 2001;358:527-33.
578.
Steinhubl SR, Berger PB, Mann JT 3rd, et al, for the Clopidogrel
for the Reduction of Events During Observation (CREDO) Investigators.
Early and sustained dual oral antiplatelet therapy following percutaneous
coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
579.
CYPHER™ sirolimus-eluting coronary stent on RAPTORTM over-the-wire
delivery system and CYPHER™ sirolimus-eluting coronary stent
on RAPTORRAIL® rapid exchange delivery system: instructions
for Use. Miami, FL: Cordis: A Johnson & Johnson Company, April
2003.
580. TAXUS: Paclitaxel-eluting coronary stent
system Monorail® and over the wire coronary stent delivery system:
directions for use. Natick, MA: Boston Scientific; March 2004.
581.
Patrono C, Bachmann F, Baigent C, et al. ESC expert consensus document
on the use of antiplatelet agents: a report by the Task Force on
the Use of Antiplatelet Agents in Patients With Atherosclerotic
Cardiovascular Disease of the European Society of Cardiology. Eur
Heart J 2004;25:166-81.
582. Antoniucci D, Rodriguez A, Hempel A, et al.
A randomized trial comparing primary infarct artery stenting with
or without abciximab in acute myocardial infarction. J Am Coll Cardiol
2003; 42:1879-85.
583.
Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy
for acute myocardial infarction. J Am Coll Cardiol 2003;42:1886-9.
584.
Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein
IIb/IIIa receptor inhibition with tirofiban before primary angioplasty
improves angiographic outcomes: results of the TIrofiban Given in
the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.
Circulation 2003;107:1497- 501.
585.
Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE inhibitor
use in patients with myocardial infarction: summary evidence from
clinical trials. Circulation 1995;92:3132-7.
586.
Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto
Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal
glyceryl trinitrate singly and together on 6-week mortality and
ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
587.
Ambrosioni E, Borghi C, Magnani B, for the Survival Myocardial Infarction
Long-Term Evaluation (SMILE) Study Investigators. The effect of
the angiotensin-converting-enzyme inhibitor zofenopril on mortality
and morbidity after anterior myocardial infarction. N Engl J Med
1995;332:80-5.
588.
Oral captopril versus placebo among 13,634 patients with suspected
acute myocardial infarction: interim report from the Chinese Cardiac
Study (CCS-1). Lancet 1995;345:686-7.
589.
ACE Inhibitor Myocardial Infarction Collaborative Group. Indications
for ACE inhibitors in the early treatment of acute myocardial infarction:
systematic overview of individual data from 100,000 patients in
randomized trials. Circulation 1998; 97:2202-12.
590. Teo K, Yusuf S, Pfeffer M, et al. Effects
of long-term treatment with angiotensin-converting-enzyme inhibitors
in the presence absence of aspirin: a systematic review. Lancet
2002;360:1037.
591.
Meune C, Mahe I, Mourad JJ, et al. Interaction between angiotensin-converting
enzyme inhibitors and aspirin: a review. Eur J Clin Pharmacol 2000;56:609-20.
592.
Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal
activation and early treatment with enalapril (CONSENSUS II) following
myocardial infarction. Eur Heart 1994;15(Suppl B):14-9; discussion
26.
593.
Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of intravenous
infusion of a potassium-glucose-insulin solution the electrocardiographic
signs of myocardial infarction: a preliminary clinical report. Am
J Cardiol 1962;9:166-81.
594.
Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for
treatment of acute myocardial infarction: an overview of randomized
placebo-controlled trials. Circulation 1997;96:1152-6.
595.
Díaz R, Paolasso EA, Piegas LS, et al, for the ECLA (Estudios
Cardiológicos Latinoamérica) Collaborative Group.
Metabolic modulation of acute myocardial infarction. Circulation
1998;98:2227-34.
596. Ceremuzynski L, Budaj A, Czepiel A, et al.
Low-dose glucoseinsulin- potassium is ineffective in acute myocardial
infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc
Drugs Ther 1999;13:191-200.
597.
van der Horst IC, Zijlstra F, van’t Hof AW, et al. Glucose-insulinpotassium
infusion in patients treated with primary angioplasty for acute
myocardial infarction: the glucose-insulin-potassium study: a randomized
trial. J Am Coll Cardiol 2003;42:784-91.
598. Coleman GM, Gradinac S, Taegtmeyer
H, Sweeney M, Frazier OH. Efficacy of metabolic support with glucose-insulin-potassium
for left ventricular pump failure after aortocoronary bypass surgery.
Circulation 1989;80:I91-6.
599.
Melidonis A, Stefanidis A, Tournis S, et al. The role of strict
metabolic control by insulin infusion on fibrinolytic profile during
acute coronary event in diabetic patients. Clin Cardiol 2000;23:160-4.
600.
Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia
and the no-reflow phenomenon in patients with acute myocardial infarction.
J Am Coll Cardiol 2003;41:1-7.
601. Oliver MF, Opie LH. Effects of glucose and
fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8.
602. Malmberg K, Rydén L, Efendic S, et
al. Randomized trial of insulin-glucose infusion followed by subcutaneous
insulin treatment in diabetic patients with acute myocardial infarction
(DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol
1995;26:57-65.
603. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose
control and mortality in critically ill patients. JAMA 2003;290:2041-7.
603a. Clement S, Braithwaite SS, Magee MF, et
al. Management of diabetes and hyperglycemia in hospitals. Diabetes
Care 2004; 27:553-97
604. van den Berghe G, Wouters P, Weekers F, et
al. Intensive insulin therapy in the critically ill patients. N
Engl J Med 2001;345:1359-67.
605. Goldberg PA, Siegel MD, Sherwin RS, et al.
Implementation of a safe and effective insulin infusion protocol
in a medical intensive care unit. Diabetes Care 2004;27:461-7.
606. Inzucchi SE. Oral antihyperglycemic therapy
for type 2 diabetes: scientific review. JAMA 2002;287:360-72.
607. DeWitt DE, Hirsch IB. Outpatient insulin
therapy in type 1 and type 2 diabetes mellitus: scientific review.
JAMA 2003;289:2254-64.
608. Davis SM, Granner DK. Insulin oral hypoglycemic
agents and the pharmacology of the endocrine pancreas. In: Hardman
J, Limbird L, eds. Goodman and Gilman’s pharmacologic basis
of therapeutics. 10th ed. USA: McGraw-Hill, 2001:1705.
609. Teo KK, Yusuf S, Collins R, Held PH, Peto
R. Effects of intravenous magnesium in suspected acute myocardial
infarction: overview of randomised trials. BMJ 1991;303:1499-503.
610. Antman EM, Lau J, Kupelnick B, Mosteller
F, Chalmers TC. A comparison of results of meta-analyses of randomized
control trials and recommendations of clinical experts: treatments
for myocardial infarction. JAMA 1992;268:240-8.
611. Woods KL, Fletcher S. Long-term outcome after
intravenous magnesium sulphate in suspected acute myocardial infarction:
the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2).
Lancet 1994;343:816-9.
612. Antman EM. Magnesium in acute myocardial
infarction: overview of available evidence. Am Heart J 1996;132:487-95;
discussion 4.
613. Baxter GF, Sumeray MS,Walker JM. Infarct
size and magnesium: insights into LIMIT-2 and ISIS-4 from experimental
studies. Lancet 1996;348:1424-6.
614. Magnesium in Coronaries (MAGIC) Trial Investigators.
Early administration of intravenous magnesium to high-risk patients
with acute myocardial infarction in the agnesium in Coronaries (MAGIC)
Trial: a randomised controlled trial. Lancet 2002; 360:1189-96.
615.
Morton BC, Nair RC, Smith FM, McKibbon TG, Poznanski WJ. Magnesium
therapy in acute myocardial infarction: a doubleblind study. Magnesium
1984;3:346-52.
616. Rasmussen HS, McNair P, Norregard P, Backer
V, Lindeneg O, Balslev S. Intravenous magnesium in acute myocardial
infarction. Lancet 1986;1:234-6.
617.
Smith LF, Heagerty AM, Bing RF, Barnett DB. Intravenous infusion
of magnesium sulphate after acute myocardial infarction: effects
on arrhythmias and mortality. Int J Cardiol 1986;12:175-83.
618.
Woods KL, Fletcher S, Smith LF. Intravenous magnesium in suspected
acute myocardial infarction. BMJ 1992;304:119.
619.
Abraham AS, Rosenmann D, Kramer M, et al. Magnesium in the prevention
of lethal arrhythmias in acute myocardial infarction. Arch Intern
Med 1987;147:753-5.
1620.
Ceremuzynski L, Jurgiel R, Kulakowski P, Gebalska J. Threatening
arrhythmias in acute myocardial infarction are prevented by intravenous
magnesium sulfate. Am Heart J 1989;118:1333-4.
621.
Shechter M, Hod H, Marks N, et al. Beneficial effect of magnesium
sulfate in acute myocardial infarction. Am J Cardiol 1990;66:271-4.
622.
Feldstedt M, Boesgaard S, Bouchelouche P, et al. Magnesium substitution
in acute ischaemic heart syndromes. Eur Heart J 1991;12:1215-8.
623.
Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate
in suspected acute myocardial infarction: results of the second
Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet
1992;339:1553-8.
624. Thögersen AM, Johnson O, Wester PO.
Effects of magnesium infusion on thrombolytic and non-thrombolytic
treated patients with acute myocardial infarction. Int J Cardiol
1993;39:13-22.
625.
Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B. Magnesium
therapy in acute myocardial infarction when patients are not candidates
for thrombolytic therapy. Am J Cardiol 1995; 75:321-3.
626.
Raghu C, Peddeswara Rao P, Seshagiri Rao D. Protective effect of
intravenous magnesium in acute myocardial infarction following thrombolytic
therapy. Int J Cardiol 1999;71:209-15.
627.
Gyamlani G, Parikh C, Kulkarni AG. Benefits of magnesium in acute
myocardial infarction: timing is crucial. Am Heart J 2000;139:703.
628.
Woods KL, Abrams K. The importance of effect mechanism in the design
and interpretation of clinical trials: the role of magnesium in
acute myocardial infarction. Prog Cardiovasc Dis 2002; 44:267-74.
629.
Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency
Cardiovascular Care: part 6: advanced cardiovascular life support:
section 5: pharmacology I: agents for arrhythmias. The American
Heart Association in collaboration with the International Liaison
Committee on Resuscitation. Circulation 2000;102:I112-28.
630.
Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients
with threatened and acute myocardial infarction: a randomized, double-blind,
placebo-controlled comparison. Circulation 1984;69:740-7.
631.
Sirnes PA, Overskeid K, Pedersen TR, et al. Evolution of infarct
size during the early use of nifedipine in patients with acute myocardial
infarction: the Norwegian Nifedipine Multicenter Trial. Circulation
1984;70:638-44.
632.
Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine
in acute myocardial infarction: the Trent study. Br Med J (Clin
Res Ed) 1986;293:1204-8.
633.
The Israeli Sprint Study Group. Secondary prevention reinfarction
Israeli nifedipine trial (SPRINT): a randomized intervention trial
of nifedipine in patients with acute myocardial infarction. Eur
Heart J 1988;9:354-64.
634.
Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky
E. Early administration of nifedipine in suspected acute myocardial
infarction: the Secondary Prevention Reinfarction Israel Nifedipine
Trial 2 Study. Arch Intern Med 1993;153:345-53.
635.
Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and
myocardial infarction: a hypothesis formulated but not yet tested.
JAMA 1995;274:654-5.
636.
Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase
in mortality in patients with coronary heart disease. Circulation
1995;92:1326-31.
637. Opie LH, Messerli FH. Nifedipine and mortality:
grave defects in the dossier. Circulation 1995;92:1068-73.
638. The Danish Study Group on Verapamil in Myocardial
Infarction. Verapamil in acute myocardial infarction. Eur Heart
J 1984; 5:516-28.
639.
Gheorghiade M. Calcium channel blockers in the management of myocardial
infarction patients. Henry Ford Hosp Med J 1991;39:210-6.
640. Held PH, Yusuf S. Effects of beta-blockers
and calcium channel blockers in acute myocardial infarction. Eur
Heart J 1993;14:18- 25.
641.
Hilton TC, Miller DD, Kern MJ. Rational therapy to reduce mortality
and reinfarction following myocardial infarction. Am Heart J 1991;122:1740-50.
642. Effect of verapamil on mortality and major
events after acute myocardial infarction: the Danish Verapamil Infarction
Trial II (DAVIT II). Am J Cardiol 1990;66:779-85.
643. The Multicenter Diltiazem Postinfarction
Trial Research Group. The effect of diltiazem on mortality and reinfarction
after myocardial infarction. N Engl J Med 1988;319:385-92.
644.
Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction
in patients with non–Q-wave myocardial infarction: results
of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-9.
645. Boden WE. Non–Q-wave myocardial infarction:
a prognostic paradox. Hosp Pract (Off Ed) 1992;27:129-33,137-8,140.
646. Boden WE, van Gilst WH, Scheldewaert RG,
et al. Diltiazem in acute myocardial infarction treated with thrombolytic
agents: a randomised placebo-controlled trial. Incomplete Infarction
Trial of European Research Collaborators Evaluating Prognosis post-
Thrombolysis (INTERCEPT). Lancet 2000;355:1751-6.
647.
American Association of Critical Care Nurses White Paper. Safeguarding
the Patient and the Profession: the Value of Critical Care Nurse
Certification, Aliso Viejo, CA, December 2002.
648.
Dimick JB, Swoboda SM, Pronovost PJ, Lipsett PA. Effect of nurse-to-patient
ratio in the intensive care unit on pulmonary complications and
resource use after hepatectomy. Am J Crit Care 2001;10:376-82.
649.
Needleman J, Buerhaus P, Mattke S, Stewart M, Zelevinsky K. Nurse-staffing
levels and the quality of care in hospitals. N Engl J Med 2002;346:1715-22.
650.
Pronovost PJ, Dang D, Dorman T, et al. Intensive care unit nurse
staffing and the risk for complications after abdominal aortic surgery.
Eff Clin Pract 2001;4:199-206.
651. Pilcher T, Odell M. Position statement on
nurse-patient ratios in critical care. Nurs Stand 2000;15:38-41.
652.
“California Safe Hospital Staffing Law” AB 394.
653.
Bolton LB, Jones D, Aydin CE, et al. A response to California’s
mandated nursing ratios. J Nurs Scholarship 2001;33:179-84.
654. Maintaining patient-focused care in an environment
of nursing staff shortages and financial constraints: a statement
from the American Association of Critical-Care Nurses (AACN). Available
at http://www.aacn.org/pdfLibra.NSF/Files/burson/$file/burson.pdf,
November 2000. Accessed January 7, 2004.
655.
Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic
era: an analysis of criteria for uncomplicated infarction from the
Global Utilization of Streptokinase and t-PA for Occluded Coronary
Arteries (GUSTO) trial. J Am Coll Cardiol 1996;27:625-32.
656.
Fein A. Organization and Management of Critical Care Units. In:
Irwin RS, Rippe JM, eds. Manual of Intensive Care Medicine. 4th
ed. Baltimore, MD: Lippincott-Williams & Wilkins; 1999:2501-9.
657.
Drew BJ,Wung SF, Adams MG, Pelter MM. Bedside diagnosis of myocardial
ischemia with ST-segment monitoring technology: measurement issues
for real-time clinical decision making and trial designs. J Electrocardiol
1998;30:157-65.
658.
Bell NN. Clinical significance of ST-segment monitoring. Crit Care
Nurs Clin North Am 1992;4:313-23.
659.
Johanson P, Rössberg J, Dellborg M. Continuous ST monitoring:
a bedside instrument? A report from the Assessment of the Safety
of a New Thrombolytic (ASSENT 2) ST monitoring substudy. Am Heart
J 2001;142:58-62.
660.
Drew BJ, Ide B, Sparacino PS. Accuracy of bedside electrocardiographic
monitoring: a report on current practices of critical care nurses.
Heart Lung 1991;20:597-607.
661.
Romhilt DW, Bloomfield SS, Chou TC, Fowler NO. Unreliability of
conventional electrocardiographic monitoring for arrhythmia detection
in coronary care units. Am J Cardiol 1973;31:457-61.
662.
Drew BJ, Krucoff MW, for the ST- Segment Monitoring Practice Guideline
International Working Group. Multilead ST-segment monitoring in
patients with acute coronary syndromes: a consensus statement for
healthcare professionals. Am J Crit Care 1999;8:372-86; quiz 387-8.
663.
Pelter MM, Adams MG, Wung SF, Paul SM, Drew BJ. Peak time of occurrence
of myocardial ischemia in the coronary care unit. Am J Crit Care
1998;7:411-7.
664.
Dellborg M, Topol EJ, Swedberg K. Dynamic QRS complex and ST segment
vectorcardiographic monitoring can identify vessel patency in patients
with acute myocardial infarction treated with reperfusion therapy.
Am Heart J 1991;122:943-8.
665.
Krucoff MW, Croll MA, Pope JE, et al. Continuously updated 12- lead
ST-segment recovery analysis for myocardial infarct artery patency
assessment and its correlation with multiple simultaneous early
angiographic observations. Am J Cardiol 1993;71:145-51.
666.
Veldkamp RF, Green CL,Wilkins ML, et al, for the Thrombolysis and
Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. Comparison
of continuous ST-segment recovery analysis with methods using static
electrocardiograms for noninvasive patency assessment during acute
myocardial infarction. Am J Cardiol 1994;73:1069-74.
667.
Langer A, Krucoff MW, Klootwijk P, et al. Noninvasive assessment
of speed and stability of infarct-related artery reperfusion: results
of the GUSTO ST segment monitoring study. Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary
Arteries. J Am Coll Cardiol 1995;25:1552-7.
668. Santoro GM, Valenti R, Buonamici P, et al.
Relation between STsegment changes and myocardial perfusion evaluated
by myocardial contrast echocardiography in patients with acute myocardial
infarction treated with direct angioplasty. Am J Cardiol 1998; 82:932-7.
669. Krucoff MW, Parente AR, Bottner RK, et al.
Stability of multilead ST-segment “fingerprints” over
time after percutaneous transluminal coronary angioplasty and its
usefulness in detecting reocclusion. Am J Cardiol 1988;61:1232-7.
670.
Vatner SF, McRitchie RJ, Maroko PR, Patrick TA, Braunwald E. Effects
of catecholamines, exercise, and nitroglycerin on the normal and
ischemic myocardium in conscious dogs. J Clin Invest 1974;54:563-75.
671.
Chobanian AV, Lille RD, Tercyak A, Blevins P. The metabolic and
hemodynamic effects of prolonged bed rest in normal subjects. Circulation
1974;49:551-9.
672. Convertino VA. Value of orthostatic stress
in maintaining functional status soon after myocardial infarction
or cardiac artery bypass grafting. J Cardiovasc Nurs 2003;18:124-30.
673.
Metzger BL, Therrien B. Effect of position on cardiovascular response
during the Valsalva maneuver. Nurs Res 1990;39:198- 202.
674. Taggart P, Sutton P, John R, Lab M, Swanton
H. Monophasic action potential recordings during acute changes in
ventricular loading induced by the Valsalva manoeuvre. Br Heart
J 1992;67:221-9.
675.
Porth CJ, Bamrah VS, Tristani FE, Smith JJ. The Valsalva maneuver:
mechanisms and clinical implications. Heart Lung 1984;13:507-18.
676.
Storm DS, Metzger BL, Therrien B. Effects of age on autonomic cardiovascular
responsiveness in healthy men and women. Nurs Res 1989;38:326-30.
677.
Third Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) final report.
Circulation 2002;106:3143-421.
678.
Goldstein IB, Shapiro D, Hui KK,Yu JL. Blood pressure response to
the “second cup of coffee”. Psychosom Med 1990;52:337-45.
679.
Aro A, Teirilä J, Gref CG. Dose-dependent effect on serum cholesterol
and apoprotein B concentrations by consumption of boiled, non-filtered
coffee. Atherosclerosis 1990;83:257-61.
680.
Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley
M. Effects of caffeine on human health. Food Addit Contam 2003;20:1-30.
681.
Myers MG, Harris L. High-dose caffeine and ventricular arrhythmias.
Can J Cardiol 1990;6:95-8.
682.
Myers MG, Harris L, Leenen FH, Grant DM. Caffeine as a possible
cause of ventricular arrhythmias during the healing phase of acute
myocardial infarction. Am J Cardiol 1987;59:1024-8.
683.
Pincomb GA, Lovallo WR, Passey RB, Whitsett TL, Silverstein SM,
Wilson MF. Effects of caffeine on vascular resistance, cardiac output
and myocardial contractility in young men. Am J Cardiol 1985;56:119-22.
684.
Hughes JR, Oliveto AH, Bickel WK, Higgins ST, Badger GJ. Caffeine
self-administration and withdrawal: incidence, individual differences
and interrelationships. Drug Alcohol Depend 1993;32:239-46.
685.
van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal
among moderate coffee drinkers switched from ordinary to decaffeinated
coffee: a 12-week double-blind trial. BMJ 1990;300:1558-9.
686.
Höfer I, Bättig K. Cardiovascular, behavioral, and subjective
effects of caffeine under field conditions. Pharmacol Biochem Behav
1994;48:899-908.
687.
Lynn LA, Kissinger JF. Coronary precautions: should caffeine be
restricted in patients after myocardial infarction? Heart Lung 1992;21:365-71.
688. Boyd MD. Strategies for effective health
teaching. In: Boyd MD, Graham BA, Gleit CJ, Whitman NI, eds. Health
teaching in nursing practice: a professional model. 3rd ed. Stanford,
CT: Appleton and Lange;1998:201-29.
689.
Fleury J, Moore SM. Family-centered care after acute myocardial
infarction. J Cardiovasc Nurs 1999;13:73-82.
690. Duryée R. The efficacy of inpatient
education after myocardial infarction. Heart Lung 1992;21:217-25.ise,
and nitroglycerin on the normal and ischemic myocardium in conscious
dogs. J Clin Invest 1974;54:563-75.
691.
Saarmann L, Daugherty J, Riegel B. Patient teaching to promote behavioral
change. Nurs Outlook 2000;48:281-7.
692.
Cooper H, Booth K, Fear S, Gill G. Chronic disease patient education:
lessons from meta-analyses. Patient Educ Couns 2001;44:107-17.
693.
Prochaska JO, DiClemente CC, Norcross JC. In search of how people
change: applications to addictive behaviors. Am Psychol 1992;47:1102-14.
694.
Nigg CR, Burbank PM, Padula C, et al. Stages of change across ten
health risk behaviors for older adults. Gerontologist 1999;39:473-82.
695.
Glazer HR, Kirk LM, Bosler FE. Patient education pamphlets about
prevention, detection, and treatment of breast cancer for low literacy
women. Patient Educ Couns 1996;27:185-9.
696.
Antman EM, Kuntz KM. The length of the hospital stay after myocardial
infarction. N Engl J Med 2000;342:808-10.
697.
Visser A,Wissow L. From patient education to communication in health
care. Patient Educ Couns 2003;50:227-8.
698.
Frazier SK, Moser DK, O’Brien JL, Garvin BJ, An K, Macko M.
Management of anxiety after acute myocardial infarction. Heart Lung
2002;31:411-20.
699. Frazier SK, Moser DK, Daley LK, et al. Critical
care nurses’ beliefs about and reported management of anxiety.
Am J Crit Care 2003;12:19-27.
700.
Devine EC. Effects of psychoeducational care for adult surgical
patients: a meta-analysis of 191 studies. Patient Educ Couns 1992;19:129-42.
701.
Bartlett EE. Cost-benefit analysis of patient education. Patient
Educ Couns 1995;26:87-91.
702.
LaBresh KA, Gliklich R, Liljestrand J, Peto R, Ellrodt AG. Using
“get with the guidelines” to improve cardiovascular
secondary prevention. Jt Comm J Qual Saf 2003;29:539-50.
703.
The Mended Hearts, Inc., Dallas, TX. Available at http://www.mendedhearts.org/,
November 2003. Accessed December 16, 2002.
704.
Hughes JR, Higgins ST, Bickel WK. Nicotine withdrawal versus other
drug withdrawal syndromes: similarities and dissimilarities. Addiction
1994;89:1461-70.
705. Malan SS. Psychosocial adjustment following
MI: current views and nursing implications. J Cardiovasc Nurs 1992;6:57-70.
706.
Havik OE, Maeland JG. Patterns of emotional reactions after a myocardial
infarction. J Psychosom Res 1990;34:271-85.
707.
Moser DK, Dracup K. Is anxiety early after myocardial infarction
associated with subsequent ischemic and arrhythmic events? Psychosom
Med 1996;58:395-401.
708. Frasure-Smith N, Lespérance F, Talajic
M. The impact of negative emotions on prognosis following myocardial
infarction: is it more than depression? Health Psychol 1995;14:388-98.
709.
O’Brien JL, Moser DK, Riegel B, Frazier SK, Garvin BJ, Kim
KA. Comparison of anxiety assessments between clinicians and patients
with acute myocardial infarction in cardiac critical care units.
Am J Crit Care 2001;10:97-103.
710.
Frazier SK, Moser DK, Riegel B, et al. Critical care nurses’
assessment of patients’ anxiety: reliance on physiological
and behavioral parameters. Am J Crit Care 2002;11:57-64.
711.
Simpson T, Shaver J. Cardiovascular responses to family visits in
coronary care unit patients. Heart Lung 1990;19:344-51.
712.
Schulte DA, Burrell LO, Gueldner SH, et al. Pilot study of the relationship
between heart rate and ectopy and unrestricted vs restricted visiting
hours in the coronary care unit. Am J Crit Care 1993;2:134-6.
713.
Thompson DR, Meddis R. A prospective evaluation of inhospitalcounselling
for first-time myocardial infarction men. J Psychosom Res 1990;34:237-48.
714. Thompson DR. A randomized controlled trial
of in-hospital nursing support for first-time myocardial infarction
patients and their partners: effects on anxiety and depression.
J Adv Nurs 1989; 14:291-7.
715.
Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson
ED,Armstrong PW,Van de Werf F, White HD, Topol EJ, Mark DB. Cost
effectiveness of early discharge after uncomplicated acute myocardial
infarction. N Engl J Med 2000;342:749- 55.
716.
Brooten D, Naylor MD, York R, et al. Lessons learned from testing
the quality cost model of Advanced Practice Nursing (APN) transitional
care. J Nurs Scholarship 2002;34:369-75.
717.
Chae CU, Hennekens CH . Beta blockers. In: Hennekens CH, ed. Clinical
trials in cardiovascular disease: a companion to Braunwald’s
Heart Disease. Philadelphia, PA: WB Saunders Co Ltd; 1999:79-94.
718.
Antman E, Braunwald E. Acute myocardial infarction. In: Braunwald
E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular
medicine. 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1231.
719.
Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack
trial. JAMA 1981;246:2073-4.
720.
Flather MD, Yusuf S, Køber L, et al, for the ACE-Inhibitor
Myocardial Infarction Collaborative Group. Long-term ACEinhibitor
therapy in patients with heart failure or left-ventricular dysfunction:
a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
721.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for
the Heart Outcomes Prevention Evaluation Study Investigators. Effects
of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. N Engl J Med 2000;342:145-53.
722.
Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone
Evaluation Study Investigators. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. N
Engl J Med 1999;341:709-17.
723.
Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Survival Study
Investigators. Eplerenone, a selective aldosterone blocker, in patients
with left ventricular dysfunction after myocardial infarction. N
Engl J Med 2003;348:1309-21.
724.
Dickstein K, Kjekshus J, for the OPTIMAAL Steering Committee of
the OPTIMAAL Study Group. Effects of losartan and captopril on mortality
and morbidity in high-risk patients after acute myocardial infarction:
the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction
with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
725.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al, for the Valsartan
in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril,
or both in myocardial infarction complicated by heart failure, left
ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
726.
Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial
infarction: a matter of dose. N Engl J Med 2003; 349:1963-5.
727.
Antiplatelet Trialists’ Collaboration. Collaborative overview
of randomised trials of antiplatelet therap: I–Prevention
of death, myocardial infarction, and stroke by prolonged antiplatelet
therapy in various categories of patients. BMJ 1994;308:81-106.
728.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for
the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
Investigators. Effects of clopidogrel in addition to aspirin in
patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med 2001; 345:494-502.
729.
Plavix (clopidogrel) package insert. Sanofi-Synthelabo. New York,
NY. March 2002.
730.
Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and
other platelet-active drugs: the relationship between dose, effectiveness,
and side effects. Chest 1992;102:327S-336S.
731.
Leonards JR, Levy G. Effect of pharmaceutical formulation on gastrointestinal
bleeding from aspirin tablets. Arch Intern Med 1972;129:457-60.
732.
MacKercher PA, Ivey KJ, Baskin WN, Krause WJ. Protective effect
of cimetidine on aspirin-induced gastric mucosal damage. Ann Intern
Med 1977;87:676-9.
733.
Bowen BK, Krause WJ, Ivey KJ. Effect of sodium bicarbonate on aspirin-induced
damage and potential difference changes in human gastric mucosa.
Br Med J 1977;2:1052-5.
734. Graham DY, Smith JL. Aspirin and the stomach.
Ann Intern Med 1986;104:390-8.
735.
Mielants H, Verbruggen G, Schelstraete K, Veys EM. Salicylateinduced
gastrointestinal bleeding: comparison between soluble buffered,
enteric-coated, and intravenous administration. J Rheumatol 1979;6:210-8.
736.
Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous
vein graft patency after coronary artery bypass surgery with antiplatelet
therapy: results of a Veterans Administration Cooperative Study.
Circulation 1988;77:1324-32.
737.
Chesebro JH, Clements IP, Fuster V, et al. A platelet-inhibitordrug
trial in coronary-artery bypass operations: benefit of perioperative
dipyridamole and aspirin therapy on early postoperative vein-graft
patency. N Engl J Med 1982;307:73-8.
738. Sanz G, Pajarón A, Alegría
E, et al, for the Grupo Español para el Seguimiento del Injerto
Coronario (GESIC). Prevention of early aortocoronary bypass occlusion
by low-dose aspirin and dipyridamole. Circulation 1990;82:765-73.
739.
Goldman S, Copeland J, Moritz T, et al, for the Department of Veterans
Affairs Cooperative Study Group. Starting aspirin therapy after
operation: effects on early graft patency. Circulation 1991;84:520-6.
740.
Hass WK, Easton JD, Adams HP, et al, for the Ticlopidine Aspirin
Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride
with aspirin for the prevention of stroke in highrisk patients.
N Engl J Med 1989;321:501-7.
741.
Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison
of antiplatelet and anticoagulant therapy after the placement of
coronary-artery stents. N Engl J Med 1996;334:1084-9.
742.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel
versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet 1996;348:1329-39.
743. Leon MB, Baim DS, Popma JJ, et al, for the
Stent Anticoagulation Restenosis Study Investigators. A clinical
trial comparing three antithrombotic-drug regimens after coronary-artery
stenting. N Engl J Med 1998;339:1665-71.
744.
The SCATI (Studio sulla Calciparina nell’Angina e nella Trombosi
Ventricolare nell’Infarto) Group. Randomised controlled trial
of subcutaneous calcium-heparin in acute myocardial infarction.
Lancet 1989;2:182-6.
745.
Deleted in press.
746.
4th American College of Chest Physicians Consensus Conference on
Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings.
Chest 1995;108:225S-522S.
747.
Chesebro JH, Fuster V. Antithrombotic therapy for acute myocardial
infarction: mechanisms and prevention of deep venous, left ventricular,
and coronary artery thromboembolism. Circulation 1986;74:III1-10.
748. Sevilla DC, Wagner NB, Anderson WD, et al.
Sensitivity of a set of myocardial infarction screening criteria
in patients with anatomically documented single and multiple infarcts.
Am J Cardiol 1990;66:792-5.
749.
Ideker RE,Wagner GS, Ruth WK, et al. Evaluation of a QRS scoring
system for estimating myocardial infarct size–II: correlation
with quantitative anatomic findings for anterior infarcts. Am J
Cardiol 1982;49:1604-14.
750.
Goodman SG, Langer A, Ross AM, et al, for the GUSTO-I Angiographic
Investigators. Non–Q-wave versus Q-wave myocardial infarction
after thrombolytic therapy: angiographic and prognostic insights
from the global utilization of streptokinase and tissue plasminogen
activator for occluded coronary arteries-I angiographic substudy.
Circulation 1998;97:444-50.
751. Buja LM, Willerson JT. Infarct size: can
it be measured or modified in humans? Prog Cardiovasc Dis 1987;29:271-89.
752.
Hackel DB, Reimer KA, Ideker RE, et al. Comparison of enzymatic
and anatomic estimates of myocardial infarct size in man. Circulation
1984;70:824-35.
753.
Panteghini M, Cuccia C, Bonetti G, Giubbini R, Pagani F, Bonini
E. Single-point cardiac troponin T at coronary care unit discharge
after myocardial infarction correlates with infarct size and ejection
fraction. Clin Chem 2002;48:1432-6.
754.
Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kübler
W. Troponin T concentrations 72 hours after myocardial infarction
as a serological estimate of infarct size. Heart 2002; 87:520-4.
755.
Myocardial infarction redefined: a consensus document of the Joint
European Society of Cardiology/American College of Cardiology Committee
for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502-13.
756.
Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single
photon emission computed tomographic imaging with (99m)Tc-sestamibi:
a measure of the efficacy of therapy in acute myocardial infarction.
Circulation 2000;101:101-8.
757.
Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic
infarct size measurement by contrast-enhanced magnetic resonance
imaging. Circulation 2002;106:2322-7.
758.
Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus
document on the present use of bedside right heart catheterization
in patients with cardiac disease. American College of Cardiology.
J Am Coll Cardiol 1998;32:840-64.
759.
Menon V, Slater JN, White HD, Sleeper LA, Cocke T, Hochman JS. Acute
myocardial infarction complicated by systemic hypoperfusion without
hypotension: report of the SHOCK trial registry. Am J Med 2000;108:374-80.
760.
Hollenberg SM, Hoyt J. Pulmonary artery catheters in cardiovascular
disease. New Horiz 1997;5:207-13.
761. Weil MH. The assault on the Swan-Ganz catheter:
a case history of constrained technology, constrained bedside clinicians,
and constrained monetary expenditures. Chest 1998;113:1379-86.
762.
Dalen JE. The pulmonary artery catheter-friend, foe, or accomplice?
JAMA 2001;286:348-50.
763.
O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for
the prevention of intravascular catheter-related infections. Centers
for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1-29.
764.
Killip T, Kimball JT. Treatment of myocardial infarction in a coronary
care unit: a two-year experience with 250 patients. Am J Cardiol
1967;20:457-64.
765.
Hochman JS, Jaber W, Bates ER, et al. Angioplasty versus thrombolytics
for patients presenting with congestive heart failure: GUSTO IIb
substudy findings. J Am Coll Cardiol 1998;31:856-4.
766.
Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care: part 7–the era of reperfusion: section
1–acute coronary syndromes (acute myocardial infarction).
Circulation 2000;102:I172-203.
767.
Prewitt RM, Gu S, Garber PJ, Ducas J. Marked systemic hypotension
depresses coronary thrombolysis induced by intracoronary administration
of recombinant tissue-type plasminogen activator. J Am Coll Cardiol
1992;20:1626-33.
768.
Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation
enhances coronary thrombolysis induced by intravenous administration
of a thrombolytic agent. J Am Coll Cardiol 1994;23:794-8.
769.
Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel
H. Effects of the early administration of enalapril on mortality
in patients with acute myocardial infarction: results of the Cooperative
New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl
J Med 1992;327:678-84.
770.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated
congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
771.
Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation
and management of chronic heart failure in the adult: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Revise the 1995 Guidelines
for the Evaluation and Management of Heart Failure). American College
of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/failure/
hf_index.htm, 2001. Accessed August 5, 2003.
772.
Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after
acute myocardial infarction: incidence and mortality from a community-
wide perspective, 1975 to 1988. N Engl J Med 1991;325:1117-22.
773.
Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic
shock after acute myocardial infarction in the interventional era.
J Am Coll Cardiol 1992;20:1482-9.
774. Berger AK, Radford MJ, Krumholz HM. Cardiogenic
shock complicating acute myocardial infarction in elderly patients:
does admission to a tertiary center improve survival? Am Heart J
2002;143:768-76.
775.
Allen BS, Rosenkranz E, Buckberg GD, et al. Studies on prolonged
acute regional ischemia: VI–myocardial infarction with left
ventricular power failure: a medical/surgical emergency requiring
urgent revascularization with maximal protection of remote muscle.
J Thorac Cardiovasc Surg 1989;98:691-702; discussion.
776.
Allen BS, Buckberg GD, Fontan FM, et al. Superiority of controlled
surgical reperfusion versus percutaneous transluminal coronary angioplasty
in acute coronary occlusion. J Thorac Cardiovasc Surg 1993;105:864-79;
discussion 8.
777.
Dixon SR, Alkafri H, Chami A. Clinical predictors of in-hospital
death in patients with cardiogenic shock selected to undergo early
revascularization [abstr]. J Am Coll Cardiol 2002;39:808–1.
778.
Barron HV, Every NR, Parsons LS, et al, for the Investigators in
the National Registry of Myocardial Infarction 2. The use of intraaortic
balloon counterpulsation in patients with cardiogenic shock complicating
acute myocardial infarction: data from the National Registry of
Myocardial Infarction 2. Am Heart J 2001;141:933-9.
779.
Deleted in press.
780.
Zehender M, Kasper W, Kauder E, et al H. Right ventricular infarction
as an independent predictor of prognosis after acute inferior myocardial
infarction. N Engl J Med 1993;328:981-8.
781.
Berger PB, Ryan TJ. Inferior myocardial infarction: high-risk subgroups.
Circulation 1990;81:401-11.
782.
Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused
by right ventricular infarction: a report from the SHOCK registry.
J Am Coll Cardiol 2003;41:1273-9.
783.
Weinshel AJ, Isner JM, Salem DN. The coronary anatomy of right ventricular
infarction: relationship between the site of right coronary artery
occlusion and origin of the right ventricular free wall branches.
Circulation 1983;68:III-351.
784.
Andersen HR, Falk E, Nielsen D. Right ventricular infarction: frequency,
size and topography in coronary heart disease: a prospective study
comprising 107 consecutive autopsies from a coronary care unit.
J Am Coll Cardiol 1987;10:1223-32.
785.
Lee FA. Hemodynamics of the right ventricle in normal and disease
states. Cardiol Clin 1992;10:59-67.
786.
Cross CE. Right ventricular pressure and coronary flow. Am J Physiol
1962;202:12-16.
787.
Haupt HM, Hutchins GM, Moore GW. Right ventricular infarction: role
of the moderator band artery in determining infarct size. Circulation
1983;67:1268-72.
788.
Setaro JF, Cabin HS. Right ventricular infarction. Cardiol Clin
1992;10:69-90.
789.
Goldstein JA, Vlahakes GJ, Verrier ED, et al. The role of right
ventricular systolic dysfunction and elevated intrapericardial pressure
in the genesis of low output in experimental right ventricular infarction.
Circulation 1982;65:513-22.
790.
Ferguson JJ, Diver DJ, Boldt M, Pasternak RC. Significance of nitroglycerin-induced
hypotension with inferior wall acute myocardial infarction. Am J
Cardiol 1989;64:311-4.
791.
Goldstein JA, Barzilai B, Rosamond TL, Eisenberg PR, Jaffe AS. Determinants
of hemodynamic compromise with severe right ventricular infarction.
Circulation 1990;82:359-68.
792.
Goldstein JA, Tweddell JS, Barzilai B, Yagi Y, Jaffe AS, Cox JL.
Importance of left ventricular function and systolic ventricular
interaction to right ventricular performance during acute right
heart ischemia. J Am Coll Cardiol 1992;19:704-11.
793. Bowers TR, O’Neill WW, Grines C, Pica
MC, Safian RD, Goldstein JA. Effect of reperfusion on biventricular
function and survival after right ventricular infarction. N Engl
J Med 1998;338:933-40.
794.
Bowers TR, O’Neill WW, Pica M, Goldstein JA. Patterns of coronary
compromise resulting in acute right ventricular ischemic dysfunction.
Circulation 2002;106:1104-9.
795.
Dell’Italia LJ, Starling MR, O’Rourke RA. Physical examination
for exclusion of hemodynamically important right ventricular infarction.
Ann Intern Med 1983;99:608-11.
796.
Dell’Italia LJ, Starling MR, Crawford MH, Boros BL, Chaudhuri
TK, O’Rourke RA. Right ventricular infarction: identification
by hemodynamic measurements before and after volume loading and
correlation with noninvasive techniques. J Am Coll Cardiol 1984;4:931-9.
797.
Cohn JN, Guiha NH, Broder MI, Limas CJ. Right ventricular infarction:
clinical and hemodynamic features. Am J Cardiol 1974;33:209-14.
798. Robalino BD, Whitlow PL, Underwood DA, Salcedo
EE. Electrocardiographic manifestations of right ventricular infarction.
Am Heart J 1989;118:138-44. 799. Braat SH, Brugada P, de Zwaan C,
Coenegracht JM, Wellens HJ.
799.
Braat SH, Brugada P, de Zwaan C, Coenegracht JM, Wellens HJ.Value
of electrocardiogram in diagnosing right ventricular involvement
in patients with an acute inferior wall myocardial infarction. Br
Heart J 1983;49:368-72.
800. Sharkey SW, Shelley W, Carlyle PF, Rysavy
J, Cohn JN. M-mode and two-dimensional echocardiographic analysis
of the septum in experimental right ventricular infarction: correlation
with hemodynamic alterations. Am Heart J 1985;110:1210-8.
801. López-Sendón J, López
de Sá E, Roldán I, Fernández de Soria R, Ramos
F, Martín Jadraque L. Inversion of the normal interatrial
septum convexity in acute myocardial infarction: incidence, clinical
relevance and prognostic significance. J Am Coll Cardiol
1990;15:801-5.
802. Manno BV, Bemis CE, Carver J, Mintz GS. Right
ventricular infarction complicated by right to left shunt. J Am
Coll Cardiol 1983;1:554-7.
803. Wellens HJ. The value of the right precordial
leads of the electrocardiogram. N Engl J Med 1999;340:381-3.
804. Goldstein JA, Vlahakes GJ, Verrier ED, et
al. Volume loading improves low cardiac output in experimental right
ventricular infarction. J Am Coll Cardiol 1983;2:270-8.
805. Dell’Italia LJ, Starling MR, Blumhardt
R, Lasher JC, O’Rourke RA. Comparative effects of volume loading,
dobutamine, and nitroprusside in patients with predominant right
ventricular infarction. Circulation 1985;72:1327-35.
806. Love JC, Haffajee CI, Gore JM, Alpert JS.
Reversibility of hypotension and shock by atrial or atrioventricular
sequential pacing in patients with right ventricular infarction.
Am Heart J 1984;108:5-13.
807. Sugiura T, Iwasaka T, Takahashi N, et al.
Atrial fibrillation in inferior wall Q-wave acute myocardial infarction.
Am J Cardiol 1991;67:1135-6.
808. Braat SH, de Zwaan C, Brugada P, Coenegracht
JM, Wellens HJ. Right ventricular involvement with acute inferior
wall myocardial infarction identifies high risk of developing atrioventricular
nodal conduction disturbances. Am Heart J 1984;107:1183-7.
809. Fantidis P, Castejon R, Fernández
Ruiz A, Madero-Jarabo R, Cordovilla G, Sanz Galeote E. Does a critical
hemodynamic situation develop from right ventriculotomy and free
wall infarct or from small changes in dysfunctional right ventricle
afterload? J Cardiovasc Surg (Torino) 1992;33:229-34.
810. Braat SH, Ramentol M, Halders S, Wellens
HJ. Reperfusion with streptokinase of an occluded right coronary
artery: effects on early and late right and left ventricular ejection
fraction. Am Heart J 1987;113:257-60.
811. Schuler G, Hofmann M, Schwarz F, et al. Effect
of successful thrombolytic therapy on right ventricular function
in acute inferior wall myocardial infarction. Am J Cardiol 1984;54:951-7.
812. Moreyra AE, Suh C, Porway MN, Kostis JB.
Rapid hemodynamic improvement in right ventricular infarction after
coronary angioplasty. Chest 1988;94:197-9.
813. Gott JP, Han DC. Surgical treatment of acute
myocardial infarct: clinical considerations. Semin Thorac Cardiovasc
Surg 1995;7: 198-207.
814. Roberts N, Harrison DG, Reimer KA, Crain
BS, Wagner GS. Right ventricular infarction with shock but without
significant left ventricular infarction: a new clinical syndrome.
Am Heart J 1985;110:1047-53.
815. Dell’Italia LJ, Starling MR, O’Rourke
RA. Physical examination for exclusion of hemodynamically important
right ventricular infarction. Ann Intern Med 1983;99:608-11.
816. Serrano Júnior CV, Ramires JA, César
LA, et al. Prognostic significance of right ventricular dysfunction
in patients with acute inferior myocardial infarction and right
ventricular involvement. Clin Cardiol 1995;18:199-205.
817. Berger PB, Ruocco NA, Ryan TJ, et al, for
the The TIMI Research Group. Frequency and significance of right
ventricular dysfunction during inferior wall left ventricular myocardial
infarction treated with thrombolytic therapy (results from the thrombolysis
in myocardial infarction [TIMI] II trial). Am J Cardiol 1993;71:1148-52.
818.
Andersen HR, Falk E, Nielsen D. Right ventricular infarction: frequency,
size and topography in coronary heart disease: a prospective study
comprising 107 consecutive autopsies from a coronary care unit.
J Am Coll Cardiol 1987;10:1223-32.
819.
Roberts N, Harrison DG, Reimer KA, Crain BS, Wagner GS. Right ventricular
infarction with shock but without significant ventricular infarction:
a new clinical syndrome. Am Heart 1985;110:1047-53.
820.
Serrano Júnior CV, Ramires JA, César LA, et al. Prognostic
significance of right ventricular dysfunction in patients with acute
inferior myocardial infarction and right ventricular involvement.
Clin Cardiol 1995;18:199-205.
821.
Berger PB, Ruocco NA, Ryan TJ, et al, for the TIMI Research Group.
Frequency and significance of right ventricular dysfunction during
inferior wall left ventricular myocardial infarction treated with
thrombolytic therapy (results from the thrombolysis in myocardial
infarction [TIMI] II trial). Am J Cardiol 1993;71:1148-52.
822.
Calvin JE. Optimal right ventricular filling pressures and the role
of pericardial constraint in right ventricular infarction in dogs.
Circulation 1991;84:852-61.
823.
Tobinick E, Schelbert HR, Henning H, et al. Right ventricular ejection
fraction in patients with acute anterior and inferior myocardial
infarction assessed by radionuclide angiography. Circulation 1978;57:1078-84.
824.
Boldt J, Kling D, Thiel A, Scheld HH, Hempelmann Revascularization
of the right coronary artery: influence on thermodilution right
ventricular ejection fraction. J Cardiothoracic Anesth 1998;2:140-146.
825.
Polak JF, Holman BL, Wynne J, Colucci WS. Right ventricular ejection
fraction: an indicator of increased mortality in patients with congestive
heart failure associated with coronary artery disease. J Am Coll
Cardiol 1983;2:217-24.
826.
Lloyd EA, Gersh BJ, Kennelly BM. Hemodynamic spectrum “‘dominant”
right ventricular infarction in 19 patients. Am Cardiol 1981;48:1016-22.
827.
Klein HO, Tordjman T, Ninio R, et al. The early recognition right
ventricular infarction: diagnostic accuracy of the electrocardiographic
V4R lead. Circulation 1983;67:558-65.
828.
Bellamy GR, Rasmussen HH, Nasser FN, Wiseman JC, Cooper RA. Value
of two-dimensional echocardiography, electrocardiography, and clinical
signs in detecting right ventricular infarction. Am Heart J 1986;112:304-9.
829.
Birnbaum Y, Fishbein MC, Blanche C, Siegel RJ. Ventricular septal
rupture after acute myocardial infarction. N Engl J Med 2002;347:1426-32.
830.
Snyder RW, Glamann DB, Lange RA, et al. Predictive value prominent
pulmonary arterial wedge V waves in assessing presence and severity
of mitral regurgitation. Am J Cardiol 1994;73:568-70.
831.
Dalrymple-Hay MJ, Langley SM, Sami SA, et al. Should coronary artery
bypass grafting be performed at the same time repair of a post-infarct
ventricular septal defect? Eur Cardiothorac Surg 1998;13:286-92.
832.
Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due
to acute severe mitral regurgitation complicating acute myocardial
infarction: a report from the SHOCK Trial Registry. SHould we use
emergently revascularize Occluded Coronaries cardiogenic shocK?
J Am Coll Cardiol 2000;36:1104-9.
833.
Lamas GA, Mitchell GF, Flaker GC, et al, for the Survival and Ventricular
Enlargement Investigators. Clinical significance of mitral regurgitation
after acute myocardial infarction. Circulation 1997;96:827-33.
834.
Tepe NA, Edmunds LH. Operation for acute postinfarction mitral insufficiency
and cardiogenic shock. J Thorac Cardiovasc Surg 1985;89:525-30.
835.
Tavakoli R, Weber A, Vogt P, Brunner HP, Pretre R, Turina M. Surgical
management of acute mitral valve regurgitation due post-infarction
papillary muscle rupture. J Heart Valve Dis 2002;11:20-5; discussion
26.
836.
Chen Q, Darlymple-Hay MJ, Alexiou C, et al. Mitral valve surgery
for acute papillary muscle rupture following myocardial infarction.
J Heart Valve Dis 2002;11:27-31.
837.
Kishon Y, Oh JK, Schaff HV, Mullany CJ, Tajik AJ, Gersh BJ. Mitral
valve operation in postinfarction rupture of a papillary muscle:
immediate results and long-term follow-up of 22 patients. Mayo Clin
Proc 1992;67:1023-30.
838.
Fasol R, Lakew F, Wetter S. Mitral repair in patients with a ruptured
papillary muscle. Am Heart J 2000;139:549-54.
839.
Nishimura RA, Gersh BJ, Schaff HV. The case for an aggressive surgical
approach to papillary muscle rupture following myocardial infarction:
“from paradise lost to paradise regained”. Heart 2000;83:611-3.
840.
Byrne JG, Aranki SF, Cohn LH. Repair versus replacement of mitral
valve for treating severe ischemic mitral regurgitation. Coron Artery
Dis 2000;11:31-3.
841.
Adams DH, Filsoufi F, Aklog L. Surgical treatment of the ischemic
mitral valve. J Heart Valve Dis 2002;11:S21-5.
842.
Crenshaw BS, Granger CB, Birnbaum Y, et al, for the GUSTO- (Global
Utilization of Streptokinase and TPA for Occluded Coronary Arteries)
Trial Investigators. Risk factors, angiographic patterns, and outcomes
in patients with ventricular septal defect complicating acute myocardial
infarction. Circulation 2000; 101:27-32.
843.
Prêtre R, Ye Q, Grünenfelder J, Lachat M, Vogt PR, Turina
MI. Operative results of “repair” of ventricular septal
rupture after acute myocardial infraction. Am J Cardiol 1999;84:785-8.
844.
Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture
of the ventricular septum after acute myocardial infarction and
role of early surgical intervention. Am J Cardiol 1992;70:147- 51.
845.
Skillington PD, Davies RH, Luff AJ, et al. Surgical treatment for
infarct-related ventricular septal defects: improved early results
combined with analysis of late functional status. J Thorac Cardiovasc
Surg 1990;99:798-808.
846.
Topaz O, Taylor AL. Interventricular septal rupture complicating
acute myocardial infarction: from pathophysiologic features to the
role of invasive and noninvasive diagnostic modalities in current
management. Am J Med 1992;93:683-8.
847.
Westaby S, Parry A, Ormerod O, Gooneratne P, Pillai R. Thrombolysis
and postinfarction ventricular septal rupture. Thorac Cardiovasc
Surg 1992;104:1506-9.
848.
Muehrcke DD, Daggett WM, Buckley MJ, Akins CW, Hilgenberg AD, Austen
WG. Postinfarct ventricular septal defect repair: effect of coronary
artery bypass grafting. Ann Thorac Surg 1992;54:876-82; discussion
8.
849.
Menon V,Webb JG, Hillis LD, et al. Outcome and profile of ventricular
septal rupture with cardiogenic shock after myocardial infarction:
a report from the SHOCK Trial Registry. SHould we emergently revascularize
Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000;36:1110-6.
850.
Szkutnik M, Bialkowski J, Kusa J, et al. Postinfarction ventricular
septal defect closure with Amplatzer occluders. Eur J Cardiothorac
Surg 2003;23:323-7.
851.
Yusuf S,Wittes J, Friedman L. Overview of results of randomized
clinical trials in heart disease: I–treatments following myocardial
infarction. JAMA 1988;260:2088-93. 852. Nakamura F, Minamino T,
Higashino Y, et al. Cardiac free wall rupture in acute myocardial
infarction: ameliorative effect of coronary reperfusion. Clin Cardiol
1992;15:244-50.
853.
Pollak H, Nobis H, Mlczoch J. Frequency of left ventricular free
wall rupture complicating acute myocardial infarction since the
advent of thrombolysis. Am J Cardiol 1994;74:184-6.
854.
Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac
rupture in the United States National Registry of Myocardial Infarction.
J Am Coll Cardiol 1996;27:1321-6.
855.
Honan MB, Harrell FE, Reimer KA, et al. Cardiac rupture, mortality
and the timing of thrombolytic therapy: a meta-analysis. J Am Coll
Cardiol 1990;16:359-67.
856. Becker RC, Charlesworth A, Wilcox RG, et
al. Cardiac rupture associated with thrombolytic therapy: impact
of time to treatment in the Late Assessment of Thrombolytic Efficacy
(LATE) study. J Am Coll Cardiol 1995;25:1063-8.
857.
Núñez L, de la Llana R, López Sendón
J, et al. Diagnosis and treatment of subacute free wall ventricular
rupture after infarction. Ann Thorac Surg 1983;35:525-9.
858. Balakumaran K,Verbaan CJ, Essed CE, et al.
Ventricular free wall rupture: sudden, subacute, slow, sealed and
stabilized varieties. Eur Heart J 1984;5:282-8.
859.
McMullan MH, Maples MD, Kilgore TL, Hindman SH. Surgical experience
with left ventricular free wall rupture. Ann Thorac Surg 2001;71:1894-8;
discussion 1.
860.
Padró JM, Mesa JM, Silvestre J, et al. Subacute cardiac rupture:
repair with a sutureless technique. Ann Thorac Surg 1993;55:20-
3; discussion 23.
861.
Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to
cardiac free-wall rupture or tamponade after acute myocardial infarction:
a report from the SHOCK Trial Registry. Should we emergently revascularize
occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000;36:1117-22.
862.
Tikiz H, Balbay Y, Atak R, Terzi T, Genç Y, Kütük
E. The effect of thrombolytic therapy on left ventricular aneurysm
formation in acute myocardial infarction: relationship to successful
reperfusion and vessel patency. Clin Cardiol 2001;24:656-62.
863.
Premaratne S, Razzuk AM, Koduru SB, Behling A, McNamara JJ. Incidence
of postinfarction aneurysm within one month of infarct: experiences
with sixteen patients in Hawaii. J Cardiovasc Surg (Torino) 1999;40:473-6.
864.
Pasini S, Gagliardotto P, Punta G, et al. Early and late results
after surgical therapy of postinfarction left ventricular aneurysm.
J Cardiovasc Surg (Torino) 1998;39:209-15.
865.
Ohara K. Current surgical strategy for post-infarction left ventricular
aneurysm: from linear aneurysmectomy to Dor’s operation. Ann
Thorac Cardiovasc Surg 2000;6:289-94.
866.
Di Donato M, Sabatier M, Montiglio F, et al. Outcome of left ventricular
aneurysmectomy with patch repair in patients with severely depressed
pump function. Am J Cardiol 1995;76:557-61.
867.
Di Donato M, Toso A, Maioli M, et al, for the RESTORE Group. Intermediate
survival and predictors of death after surgical ventricular restoration.
Semin Thorac Cardiovasc Surg 2001;13:468-75.
868. Stevenson LW, Kormos RL, Bourge RC, et al.
Mechanical cardiac support 2000: current applications and future
trial design. June 15-16, 2000 Bethesda, Maryland. J Am Coll Cardiol
2001;37:340-70.
869. Pennington DG, Smedira NG, Samuels LE, Acker
MA, Curtis JJ, Pagani FD. Mechanical circulatory support for acute
heart failure. Ann Thorac Surg 2001;71:S56-9; discussion S8.
870. Chen JM, DeRose JJ, Slater JP, et al. Improved
survival rates support left ventricular assist device implantation
early after myocardial infarction. J Am Coll Cardiol 1999;33:1903-8.
871. Champagnac D, Claudel JP, Chevalier P, et
al. Primary cardiogenic shock during acute myocardial infarction:
results of emergency cardiac transplantation. Eur Heart J 1993;14:925-9.
872. Park SJ, Nguyen DQ, Bank AJ, Ormaza S, Bolman
RM. Left ventricular assist device bridge therapy for acute myocardial
infarction. Ann Thorac Surg 2000;69:1146-51.
873. Hendry PJ, Masters RG, Mussivand TV, et al.
Circulatory support for cardiogenic shock due to acute myocardial
infarction: a Canadian experience. Can J Cardiol 1999;15:1090-4.
874. Karagueuzian HS, Mandel WJ. Electrophysiologic
mechanisms of ischemic ventricular arrhythmias: experimental and
clinical correlations. In Mandel WJ, ed. Cardiac arrhythmias: their
mechanisms, diagnosis, and management. Philadelphia, PA: JB Lippincott;1995:563-603.
875. Carmeliet E. Cardiac ionic currents and acute
ischemia: from channels to arrhythmias. Physiol Rev 1999;79:917-1017.
876. Campbell RWF. Arrhythmias. In: Julian DG.
Braunwald E, eds. Management of acute myocardial infarction. London,
England: WB Saunders Co. Ltd;1994:223-240.
877. Nordrehaug JE, von der Lippe G. Hypokalaemia
and ventricular fibrillation in acute myocardial infarction. Br
Heart J 1983;50:525-9.
878. Higham PD, Adams PC, Murray A, Campbell RW.
Plasma potassium, serum magnesium and ventricular fibrillation:
a prospective study. Q J Med 1993;86:609-17.
879. Volpi A, Cavalli A, Santoro E, Tognoni G,
for the GISSI Investigators. Incidence and prognosis of secondary
ventricular fibrillation in acute myocardial infarction: evidence
for a protective effect of thrombolytic therapy. Circulation 1990;82:1279-88.
880. Ornato JP, Peberdy MA, Tadler SC, Strobos
NC. Factors associated with the occurrence of cardiac arrest during
hospitalization for acute myocardial infarction in the second national
registry of myocardial infarction in the US. Resuscitation 2001;48:117-23.
881. Campbell RW, Murray A, Julian DG. Ventricular
arrhythmias in first 12 hours of acute myocardial infarction: natural
history study. Br Heart J 1981;46:351-7.
882. Antman EM, Berlin JA. Declining incidence
of ventricular fibrillation in myocardial infarction: implications
for the prophylactic use of lidocaine. Circulation 1992;86:764-73.
883. Thompson CA, Yarzebski J, Goldberg RJ, Lessard
D, Gore JM, Dalen JE. Changes over time in the incidence and case-fatality
rates of primary ventricular fibrillation complicating acute myocardial
infarction: perspectives from the Worcester Heart Attack Study.
Am Heart J 2000;139:1014-21.
884. Behar S, Goldbourt U, Reicher-Reiss H, Kaplinsky
E, for the Principal Investigators of the SPRINT Study. Prognosis
of acute myocardial infarction complicated by primary ventricular
fibrillation. Am J Cardiol 1990;66:1208-11.
885. Lown B, Fakhro AM, Hood WB, Thorn GW. The
coronary care unit: new perspectives and directions. JAMA 1967;199:188-98.
886.
Dhurandhar RW, MacMillan RL, Brown KW. Primary ventricular fibrillation
complicating acute myocardial infarction. Am J Cardiol 1971;27:347-51.
887.
El-Sherif N, Myerburg RJ, Scherlag BJ, et al. Electrocardiographic
antecedents of primary ventricular fibrillation: value of the R-on-T
phenomenon in myocardial infarction. Br Heart J 1976;38:415-22.
888.
Lie KI, Wellens HJ, Durrer D. Characteristics and predictability
of primary ventricular fibrillation. Eur J Cardiol 1974;1:379-84.
889.
Solomon SD, Ridker PM, Antman EM. Ventricular arrhythmias in trials
of thrombolytic therapy for acute myocardial infarction: a meta-analysis.
Circulation 1993;88:2575-81.
890.
MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic
lidocaine in suspected acute myocardial infarction: an overview
of results from the randomized, controlled trials. JAMA 1988;260:1910-6.
891.
Alexander JH, Granger CB, Sadowski Z, et al, for the GUSTO-I and
GUSTO-IIb Investigators. Prophylactic lidocaine use in acute myocardial
infarction: incidence and outcomes from two international trials.
Am Heart J 1999;137:799-805.
892.
Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol
trial: effects on mortality and morbidity in acute myocardial infarction.
Circulation 1983;67:I26-32.
893.
Guidelines for cardiopulmonary resuscitation and emergency cardiac
care: part III–adult advanced cardiac life support. Emergency
Cardiac Care Committee and Subcommittees, American Heart Association.
JAMA 1992;268:2199-241.
894.
de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Circumstances
and causes of out-of-hospital cardiac arrest in sudden death survivors.
Heart 1998;79:356-61.
895.
Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation
after out-of-hospital cardiac arrest due to ventricular fibrillation.
N Engl J Med 1999;341:871-8.
896.
Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone
as compared with lidocaine for shock-resistant ventricular fibrillation.
N Engl J Med 2002;346:884-90.
897. Haynes RE, Chinn TL, Copass MK, Cobb LA.
Comparison of bretylium tosylate and lidocaine in management of
out of hospital ventricular fibrillation: a randomized clinical
trial. Am J Cardiol 1981;48:353-6.
898.
Olson DW, Thompson BM, Darin JC, Milbrath MH. A randomized comparison
study of bretylium tosylate and lidocaine in resuscitation of patients
from out-of-hospital ventricular fibrillation in a paramedic system.
Ann Emerg Med 1984;13:807-10.
899.
Stiell IG, Wells GA, Hebert PC, Laupacis A, Weitzman BN. Association
of drug therapy with survival in cardiac arrest: limited role of
advanced cardiac life support drugs. Acad Emerg Med 1995;2:264-73.
900.
Guidelines 2000 for cardiopulmonary resuscitation and emergency
cardiovascular care: part 6–advanced cardiovascular life support:
section 6–pharmacology II: agents to optimize cardiac output
and blood pressure. The American Heart Association in collaboration
with the International Liaison Committee on Resuscitation. Circulation
2000;102:I129-35.
901.
Eldar M, Sievner Z, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar
S, for the SPRINT Study Group. Primary ventricular tachycardia in
acute myocardial infarction: clinical characteristics and mortality.
Ann Intern Med 1992;117:31-6.
902.
Wolfe CL, Nibley C, Bhandari A, Chatterjee K, Scheinman M. Polymorphous
ventricular tachycardia associated with acute myocardial infarction.
Circulation 1991;84:1543-51.
903.
Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ. Incidence
and significance of ventricular tachycardia and fibrillation in
the absence of hypotension or heart failure in acute myocardial
infarction treated with recombinant tissue-type plasminogen activator:
results from the Thrombolysis in Myocardial Infarction (TIMI) Phase
II trial. J Am Coll Cardiol 1993;22:1773-9.
904.
Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic
amiodarone on mortality after acute myocardial infarction and in
congestive heart failure: meta-analysis of individual data from
6500 patients in randomised trials. Lancet 1997;350:1417- 24.
905.
Nademanee K, Taylor R, Bailey WE, et al. Management and longterm
outcome of patients with electrical storm [abstr]. J Am Coll Cardiol
1995;l25:187A.
906. Scheinman MM, Levine JH, Cannom DS, et al,
for the Intravenous Amiodarone Multicenter Investigators Group.
Doseranging study of intravenous amiodarone in patients with lifethreatening
ventricular tachyarrhythmias. Circulation 1995; 92:3264-72.
907.
Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating
electrical storm: sympathetic blockade versus advanced cardiac life
support-guided therapy. Circulation 2000;102:742-7.
908.
Correction: a randomized study of the prevention of sudden death
in patients with coronary artery disease. N Engl J Med 2000;342:1300.
909.
Shea S, Bigger JT, Campion J, et al. Enrollment in clinical trials:
institutional factors affecting enrollment in the cardiac arrhythmia
suppression trial (CAST). Control Clin Trials 1992;13:466-86.
910.
Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A,
for the GUSTO Investigators. Sustained ventricular arrhythmias in
patients receiving thrombolytic therapy: incidence and outcomes.
Circulation 1998;98:2567-73.
911.
Al-Khatib SM, Stebbins AL, Califf RM, et al. Sustained ventricular
arrhythmias and mortality among patients with acute myocardial infarction:
results from the GUSTO-III trial. Am Heart J 2003;145:515-21.
912.
The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.
A comparison of antiarrhythmic-drug therapy with implantable defibrillators
in patients resuscitated from near-fatal ventricular arrhythmias.
N Engl J Med 1997;337:1576-83.
913.
Siebels J, Kuck KH. Implantable cardioverter defibrillator compared
with antiarrhythmic drug treatment in cardiac arrest survivors (the
Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-44.
914.
Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator
study (CIDS): a randomized trial of the implantable cardioverter
defibrillator against amiodarone. Circulation 2000;101:1297-302.
915.
Moss AJ, Hall WJ, Cannom DS, et al, for the Multicenter Automatic
Defibrillator Implantation Trial Investigators. Improved survival
with an implanted defibrillator in patients with coronary disease
at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
916.
Buxton AE, Lee KL, Fisher JD, et al, for the Multicenter Unsustained
Tachycardia Trial Investigators. A randomized study of the prevention
of sudden death in patients with coronary artery disease. N Engl
J Med 1999;341:1882-90.
917.
Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic
Defibrillator Implantation Trial II Investigators. Prophylactic
implantation of a defibrillator in patients with myocardial infarction
and reduced ejection fraction. N Engl J Med 2002;346:877- 83.
918.
Lee KL, Hafley G, Fisher JD, et al, for the Multicenter Unsustained
Tachycardia Trial Investigators. Effect of implantable defibrillators
on arrhythmic events and mortality in the multicenter unsustained
tachycardia trial. Circulation 2002;106:233-8.
919.
Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships
among ventricular arrhythmias, left ventricular dysfunction, and
mortality in the 2 years after myocardial infarction. Circulation
1984;69:250-8.
920.
Buxton AE, Marchlinski FE, Waxman HL, Flores BT, Cassidy DM, Josephson
ME. Prognostic factors in nonsustained ventricular tachycardia.
Am J Cardiol 1984;53:1275-9.
921.
Buxton AE, Lee KL, DiCarlo L, et al, for the Multicenter Unsustained
Tachycardia Trial Investigators. Electrophysiologic testing to identify
patients with coronary artery disease who are at risk for sudden
death. N Engl J Med 2000;342:1937-45.
922. Buxton AE, Lee KL, Hafley GE, et al, for
the MUSTT Investigators. Relation of ejection fraction and inducible
ventricular tachycardia to mode of death in patients with coronary
artery disease: an analysis of patients enrolled in the multicenter
unsustained tachycardia trial. Circulation 2002;106:2466-72.
923.
Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular
function after myocardial infarction in the reperfusion era: the
healing and early afterload reducing therapy study. Ann Intern Med
2001;134:451-8.
924.
Ureña PE, Lamas GA, Mitchell G, et al, for the Survival and
Ventricular Enlargement (SAVE) Investigators. Ejection fraction
by radionuclide ventriculography and contrast left ventriculogram:
a tale of two techniques. J Am Coll Cardiol 1999;33:180-5.
925.
Deleted in press.
926.
Auricchio A, Klein H, Geller CJ, Reek S, Heilman MS, Szymkiewicz
SJ. Clinical efficacy of the wearable cardioverterdefibrillator
in acutely terminating episodes of ventricular fibrillation. Am
J Cardiol 1998;81:1253-6.
927. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis
SA, Zaga AK, Nanas JN. Intravenous amiodarone decreases the duration
of atrial fibrillation associated with acute myocardial infarction.
Cardiovasc Drugs Ther 2001;15:155-60.
928.
Nielsen FE, Andersen HH, Gram-Hansen P, Sørensen HT, Klausen
IC. The relationship between ECG signs of atrial infarction and
the development of supraventricular arrhythmias in patients with
acute myocardial infarction. Am Heart J 1992;123:69-72.
929.
Kyriakidis M, Barbetseas J, Antonopoulos A, Skouros C, Tentolouris
C, Toutouzas P. Early atrial arrhythmias in acute myocardial infarction:
role of the sinus node artery. Chest 1992;101:944-7.
930.
Hildebrandt P, Jensen G, Køber L, et al. Myocardial infarction
1979-1988 in Denmark: secular trends in age-related incidence, in-hospital
mortality and complications. Eur Heart J 1994;15:877-81.
931.
Waldo AL. An approach to therapy of supraventricular tachyarrhythmias:
an algorithm versus individualized therapy. Clin Cardiol 1994;17:II21-6.
932.
Liberthson RR, Salisbury KW, Hutter AM, DeSanctis RW. Atrial tachyarrhythmias
in acute myocardial infarction. Am J Med 1976;60:956-60.
933.
Kobayashi Y, Katoh T, Takano T, Hayakawa H. Paroxysmal atrial fibrillation
and flutter associated with acute myocardial infarction: hemodynamic
evaluation in relation to the development of arrhythmias and prognosis.
Jpn Circ J 1992;56:1-11.
934.
Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction
complicated by atrial fibrillation in the elderly: prevalence and
outcomes. Circulation 2000;101:969-74.
935.
Pedersen OD, Bagger H, Køber L, Torp-Pedersen C, for the
TRAndolapril Cardiac Evaluation (TRACE) Study Group. The occurrence
and prognostic significance of atrial fibrillation/-flutter following
acute myocardial infarction. Eur Heart J 1999; 20:748-54.
936. Goldberg RJ, Seeley D, Becker RC, et al.
Impact of atrial fibrillation on the in-hospital and long-term survival
of patients
with acute myocardial infarction: a community-wide perspective.
Am Heart J 1990;119:996-1001.
937.
Hod H, Lew AS, Keltai M, et al. Early atrial fibrillation during
evolving myocardial infarction: a consequence of impaired left atrial
perfusion. Circulation 1987;75:146-50.
938.
Rechavia E, Strasberg B, Mager A, et al. The incidence of atrial
arrhythmias during inferior wall myocardial infarction with and
without right ventricular involvement. Am Heart J 1992;124:387-
91.
939.
Behar S, Tanne D, Zion M, et al, for the Secondary Prevention Reinfarction
Israeli Nifedipine Trial (SPRINT) Study Group. Incidence and prognostic
significance of chronic atrial fibrillation among 5,839 consecutive
patients with acute myocardial infarction. Am J Cardiol 1992;70:816-8.
940.
James TN. Myocardial infarction and atrial arrhythmias. Circulation
1961;24:761-76.
941.
Nielsen FE, Sørensen HT, Christensen JH, Ravn L, Rasmussen
SE. Reduced occurrence of atrial fibrillation in acute myocardial
infarction treated with streptokinase. Eur Heart J 1991;12:1081-3.
942.
Eldar M, Canetti M, Rotstein Z, et al, for the SPRINT and Thrombolytic
survey groups. Significance of paroxysmal atrial fibrillation complicating
acute myocardial infarction in the thrombolytic era. Circulation
1998;97:965-70.
943. Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss
H, for the SPRINT Study Group. Long-term prognosis of patients with
paroxysmal atrial fibrillation complicating acute myocardial infarction.
Eur Heart J 1992;13:45-50.
944.
Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf
RM. Atrial fibrillation in the setting of acute myocardial infarction:
the GUSTO-I experience. Global Utilization of Streptokinase and
TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:406-13.
945.
Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after
acute myocardial infarction independently predicts death: the GUSTO-III
experience. Am Heart J 2000;140:878-85.
946.
Incidence and prognostic significance of atrial fibrillation in
acute myocardial infarction: the GISSI-3 data. Heart 2001;86:527-32.
947.
Lesser MF. Safety and efficacy of in-office cardioversion for treatment
of supraventricular arrhythmias. Am J Cardiol 1990; 66:1267-8.
948.
Joglar JA, Hamdan MH, Ramaswamy K, et al. Initial energy for elective
external cardioversion of persistent atrial fibrillation. Am J Cardiol
2000;86:348-50.
949.
Dahl CF, Ewy GA,Warner ED, Thomas ED. Myocardial necrosis from direct
current countershock. Effect of paddle electrode size and time interval
between discharges. Circulation 1974;50:956- 61.
950.
Moss AJ, Oakes D, Benhorin J, Carleen E, for the Multicenter Diltiazem
Post-Infarction Research Group. The interaction between diltiazem
and left ventricular function after myocardial infarction. Circulation
1989;80:IV102-6.
951. Clemo HF,Wood MA, Gilligan DM, Ellenbogen
KA. Intravenous amiodarone for acute heart rate control in the critically
ill patient with
atrial tachyarrhythmias. Am J Cardiol 1998;81:594-8.
952.
Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration,
and ventricular rate of paroxysmal atrial fibrillation: the effect
of digoxin. Br Heart J 1990;63:225-7.
953.
Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind placebo-
controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation.
Circulation 1999;99:2765-70.
954.
Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular
rate control in chronic atrial fibrillation during daily activity
and programmed exercise: a crossover open-label study of five drug
regimens. J Am Coll Cardiol 1999;33:304-10.
955.
Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for
the management of patients with atrial fibrillation: executive summary:
a report of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines and the European Society of Cardiology
Committee for Practice Guidelines and Policy Conferences (Committee
to Develop Guidelines for the Management of Patients With Atrial
Fibrillation). J Am Coll Cardiol 2001;38:1231-66.
956. Lavie CJ, Gersh BJ. Mechanical and electrical
complications of acute myocardial infarction. Mayo Clin Proc 1990;65:709-30.
957.
Wong CK, White HD, Wilcox RG, et al, for the GUSTO-III Investigators.
Management and outcome of patients with atrial fibrillation during
acute myocardial infarction: the GUSTO-III experience. Global use
of strategies to open occluded coronary arteries. Heart 2002;88:357-62.
958.
A comparison of rate control and rhythm control in patients with
atrial fibrillation. N Engl J Med 2002;347:1825-33.
959.
Antman EM. General hospital management. In: Julian DG, Braunwald
E, eds. Management of acute myocardial infarction. London, England:
WB Saunders Co Ltd; 1994:42-4.
960. Brady WJ, Harrigan RA. Diagnosis and management
of bradycardia and atrioventricular block associated with acute
coronary ischemia. Emerg Med Clin North Am 2001;19:371-84, xi-xii.
961.
Pasternak RC, Braunwald E, Sobel BE. Acute myocardial infarction:
In: Braunwald E, ed. Heart disease: a textbook of cardiovascular
medicine. Philadelphia, Pa: WB Saunders Co Ltd; 1992:1240-9.
962.
Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Jacobs AK, Faxon DP.
Incidence and prognostic implications of heart block complicating
inferior myocardial infarction treated with thrombolytic therapy:
results from TIMI II. J Am Coll Cardiol 1992;20:533-40.
963.
McDonald K, O’Sullivan JJ, Conroy RM, Robinson K, Mulcahy
R. Heart block as a predictor of in-hospital death in both acute
inferior and acute anterior myocardial infarction. Q J Med 1990;74:277-82.
964.
Nicod P, Gilpin E, Dittrich H, Polikar R, Henning H, Ross J. Long-term
outcome in patients with inferior myocardial infarction and complete
atrioventricular block. J Am Coll Cardiol 1988;12:589-94.
965.
Antman EM. Cardiovascular therapeutics: a companion guide to Braunwald’s
heart disease. 2nd ed. Philadelphia, Pa: WB Saunders Co Ltd; 2001:273.
966.
Mahr NC, Valdes A, Lamas G. Use of glucagon for acute intravenous
diltiazem toxicity. Am J Cardiol 1997;79:1570-1.
967.
Topol EJ, Goldschlager N, Ports TA, et al. Hemodynamic benefit of
atrial pacing in right ventricular myocardial infarction. Ann Intern
Med 1982;96:594-7.
968.
Mavric Z, Zaputovic L, Matana A, et al. Prognostic significance
of complete atrioventricular block in patients with acute inferior
myocardial infarction with and without right ventricular involvement.
Am Heart J 1990;119:823-8.
969. Wenzel V, Krismer AC, Arntz HR, Sitter H,
Stadlbauer KH, Lindner KH, for the European Resuscitation Council
Vasopressor during Cardiopulmonary Resuscitation Study Group. A
comparison
of vasopressin and epinephrine for out-of-hospital cardiopulmonary
resuscitation. N Engl J Med 2004;350:105-13.
970. Hindman MC, Wagner GS, JaRo M, et al. The
clinical significance of bundle branch block complicating acute
myocardial infarction: 2.–Indications for temporary and permanent
pacemaker
insertion. Circulation 1978;58:689-99.
971. Col JJ,Weinberg SL. The incidence and mortality
of intraventricular conduction defects in acute myocardial infarction.
Am J Cardiol 1972;29:344-50.
972. Ritter WS, Atkins JM, Blomqvist CG, Mullins
CB. Permanent pacing in patients with transient trifascicular block
during acute myocardial infarction. Am J Cardiol 1976;38:205-8.
973. Ginks WR, Sutton R, Oh W, Leatham A. Long-term
prognosis after acute anterior infarction with atrioventricular
block. Br Heart J 1977;39:186-9.
974. Domenighetti G, Perret C. Intraventricular
conduction disturbances in acute myocardial infarction: short- and
long-term prognosis. Eur J Cardiol 1980;11:51-9.
975. Ranganathan N, Dhurandhar R, Phillips JH,
Wigle ED. His Bundle electrogram in bundle-branch block. Circulation
1972;45:282-94.
976. Lamas GA, Muller JE, Turi ZG, et al. A simplified
method to predict occurrence of complete heart block during acute
myocardial infarction. Am J Cardiol 1986;57:1213-9.
977. Harthorne JW, Barold SS. Atherosclerosis,
the conduction system and cardiac pacing. In: Fuster V, Ross R,
Topol EJ, eds. Atherosclerosis and coronary artery disease. Philadelphia,
PA: Lippincott-Raven Publishers;1996:1013-30.
978. Juma Z, Castellanos A, Myerburg
RJ. Prognostic significance of the electrocardiogram in patients
with coronary heart disease. In: Wellens HJJ, Kulbertus HE, eds.
What’s new in electrocardiography. The Hague: Martinus Nijhoff
Publishers; 1981:5-22 .
979. Clemmensen P, Bates ER, Califf RM, et al,
for the TAMI Study Group. Complete atrioventricular block complicating
inferior wall acute myocardial infarction treated with reperfusion
therapy. Am J Cardiol 1991;67:225-30.
980. Goldberg RJ, Zevallos JC, Yarzebski J, et
al. Prognosis of acute myocardial infarction complicated by complete
heart block (the Worcester Heart Attack Study). Am J Cardiol 1992;69:
1135-41.
981. Behar S, Zissman E, Zion M, et al, for the
SPRINT Study Group. Prognostic significance of second-degree atrioventricular
block in inferior wall acute myocardial infarction. Am J Cardiol
1993;72:831-4.
982. Lie KL,Wellens HJJ, Schuilenburg RM. Bundle
branch block and acute myocardial infarction. In: Wellens HJJ, Lie
KI, Janse MD, Eds. The conduction system of the heart: structure,
function and
clinical implications. Philadelphia, Pa: Lea & Febiger;1976:662-72.
983. Dubois C, Piérard LA, Smeets JP, Carlier
J, Kulbertus HE. Longterm prognostic significance of atrioventricular
block in inferior acute myocardial infarction. Eur Heart J 1989;10:816-20.
984. Gregoratos G, Abrams J, Epstein AE, et al.
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac
pacemakers and antiarrhythmia devices: summary article: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update
the 1998 Pacemaker Guidelines). J Am Coll Cardiol 2002;
40:1703-19.
985.
Wilkoff BL, Cook JR, Epstein AE, et al, for the Dual Chamber and
VVI Implantable Defibrillator Trial Investigators. Dualchamber pacing
or ventricular backup pacing in patients with an implantable defibrillator:
the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
JAMA 2002;288: 3115- 23.
986. Lamas GA, Ellenbogen KA. Evidence base for
pacemaker mode selection: from physiology to randomized trials.
Circulation 2004;109:443-51.
987. Rude RE, Poole WK, Muller JE, et al. Electrocardiographic
and clinical criteria for recognition of acute myocardial infarction
based on analysis of 3,697 patients. Am J Cardiol 1983;52:936- 42.
988.
Tofler GH, Muller JE, Stone PH, et al. Pericarditis in acute myocardial
infarction: characterization and clinical significance. Am Heart
J 1989;117:86-92.
989.
Wall TC, Califf RM, Harrelson-Woodlief L, et al, for the TAMI Study
Group. Usefulness of a pericardial friction rub after thrombolytic
therapy during acute myocardial infarction in predicting amount
of myocardial damage. Am J Cardiol 1990;66:1418-21.
990.
Oliva PB, Hammill SC. The clinical distinction between regional
postinfarction pericarditis and other causes of postinfarction chest
pain: ancillary observations regarding the effect of lytic therapy
upon the frequency of postinfarction pericarditis, postinfarction
angina, and reinfarction. Clin Cardiol 1994;17:471-8.
991.
Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines
for the clinical application of echocardiography: executive summary:
a report of the American College of Cardiology/ American Heart Association
Task Force on Practice Guidelines (Committee on Clinical Application
of Echocardiography). J Am Coll Cardiol 1997;29:862-79.
992. Oliva PB, Hammill SC, Talano JV. T wave changes
consistent with epicardial involvement in acute myocardial infarction:
observations in patients with a postinfarction pericardial effusion
without clinically recognized postinfarction pericarditis. J Am
Coll Cardiol 1994;24:1073-7.
993. Widimský P, Gregor P. Recent atrial
fibrillation in acute myocardial infarction: a sign of pericarditis.
Cor Vasa 1993;35:230-2.
994.
Erhardt LR. Clinical and pathological observations in different
types of acute myocardial infarction. Acta Med Scand 1974; 560:1-78.
995.
Spodick D. Pericardial complications of myocardial infarction. In:
Francis GS, Alpert JS, eds. Modern coronary care. Boston, MA: Little
Brown and Co; 1990:331-9.
996.
Shahar A, Hod H, Barabash GM, Kaplinsky E, Motro M. Disappearance
of a syndrome: Dressler’s syndrome in the era of thrombolysis.
Cardiology 1994;85:255-8.
997.
Jain A. “Tombstone” anterior ST-segment elevations secondary
to acute pericarditis: the role of two-dimensional echocardiogram.
Clin Cardiol 1997;20:404-6.
998.
Bonnefoy E, Godon P, Kirkorian G, Fatemi M, Chevalier P, Touboul
P. Serum cardiac troponin I and ST-segment elevation in patients
with acute pericarditis. Eur Heart J 2000;21:832-6.
999.
Berman J, Haffajee CI, Alpert JS. Therapy of symptomatic pericarditis
after myocardial infarction: retrospective and prospective studies
of aspirin, indomethacin, prednisone, and spontaneous resolution.
Am Heart J 1981;101:750-3.
1000.
Bulkley BH, Roberts WC. Steroid therapy during acute myocardial
infarction: a cause of delayed healing and of ventricular aneurysm.
Am J Med 1974;56:244-50.
1001.
Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E. Mummification
of the infarcted myocardium by high-dose corticosteroids. Circulation
1978;57:56-63.
1002.
Taylor SD, Chey WY, Scheiman JM. Acid secretion during indomethacin
therapy: effect of misoprostol. J Clin Gastroenterol 1995;20:131-5.
1003.
Weir MR, Klassen DK, Hall PS, et al. Minimization indomethacin-induced
reduction in renal function by misoprostol. J Clin Pharmacol 1991;31:729-35.
1004.
Spodick DH. Pericardial diseases. Eds. Braunwald E, Zipes DP, Libby
P. Heart disease: a textbook of cardiovascular medicine. 6th ed.
Philadelphia, PA: WB Saunders Co Ltd; 2001:1823.
1005.
O’Rourke RA, Fuster V, Alexander RW, Roberts R, King, SB III,
Welens HJJ. Hurst’s the heart. 10th ed. Manual of cardiology.
United States: McGraw-Hill Companies, Inc; 2001:2066.
1006.
Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for
recurrent pericarditis: a decade of experience. Circulation 1998;97:2183-5.
1007.
Brucato A, Cimaz R, Balla E. Prevention of recurrences of corticosteroid-
dependent idiopathic pericarditis by colchicine in an adolescent
patient. Pediatr Cardiol 2000;21:395-6.
1008.
Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004;363:717-27.
1009.
Antman EM. General hospital management. In: Julian DG, Braunwald
E, eds. Management of acute myocardial infarction. London, England:
WB Saunders Co Ltd; 1994:42-44.
1010.
Hutchins GM, Bulkley BH. Infarct expansion versus extension: two
different complications of acute myocardial infarction. Am J Cardiol
1978;41:1127-32.
1011.
Ohman EM, Califf RM, Topol EJ, et al, for the TAMI Study Group.
Consequences of reocclusion after successful reperfusion therapy
in acute myocardial infarction. Circulation 1990;82:781-91.
1012.
Antman E, Braunwald E. Acute myocardial infarction. In: Braunwald
E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular
medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001:1114-1251.
1013.
Tanne D, Gottlieb S, Hod H, Reicher-Reiss H, Boyko V, Behar for
the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT)
and Israeli Thrombolytic Survey Groups. Incidence and mortality
from early stroke associated with acute myocardial infarction in
the prethrombolytic and thrombolytic eras. J Am Coll Cardiol 1997;30:1484-90.
1014.
Mooe T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial
infarction: a population-based study. Stroke 1997; 28:762-7.
1015.
Mahaffey KW, Granger CB, Sloan MA, et al. Risk factors for inhospital
nonhemorrhagic stroke in patients with acute myocardial infarction
treated with thrombolysis: results from GUSTOI. Circulation 1998;97:757-64.
1016.
Prieto A, Eisenberg J, Thakur RK. Nonarrhythmic complications of
acute myocardial infarction. Emerg Med Clin North Am 2001; 19:397-415,
xii-xiii.
1017.
Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the
risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-7.
1018.
Bodenheimer MM, Sauer D, Shareef B, Brown MW, Fleiss JL, Moss AJ.
Relation between myocardial infarct location and stroke. J Am Coll
Cardiol 1994;24:61-6.
1019.
Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky Behar S,
for the SPRINT Study Group. Frequency and prognosis of stroke/TIA
among 4808 survivors of acute myocardial infarction. Stroke 1993;24:1490-5.
1020.
Spirito P, Bellotti P, Chiarella F, Domenicucci S, Sementa A, Vecchio
C. Prognostic significance and natural history of left ventricular
thrombi in patients with acute anterior myocardial infarction: a
two-dimensional echocardiographic study. Circulation 1985;72:774-80.
1021.
Celik S, Ovali E, Baykan M, et al. Factor V Leiden and its relation
to left ventricular thrombus in acute myocardial infarction. Acta
Cardiol 2001;56:1-6.
1022.
Stratton JR, Resnick AD. Increased embolic risk in patients with
left ventricular thrombi. Circulation 1987;75:1004-11.
1023.
Nordrehaug JE, Johannessen KA, von der Lippe G. Usefulness of high-dose
anticoagulants in preventing left ventricular thrombus in acute
myocardial infarction. Am J Cardiol 1985;55:1491- 3.
1024.
Vaitkus PT, Berlin JA, Schwartz JS, Barnathan ES. Stroke complicating
acute myocardial infarction: a meta-analysis of risk modification
by anticoagulation and thrombolytic therapy. Arch Intern Med 1992;152:2020-4.
1025. Arvan S, Boscha K. Prophylactic anticoagulation
for left ventricular thrombi after acute myocardial infarction:
a prospective randomized trial. Am Heart J 1987;113:688-93.
1026.
Eigler N, Maurer G, Shah PK. Effect of early systemic thrombolytic
therapy on left ventricular mural thrombus formation in acute anterior
myocardial infarction. Am J Cardiol 1984;54:261-3.
1027.
Motro M, Barbash GI, Hod H, et al. Incidence of left ventricular
thrombi formation after thrombolytic therapy with recombinant tissue
plasminogen activator, heparin, and aspirin in patients with acute
myocardial infarction. Am Heart J 1991;122:23-6.
1028.
Heik SC, Kupper W, Hamm C, et al. Efficacy of high-dose intravenous
heparin for treatment of left ventricular thrombi with high embolic
risk. J Am Coll Cardiol 1994;24:1305-9.
1029.
Barnett HJ, Taylor DW, Eliasziw M, et al, for the North American
Symptomatic Carotid Endarterectomy Trial Collaborators. Benefit
of carotid endarterectomy in patients with symptomatic moderate
or severe stenosis. N Engl J Med 1998;339:1415-25.
1030.
Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of
coagulation mechanism in unstable angina and myocardial infarction.
Circulation 1994;90:61-8.
1031.
AIMS Trial Study Group. Effect of intravenous APSAC on mortality
after acute myocardial infarction: preliminary report of a placebo-controlled
clinical trial. Lancet 1988;1:545-9.
1032.
Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W, for the Clopidogrel
Versus Aspirin in Patients at Risk of Ischemic Events Investigators.
Benefit of clopidogrel over aspirin is amplified in patients with
a history of ischemic events. Stroke 2004;35:528-32.
1033.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A.
European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic
acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
1034.
Rothwell PM, Gutnikov SA, Warlow CP, for the European Carotid Surgery
Trialists Collaboration. Reanalysis of the final results of the
European Carotid Surgery Trial. Stroke 2003;34:514-23.
1035.
Rothwell PM, Eliasziw M, Gutnikov SA, et al, for the Carotid Endarterectomy
Trialists’ Collaboration. Analysis of pooled data from the
randomised controlled trials of endarterectomy for symptomatic carotid
stenosis. Lancet 2003;361:107-16.
1036.
Wholey MH, Wholey M, Mathias K, et al. Global experience in cervical
carotid artery stent placement. Catheter Cardiovasc Interv 2000;50:160-7.
1037.
Malek AM, Higashida RT, Phatouros CC, et al. Stent angioplasty for
cervical carotid artery stenosis in high-risk symptomatic NASCET-ineligible
patients. Stroke 2000;31:3029-33.
1038.
Deleted in press.
1039.
Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology,
clinical features, and prevention. BMJ 2002; 325:887-90. 1040. Geerts
WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism.
Chest 2001;119:132S-175S.
1041.
Green L, Fay W, Frey KA, et al. Diagnosis and Treatment of Venous
Thromboembolic Disease Guideline. University of Michigan Health
System. National Guidelines Clearinghouse 2004. In press.
1042.
Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis
comparing low-molecular-weight heparins with unfractionated heparin
in the treatment of venous thromboembolism: examining some unanswered
questions regarding location of treatment, product type, and dosing
frequency. Arch Intern Med 2000;160:181-188.
1043.
Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for
venous thromboembolic disease. Chest 2001;119:176S-193S.
1044. American Heart Association/American College
of Cardiology Foundation guide to warfarin therapy. Circulation
2003; 107:1692-711.
1045.
Boden WE. Is it time to reassess the optimal timing of coronary
artery bypass graft surgery following acute myocardial infarction?
Am J Cardiol 2002;90:35-8.
1046.
Crossman AW, D’Agostino HJ, Geraci SA. Timing of coronary
artery bypass graft surgery following acute myocardial infarction:
a critical literature review. Clin Cardiol 2002;25:406-10.
1047. Braxton JH, Hammond GL, Letsou GV, et al.
Optimal timing of coronary artery bypass graft surgery after acute
myocardial infarction. Circulation 1995;92:II66-8.
1048.
Lee DC, Oz MC,Weinberg AD, Lin SX, Ting W. Optimal timing of revascularization:
transmural versus nontransmural acute myocardial infarction. Ann
Thorac Surg 2001;71:1197-202; discussion.
1049.
Creswell LL, Moulton MJ, Cox JL, Rosenbloom M. Revascularization
after acute myocardial infarction. Ann Thorac Surg 1995;60:19-26.
1050.
Acinapura AJ, Rose DM, Jacobowitz IJ, et al. Internal mammary artery
bypass grafting: influence on recurrent angina and survival in 2,100
patients. Ann Thorac Surg 1989;48:186-91.
1051.
Hirose H, Amano A, Yoshida S, et al. Surgical management of unstable
patients in the evolving phase of acute myocardial infarction. Ann
Thorac Surg 2000;69:425-8.
1052.
Hirotani T, Kameda T, Shirota S, Nakao Y. Coronary artery bypass
grafting within 30 days of an acute myocardial infarction. Ann Thorac
Cardiovasc Surg 2001;7:28-34.
1053.
Gersh BJ, Chesebro JH, Braunwald E, et al. Coronary artery bypass
graft surgery after thrombolytic therapy in the Thrombolysis in
Myocardial Infarction Trial, Phase II (TIMI II). J Am Coll Cardiol
1995;25:395-402.
1054.
Holmes DR, Califf RM, Topol EJ. Lessons we have learned from the
GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Arteries. J Am Coll Cardiol 1995;25:10S-17S.
1055.
Kereiakes DJ, Topol EJ, George BS, et al, for the TAMI Study Group.
Favorable early and long-term prognosis following coronary bypass
surgery therapy for myocardial infarction: results of a multicenter
trial. Am Heart J 1989;118:199-207.
1056.
Skinner JR, Phillips SJ, Zeff RH, Kongtahworn C. Immediate coronary
bypass following failed streptokinase infusion in evolving myocardial
infarction. J Thorac Cardiovasc Surg 1984;87:567-70.
1057. Barner HB, Lea JW, Naunheim KS, Stoney
WS. Emergency coronary bypass not associated with preoperative cardiogenic
shock in failed angioplasty, after thrombolysis, and for acute myocardial
infarction. Circulation 1989;79:I152-9.
1058. Efstratiadis T, Munsch C, Crossman D, Taylor
K. Aprotinin used in emergency coronary operation after streptokinase
treatment. Ann Thorac Surg 1991;52:1320-1.
1059. Breyer RH, Engelman RM, Rousou JA, Lemeshow
S. Postinfarction angina: an expanding subset of patients undergoing
coronary artery bypass. J Thorac Cardiovasc Surg 1985; 90:532-40.
1060. Hochberg MS, Parsonnet V, Gielchinsky I,
Hussain SM, Fisch DA, Norman JC. Timing of coronary revascularization
after acute myocardial infarction: early and late results in patients
revascularized within seven weeks. J Thorac Cardiovasc Surg 1984;88:914-21.
1061. Fremes SE, Goldman BS, Weisel RD, et al.
Recent preoperative myocardial infarction increases the risk of
surgery for unstable angina. J Card Surg 1991;6:2-12.
1062. Omoigui NA, Miller DP, Brown KJ, et al.
Outmigration for coronary bypass surgery in an era of public dissemination
of clinical outcomes. Circulation 1996;93:27-33.
1063. Burack JH, Impellizzeri P, Homel P, Cunningham
JN. Public reporting of surgical mortality: a survey of New York
State cardiothoracic surgeons. Ann Thorac Surg 1999;68:1195-200;
discussion.
1064. Nallamothu BK, Saint S, Ramsey SD, Hofer
TP, Vijan S, Eagle KA. The role of hospital volume in coronary artery
bypass grafting: is more always better? J Am Coll Cardiol 2001;38:1923-30.
1065. Applebaum R, House R, Rademaker A, et al.
Coronary artery bypass grafting within thirty days of acute myocardial
infarction: early and late results in 406 patients. J Thorac Cardiovasc
Surg 1991;102:745-52.
1066. Mangano DT, for the Multicenter Study of
Perioperative Ischemia Research Group. Aspirin and mortality from
coronary bypass surgery. N Engl J Med 2002;347:1309-17.
1067. Topol EJ. Aspirin with bypass
surgery: from taboo to new standard of care. N Engl J Med 2002;347:1359-60.
1068. Hongo RH, Ley J, Dick SE,Yee RR. The effect
of clopidogrel in combination with aspirin when given before coronary
artery bypass grafting. J Am Coll Cardiol 2002;40:231-7.
1069. Boehrer JD, Kereiakes DJ, Navetta FI, Califf
RM, Topol EJ, for the Evaluation Prevention of Ischemic Complications
(EPIC) Investigators. Effects of profound platelet inhibition with
c7E3 before coronary angioplasty on complications of coronary bypass
surgery. Am J Cardiol 1994;74:1166-70.
1070. Singh M, Nuttall GA, Ballman KV, et al.
Effect of abciximab on the outcome of emergency coronary artery
bypass grafting after failed percutaneous coronary intervention.
Mayo Clin Proc
2001;76:784-8.
1071. Lincoff AM, LeNarz LA, Despotis GJ, et
al. Abciximab and bleeding during coronary surgery: results from
the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab
GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition
in STENTing. Ann Thorac Surg 2000;70:516-26.
1072. Dyke C, Bhatia D. Inhibitors of the platelet
receptor glycoprotein
IIb-IIIa and complications during percutaneous coronary revascularization:
management strategies for the cardiac surgeon. J
Cardiovasc Surg (Torino) 1999;40:505-16.
1073.
Clopidigrel. Package insert. Physican’s Desk Reference. Medical
Economics Co. Montvale, NJ:2756.
1074.
Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines
for ambulatory electrocardiography: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography).
J Am Coll Cardiol 1999;34:912-48.
1075. Gibbons RJ, Balady GJ, Bricker JT, et al.
ACC/AHA 2002 guideline update for exercise testing: a report of
the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Exercise Testing). 2002.
Available at: http://www.acc.org/clinical/guidelines/exercise/ exercise_clean.pdf.
Accessed January 4, 2004.
1076.
Théroux P, Waters DD, Halphen C, Debaisieux JC, Mizgala HF.
Prognostic value of exercise testing soon after myocardial infarction.
N Engl J Med 1979;301:341-5.
1077. DeBusk RF, Kraemer HC, Nash E, Berger WE,
Lew H. Stepwise risk stratification soon after acute myocardial
infarction. Am J Cardiol 1983;52:1161-6.
1078.
Krone RJ, Gillespie JA,Weld FM, Miller JP, Moss AJ. Low-level exercise
testing after myocardial infarction: usefulness in enhancing clinical
risk stratification. Circulation 1985;71:80-9.
1079.
Valentine PA, Frew JL, Mashford ML, Sloman JG. Lidocaine in the
prevention of sudden death in the pre-hospital phase of acute infarction:
a double-blind study. N Engl J Med 1974;291:1327- 31.
1080.
Ross J, Gilpin EA, Madsen EB, et al. A decision scheme for coronary
angiography after acute myocardial infarction. Circulation 1989;79:292-303.
1081.
Ritchie JL, Cerqueira M, Maynard C, Davis K, Kennedy JW. Ventricular
function and infarct size: the Western Washington Intravenous Streptokinase
in Myocardial Infarction Trial. J Am Coll Cardiol 1988;11:689-97.
1082.
TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI)
trial: phase I findings. N Engl J Med 1985;312:932-6.
1083.
Hamm LF, Crow RS, Stull GA, Hannan P. Safety and characteristics
of exercise testing early after acute myocardial infarction. Am
J Cardiol 1989;63:1193-7.
1084.
Juneau M, Colles P, Théroux P, et al. Symptom-limited versus
low level exercise testing before hospital discharge after myocardial
infarction. J Am Coll Cardiol 1992;20:927-33.
1085. Jain A, Myers GH, Sapin PM, O’Rourke
RA. Comparison of symptom-limited and low level exercise tolerance
tests early after myocardial infarction. J Am Coll Cardiol 1993;22:1816-
20.
1086.
Mark DB, Shaw L, Harrell FE, et al. Prognostic value of a treadmill
exercise score in outpatients with suspected coronary artery disease.
N Engl J Med 1991;325:849-53.
1087.
Piccalò G, Pirelli S, Massa D, Cipriani M, Sarullo FM, De
Vita C. Value of negative predischarge exercise testing in identifying
patients at low risk after acute myocardial infarction treated by
systemic thrombolysis. Am J Cardiol 1992;70:31-3.
1088.
Heger JJ, Weyman AE, Wann LS, Rogers EW, Dillon JC, Feigenbaum H.
Cross-sectional echocardiographic analysis of the extent of left
ventricular asynergy in acute myocardial infarction. Circulation
1980;61:1113-8.
1089.
Gibson RS, Bishop HL, Stamm RB, Crampton RS, Beller GA, Martin RP.
Value of early two dimensional echocardiography in patients with
acute myocardial infarction. Am J Cardiol 1982;49:1110-9.
1090.
Nishimura RA, Tajik AJ, Shub C, Miller FA, Ilstrup DM, Harrison
CE. Role of two-dimensional echocardiography in the prediction of
in-hospital complications after acute myocardial infarction. J Am
Coll Cardiol 1984;4:1080-7.
1091.
Horowitz RS, Morganroth J. Immediate detection of early highrisk
patients with acute myocardial infarction using two-dimensional
echocardiographic evaluation of left ventricular regional wall motion
abnormalities. Am Heart J 1982;103:814-22.
1092.
Minardi G, Di Segni M, Manzara CC, et al. Diagnostic and prognostic
value of dipyridamole and dobutamine stress echocardiography in
patients with Q-wave acute myocardial infarction. Am J Cardiol 1997;80:847-51.
1093.
Smart S, Wynsen J, Sagar K. Dobutamine-atropine stress echocardiography
for reversible dysfunction during the first week after acute myocardial
infarction: limitations and determinants of accuracy. J Am Coll
Cardiol 1997;30:1669-78.
1094.
Bolognese L, Antoniucci D, Rovai D, et al. Myocardial contrast echocardiography
versus dobutamine echocardiography for predicting functional recovery
after acute myocardial infarction treated with primary coronary
angioplasty. J Am Coll Cardiol 1996;28:1677-83.
1095.
Poli A, Previtali M, Lanzarini L, et al. Comparison of dobutamine
stress echocardiography with dipyridamole stress echocardiography
for detection of viable myocardium after myocardial infarction treated
with thrombolysis. Heart 1996;75:240-6.
1096. Salustri A, Elhendy A, Garyfallydis P,
et al. Prediction of improvement of ventricular function after first
acute myocardial infarction using low-dose dobutamine stress echocardiography.
Am J Cardiol 1994;74:853-6.
1097.
Watada H, Ito H, Oh H, et al. Dobutamine stress echocardiography
predicts reversible dysfunction and quantitates the extent of irreversibly
damaged myocardium after reperfusion of anterior myocardial infarction.
J Am Coll Cardiol 1994;24:624-30.
1098.
Previtali M, Poli A, Lanzarini L, Fetiveau R, Mussini A, Ferrario
M. Dobutamine stress echocardiography for assessment of myocardial
viability and ischemia in acute myocardial infarction treated with
thrombolysis. Am J Cardiol 1993;72:124G- 130G.
1099.
Smart SC, Sawada S, Ryan T, et al. Low-dose dobutamine echocardiography
detects reversible dysfunction after thrombolytic therapy of acute
myocardial infarction. Circulation 1993;88:405-15.
1100.
Piérard LA, De Landsheere CM, Berthe C, Rigo P, Kulbertus
HE. Identification of viable myocardium by echocardiography during
dobutamine infusion in patients with myocardial infarction after
thrombolytic therapy: comparison with positron emission tomography.
J Am Coll Cardiol 1990;15:1021-31.
1101.
Barilla F, Gheorghiade M, Alam M, Khaja F, Goldstein S. Lowdose
dobutamine in patients with acute myocardial infarction identifies
viable but not contractile myocardium and predicts the magnitude
of improvement in wall motion abnormalities in response to coronary
revascularization. Am Heart J 1991; 122:1522-31.
1102.
Lundgren C, Bourdillon PD, Dillon JC, Feigenbaum H. Comparison of
contrast angiography and two-dimensional echocardiography for the
evaluation of left ventricular regional wall motion abnormalities
after acute myocardial infarction. Am J Cardiol 1990;65:1071-7.
1103.
Applegate RJ, Dell’Italia LJ, Crawford MH. Usefulness of twodimensional
echocardiography during low-level exercise testing early after uncomplicated
acute myocardial infarction. Am J Cardiol 1987;60:10-4.
1104.
Picano E, Pingitore A, Sicari R, et al, for the Echo Persantine
International Cooperative (EPIC) Study Group. Stress echocardiographic
results predict risk of reinfarction early after uncomplicated acute
myocardial infarction: large-scale multicenter study. J Am Coll
Cardiol 1995;26:908-13.
1105.
Bolognese L, Rossi L, Sarasso G, et al. Silent versus symptomatic
dipyridamole-induced ischemia after myocardial infarction: clinical
and prognostic significance. J Am Coll Cardiol 1992;19:953-9.
1106.
Quintana M, Lindvall K, Rydén L, Brolund F. Prognostic value
of predischarge exercise stress echocardiography after acute myocardial
infarction. Am J Cardiol 1995;76:1115-21.
1107.
Orlandini AD, Tuero EI, Diaz R, Vilamajó OA, Paolasso EA.
Acute cardiac rupture during dobutamine-atropine echocardiography
stress test. J Am Soc Echocardiogr 2000;13:152-3.
1108.
Carlos ME, Smart SC,Wynsen JC, Sagar KB. Dobutamine stress echocardiography
for risk stratification after myocardial infarction. Circulation
1997;95:1402-10.
1109.
Greco CA, Salustri A, Seccareccia F, et al. Prognostic value of
dobutamine echocardiography early after uncomplicated acute myocardial
infarction: a comparison with exercise electrocardiography. J Am
Coll Cardiol 1997;29:261-7.
1110.
Sclavo MG, Noussan P, Pallisco O, Presbitero P. Usefulness of dipyridamole-echocardiographic
test to identify jeopardized myocardium after thrombolysis: limited
clinical predictivity of dipyridamole-echocardiographic test in
convalescing acute myocardial infarction: correlation with coronary
angiography. Eur Heart J 1992;13:1348-55.
1111. Picano E, Landi P, Bolognese
L, et al, for the EPIC Study Group. Prognostic value of dipyridamole
echocardiography early after uncomplicated myocardial infarction:
a large-scale, multicenter trial. Am J Med 1993;95:608-18.
1112.
Sicari R, Picano E, Landi P, et al. Prognostic value of dobutamine-
atropine stress echocardiography early after acute myocardial infarction.
Echo Dobutamine International Cooperative (EDIC) Study. J Am Coll
Cardiol 1997;29:254-60.
1113.
Gibson RS, Watson DD, Craddock GB, et al. Prediction of cardiac
events after uncomplicated myocardial infarction: a prospective
study comparing predischarge exercise thallium- 201 scintigraphy
and coronary angiography. Circulation 1983;68:321-36.
1114.
Hung J, Goris ML, Nash E, et al. Comparative value of maximal treadmill
testing, exercise thallium myocardial perfusion scintigraphy and
exercise radionuclide ventriculography for distinguishing high-
and low-risk patients soon after acute myocardial infarction. Am
J Cardiol 1984;53:1221-7.
1115.
Abraham RD, Freedman SB, Dunn RF, et al. Prediction of multivessel
coronary artery disease and prognosis early after acute myocardial
infarction by exercise electrocardiography and thallium- 201 myocardial
perfusion scanning. Am J Cardiol 1986;58:423-7.
1116. Wilson WW, Gibson RS, Nygaard
TW, et al. Acute myocardial infarction associated with single vessel
coronary artery disease: an analysis of clinical outcome and the
prognostic importance of vessel patency and residual ischemic myocardium.
J Am Coll Cardiol 1988;11:223-34.
1117.
Leppo JA, O’Brien J, Rothendler JA, Getchell JD, Lee VW. Dipyridamole-thallium-201
scintigraphy in the prediction of future cardiac events after acute
myocardial infarction. N Engl J Med 1984;310:1014-8.
1118.
Pirelli S, Inglese E, Suppa M, Corrada E, Campolo L. Dipyridamole-thallium
201 scintigraphy in the early post-infarction
period: safety and accuracy in predicting the extent of coronary
disease and future recurrence of angina in patients suffering from
their first myocardial infarction. Eur Heart J 1988;9:1324-31.
1119.
Younis LT, Byers S, Shaw L, Barth G, Goodgold H, Chaitman BR. Prognostic
value of intravenous dipyridamole thallium scintigraphy after an
acute myocardial ischemic event. Am J Cardiol 1989;64:161-6.
1120. Figueredo V, Cheitlin MD. Risk stratification.
In: Julian DG, Braunwald E, eds. Management of acute myocardial
infarction. London, England: WB Saunders Co Ltd; 1994:361-91.
1121.
Tilkemeier PL, Guiney TE, LaRaia PJ, Boucher CA. Prognostic value
of predischarge low-level exercise thallium testing after thrombolytic
treatment of acute myocardial infarction. Am J Cardiol 1990;66:1203-7.
1122.
Hendel RC, Gore JM, Alpert JS, Leppo JA. Prognosis following interventional
therapy for acute myocardial infarction: utility of dipyridamole
thallium scintigraphy. Cardiology 1991;79:73-80.
1123. Miller TD, Gersh BJ, Christian TF, Bailey
KR, Gibbons RJ. Limited prognostic value of thallium-201 exercise
treadmill testing early after myocardial infarction in patients
treated with thrombolysis. Am Heart J 1995;130:259-66.
1124.
Mahmarian JJ, Mahmarian AC, Marks GF, Pratt CM, Verani MS. Role
of adenosine thallium-201 tomography for defining longterm risk
in patients after acute myocardial infarction. J Am Coll Cardiol
1995;25:1333-40.
1125. Cerqueira MD, Maynard C, Ritchie
JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from
the Western Washington Streptokinase in Myocardial Infarction trials.
J Am Coll Cardiol 1992;20:1452-9.
1126.
Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons
RJ. Infarct size after acute myocardial infarction measured by quantitative
tomographic 99mTc sestamibi imaging predicts subsequent mortality.
Circulation 1995;92:334-41.
1127.
The relationships of left ventricular ejection fraction, end-systolic
volume index and infarct size to six-month mortality after hospital
discharge following myocardial infarction treated by thrombolysis.
J Am Coll Cardiol 2002;39:30-6.
1128. Brown KA, Heller GV, Landin RS, et al.
Early dipyridamole (99m)Tc-sestamibi single photon emission computed
tomographic imaging 2 to 4 days after acute myocardial infarction
predicts in-hospital and postdischarge cardiac events: comparison
with submaximal exercise imaging. Circulation 1999; 100:2060-6.
1129.
Risk stratification and survival after myocardial infarction. N
Engl J Med 1983;309:331-6.
1130.
Zaret BL,Wackers TH, Terrin M, et al. Does left ventricular ejection
fraction following thrombolytic therapy have the same prognostic
impact described in the prethrombolytic era? Results of the TIMI
II Trial [abstr]. J Am Coll Cardiol 1991;17:214A.
1131.
Roig E, Magriñá J, Garcia A, et al. Prognostic value
of exercise radionuclide angiography in low risk acute myocardial
infarction survivors. Eur Heart J 1993;14:213-8.
1132.
White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ.
Left ventricular end-systolic volume as the major determinant of
survival after recovery from myocardial infarction. Circulation
1987;76:44-51.
1133. Rashid H, Exner DV, Mirsky I, Cooper HA,
Waclawiw MA, Domanski MJ. Comparison of echocardiography and radionuclide
angiography as predictors of mortality in patients with left ventricular
dysfunction: studies of left ventricular dysfunction. Am J Cardiol
1999;84:299-303.
1134.
Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-21.
1135.
Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic
ventricular dysfunction. Circulation 1982;66:1146-9.
1136.
Rahimtoola SH. A perspective on the three large multicenter randomized
clinical trials of coronary bypass surgery for chronic stable angina.
Circulation 1985;72:V123-35.
1137.
Di Carli MF. Assessment of myocardial viability after myocardial
infarction. J Nucl Cardiol 9:229-35.
1138.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability
testing and impact of revascularization on prognosis in patients
with coronary artery disease and left ventricular dysfunction: a
meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
1139.
Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH. Myocardial
viability during dobutamine echocardiography predicts survival in
patients with coronary artery disease and severe left ventricular
systolic dysfunction. J Am Coll Cardiol 1998;32:921-6.
1140.
Rohatgi R, Epstein S, Henriquez J, et al. Utility of positron emission
tomography in predicting cardiac events and survival in patients
with coronary artery disease and severe left ventricular dysfunction.
Am J Cardiol 2001;87:1096-9, A6.
1141.
Bax JJ,Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy
of currently available techniques for prediction of functional recovery
after revascularization in patients with left ventricular dysfunction
due to chronic coronary artery disease: comparison of pooled data.
J Am Coll Cardiol 1997;30:1451-60.
1142.
Beller GA. Noninvasive assessment of myocardial viability. N Engl
J Med 2000;343:1488-90.
1143.
Beek AM, Kühl HP, Bondarenko O, et al. Delayed contrastenhanced
magnetic resonance imaging for the prediction of regional functional
improvement after acute myocardial infarction. J Am Coll Cardiol
2003;42:895-901.
1144.
Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JA. Accuracy of contrast-enhanced
magnetic resonance imaging in predicting improvement of regional
myocardial function in patients after acute myocardial infarction.
Circulation 2002;106:1083-9.
1145.
Bates DW, Miller E, Bernstein SJ, Hauptman PJ, Leape LL. Coronary
angiography and angioplasty after acute myocardial infarction. Ann
Intern Med 1997;126:539-50.
1146.
Scott IA, Harden H, Coory M. What are appropriate rates of invasive
procedures following acute myocardial infarction: a systematic review.
Med J Aust 2001;174:130-6.
1147.
Llevadot J, Giugliano RP, Antman EM, et al, for the InTIME (Intravenous
nPA for Treatment of Infarcting Myocardium Early) II Investigators.
Availability of on-site catheterization and clinical outcomes in
patients receiving fibrinolysis for ST-elevation myocardial infarction.
Eur Heart J 2001;22:2104-15.
1148.
Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate invasive,
delayed invasive, and conservative strategies after tissue- type
plasminogen activator: results of the Thrombolysis in Myocardial
Infarction (TIMI) Phase II-A trial. Circulation 1990;81:1457-76.
1149.
O’Neill WW. “Watchful waiting” after thrombolysis:
it’s time for a re-evaluation. J Am Coll Cardiol 2003;42:17-9.
1149a.
Antman EM, Van de Werf F. Pharmacoinvasive therapy: the future of
treatment for ST-elevation myocardial infarction. Circulation 2004;109:2480-6.
1150.
Gottlieb SO, Gottlieb SH, Achuff SC, Baumgardner R, Mellits ED,
Weisfeldt ML, Gerstenblith G. Silent ischemia on Holter monitoring
predicts mortality in high-risk post-infarction patients. JAMA 1988;259:1030-5.
1151.
Tzivoni D, Gavish A, Zin D, et al. Prognostic significance of ischemic
episodes in patients with previous myocardial infarction. Am J Cardiol
1988;62:661-4.
1152.
Bonaduce D, Petretta M, Lanzillo T, et al. Prevalence and prognostic
significance of silent myocardial ischaemia detected by exercise
test and continuous ECG monitoring after acute myocardial infarction.
Eur Heart J 1991;12:186-93.
1153.
Langer A, Minkowitz J, Dorian P, et al, for the Tissue Plasminogen
Activator: Toronto (TPAT) Study Group. Pathophysiology and prognostic
significance of Holter-detected ST segment depression after myocardial
infarction. J Am Coll Cardiol 1992;20:1313-7.
1154.
Petretta M, Bonaduce D, Bianchi V, et al. Characterization and prognostic
significance of silent myocardial ischemia on predischarge electrocardiographic
monitoring in unselected patients with myocardial infarction. Am
J Cardiol 1992;69:579-83.
1155.
Jereczek M, Andresen D, Schröder J, et al. Prognostic value
of ischemia during Holter monitoring and exercise testing after
acute myocardial infarction. Am J Cardiol 1993;72:8-13.
1156. Currie P, Ashby D, Saltissi S. Prognostic
significance of transient myocardial ischemia on ambulatory monitoring
after acute myocardial infarction. Am J Cardiol 1993;71:773-7.
1157.
Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of
myocardial ischemia detected by ambulatory monitoring early after
acute myocardial infarction. N Engl J Med 1996;334:65- 70.
1158.
Deedwania PC. Asymptomatic ischemia during predischarge Holter monitoring
predicts poor prognosis in the postinfarction period. Am J Cardiol
1993;71:859-61.
1159.
Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic
events after myocardial infarction: signal-averaged electrocardiogram,
Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol
1987;9:531-8.
1160.
Gomes JA, Winters SL, Martinson M, Machac J, Stewart D, Targonski
A. The prognostic significance of quantitative signalaveraged variables
relative to clinical variables, site of myocardial infarction, ejection
fraction and ventricular premature beats: a prospective study. J
Am Coll Cardiol 1989;13:377-84.
1161.
el-Sherif N, Denes P, Katz R, et al, for the Cardiac Arrhythmia
Suppression Trial/Signal-Averaged Electrocardiogram (CAST/ SAECG)
Substudy Investigators. Definition of the best prediction criteria
of the time domain signal-averaged electrocardiogram for serious
arrhythmic events in the postinfarction period. J Am Coll Cardiol
1995;25:908-14.
1162.
Vatterott PJ, Hammill SC, Bailey KR, Wiltgen CM, Gersh BJ. Late
potentials on signal-averaged electrocardiograms and patency of
the infarct-related artery in survivors of acute myocardial infarction.
J Am Coll Cardiol 1991;17:330-7.
1163.
McClements BM, Adgey AA. Value of signal-averaged electrocardiography,
radionuclide ventriculography, Holter monitoring and clinical variables
for prediction of arrhythmic events in survivors of acute myocardial
infarction in the thrombolytic era. J Am Coll Cardiol 1993;21:1419-27.
1164.
Hohnloser SH, Franck P, Klingenheben T, Zabel M, Just H. Open infarct
artery, late potentials, and other prognostic factors in patients
after acute myocardial infarction in the thrombolytic era: a prospective
trial. Circulation 1994;90:1747-56.
1165.
Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic
events in postinfarction patients based on heart rate variability,
ambulatory electrocardiographic variables and the signal-averaged
electrocardiogram. J Am Coll Cardiol 1991;18:687-97.
1166.
Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of
several short-term measures of RR variability to predict mortality
after myocardial infarction. Circulation 1993;88:927-34.
1167.
Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate
variability and its association with increased mortality after acute
myocardial infarction. Am J Cardiol 1987;59:256-62.
1168.
La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ, for
the ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction)
Investigators. Baroreflex sensitivity and heart-rate variability
in prediction of total cardiac mortality after myocardial infarction.
Lancet 1998;351:478-84.
1169.
Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and
sudden cardiac death: experimental basis and clinical observations
for post-myocardial infarction risk stratification. Circulation
1992;85:I77-91.
1170. Schwartz PJ, Vanoli E, Stramba-Badiale
M, et al. Autonomic mechanisms and sudden death: new insights from
analysis of baroreceptor reflexes in conscious dogs with and without
a myocardial infarction. Circulation 1988;78:969-79.
1171. La Rovere MT, Specchia G, Mortara A, Schwartz
PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular
mortality among patients with a first myocardial infarction: a prospective
study. Circulation 1988;78:816-24.
1172.
Farrell TG, Paul V, Cripps TR, et al. Baroreflex sensitivity and
electrophysiological correlates in patients after acute myocardial
infarction. Circulation 1991;83:945-52.
1173.
Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave
alternans, signal averaged electrocardiography and programmed ventricular
stimulation for arrhythmia risk stratification. J Am Coll Cardiol
2000;36:2247-53.
1174.
Ikeda T, Sakata T, Takami M, et al. Combined assessment of Twave
alternans and late potentials used to predict arrhythmic events
after myocardial infarction: a prospective study. J Am Coll Cardiol
2000;35:722-30.
1175. Gilman JK, Jalal S, Naccarelli GV. Predicting
and preventing sudden death from cardiac causes. Circulation 1994;90:1083-
92.
1176.
Dalal H, Evans PH, Campbell JL. Recent developments in secondary
prevention and cardiac rehabilitation after acute myocardial infarction.
BMJ 2004;328:693-7.
1177.
Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary
prevention in survivors of cardiovascular events in the US population:
report from the Third National Health and Nutrition Examination
Survey. Arch Intern Med 2001; 161:1621-8.
1178.
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting
enzyme inhibitor therapy in patients with end-stage renal disease
and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-8.
1179.
Conti CR. Management of patients with acute myocardial infarction
and end-stage renal disease. J Am Coll Cardiol 2003; 42:209-10.
1180. Shlipak MG, Heidenreich PA, Noguchi H,
Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency
with treatment and outcomes after myocardial infarction in elderly
patients. Ann Intern Med 2002;137:555-62.
1181. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand
J, Peto R. Get with the guidelines for cardiovascular secondary
prevention: pilot results. Arch Intern Med 2004;164:203-9.
1182.
Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis,
and platelet reactivity: a systematic review. Arch Intern Med 2003;163:2368-92.
1183.
Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards
for testing and training: a statement for healthcare professionals
from the American Heart Association. Circulation 2001;104:1694-740.
1184. Wenger NK, Froelicher ES, Smith LK, et
al. AHCPR Supported Guidelines. Clinical Practice Guideline Number
17: Cardiac Rehabilitation. US Dept of Health and Human Services.
Public Health Service. Agency for Health Care Policy and Research.
National Heart, Lung and Blood Institute, October 1995. AHCPR publication
No. 96-0672.
1185.
Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment
of coronary heart disease by implementation of a Cardiac Hospitalization
Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22.
1186.
Mehta RH, Montoye CK, Faul J, et al, for the American College of
Cardiology Guidelines Applied in Practice Steering Committee. Enhancing
quality of care for acute myocardial infarction: shifting the focus
of improvement from key indicators to process of care and tool use.
J Am Coll Cardiol 2004;43:2166-73
1187.
Bowles KH, Foust JB, Naylor MD. Hospital discharge referral decision
making: a multidisciplinary perspective. Appl Nurs Res 2003;16:134-43.
1188.
Plach S, Wierenga ME, Heidrich SM. Effect of a postdischarge education
class on coronary artery disease knowledge and selfreported health-promoting
behaviors. Heart Lung 1996;25:367- 72.
1189.
O’Neill C, Normand C, Cupples M, McKnight A. Cost effectiveness
of personal health education in primary care for people with angina
in the greater Belfast area of Northern Ireland. J Epidemiol Community
Health 1996;50:538-40.
1190. Larson CO, Nelson EC, Gustafson D, Batalden
PB. The relationship between meeting patients’ information
needs and their satisfaction with hospital care and general health
status outcomes. Int J Qual Health Care 1996;8:447-56.
1191.
Theis SL, Johnson JH. Strategies for teaching patients: a metaanalysis.
Clin Nurse Spec 1995;9:100-5, 120.
1192.
Hill J. A practical guide to patient education and information giving.
Baillieres Clin Rheumatol 1997;11:109-27.
1193.
Kingsbury K. Taking AIM: how to teach primary and secondary prevention
effectively. Can J Cardiol 1998;14 Suppl A:22A- 26A.
1194.
Winslow E, Bohannon N, Brunton SA, Mayhew HE. Lifestyle modification:
weight control, exercise, and smoking cessation. Am J Med 1996;101:4A25S-31S;
discussion.
1195.
The multiple risk factor intervention trial (MRFIT): a national
study of primary prevention of coronary heart disease. JAMA 1976;235:825-7.
1196.
Moore SM. Effects of interventions to promote recovery in coronary
artery bypass surgical patients. J Cardiovasc Nurs 1997;12:59-70.
1197.
Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation
after myocardial infarction: combined experience of randomized clinical
trials. JAMA 1988;260:945-50.
1198.
Wang WW. The educational needs of myocardial infarction patients.
Prog Cardiovasc Nurs 1994;9:28-36.
1199.
Chan V. Content areas for cardiac teaching: patients’ perceptions
of the importance of teaching content after myocardial infarction.
J Adv Nurs 1990;15:1139-45.
1200.
Cogswell B, Eggert MS. People want doctors to give more preventive
care: a qualitative study of health care consumers. Arch Fam
Med 1993;2:611-9.
1201.
Mittelmark MB, Leupker RV, Grimm R, Kottke TE, Blackburn H. The
role of physicians in a community-wide program for prevention of
cardiovascular disease: the Minnesota Heart Health Program. Public
Health Rep 103:360-5.
1202.
Rhodes KS, Bookstein LC, Aaronson LS, Mercer NM, Orringer CE. Intensive
nutrition counseling enhances outcomes of National Cholesterol Education
Program dietary therapy. J Am Diet Assoc 1996;96:1003-10; quiz 1011-2.
1203.
Lindsay C, Jennrich JA, Biemolt M. Programmed instruction booklet
for cardiac rehabilitation teaching. Heart Lung 1991;20:648-53.
1204.
Lewis D. Computer-based approaches to patient education: a review
of the literature. J Am Med Inform Assoc 1999;6:272-82.
1205.
Ganguli G. Consumers devise drug cost-cutting measures: medical
and legal issues to consider. Health Care Manag (Frederick) 2003;22:275-81.
1206.
Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology,
transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-97.
1207.
Randomised trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study (4S)
Lancet 1994;344:1383-9.
1208.
Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent
Events Trial investigators. The effect of pravastatin on coronary
events after myocardial infarction in patients with average cholesterol
levels. N Engl J Med 1996;335:1001-9.
1209.
The Long-Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) Study Group. Prevention of cardiovascular events and death
with pravastatin in patients with coronary heart disease and a broad
range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
1210.
Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin
on cardiac events in patients with symptomatic coronary artery disease
during one year of treatment. Atherosclerosis 1999;144:263-70.
1211.
The Post Coronary Artery Bypass Graft Trial Investigators. The effect
of aggressive lowering of low-density lipoprotein cholesterol levels
and low-dose anticoagulation on obstructive changes in saphenous-vein
coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
1212. Knatterud GL, Rosenberg Y, Campeau L, et
al, for the Post CABG Investigators. Long-term effects on clinical
outcomes of aggressive lowering of low-density lipoprotein cholesterol
levels and low-dose anticoagulation in the post coronary artery
bypass graft trial. Circulation 2000;102:157-65.
1213. MRC/BHF Heart Protection Study of cholesterol
lowering with simvastatin in 20,536 high-risk individuals: a randomised
placebo- controlled trial. Lancet 2002;360:7-22.
1214.
Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular
disease in relation to cholesterol level among men with and without
preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
1215.
Rubins HB, Robins SJ, Collins D, et al, for the Veterans Affairs
High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Gemfibrozil for the secondary prevention of coronary heart disease
in men with low levels of high-density lipoprotein cholesterol.
N Engl J Med 1999;341:410-8.
1216.
Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of
pravastatin (+/-cholestyramine/niacin) initiated immediately after
a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD]
Study). Am J Cardiol 2000;86:1293-8.
1217.
Schwartz GG, Olsson AG, Ezekowitz MD, et al, for the Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL)
Study Investigators. Effects of atorvastatin on early recurrent
ischemic events in acute coronary syndromes: the MIRACL study: a
randomized controlled trial. JAMA 2001;285:1711-8.
1218. Stenestrand U, Wallentin L for the Swedish
Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment
following acute myocardial infarction and 1-year survival. JAMA
2001;285:430-6.
1219.
Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive
and moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med 2004;350:1562-4.
1220.
Aronow HD, Novaro GM, Lauer MS, et al. In-hospital initiation of
lipid-lowering therapy after coronary intervention as a predictor
of long-term utilization: a propensity analysis. Arch Intern Med
2003;163:2576-82.
1221.
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends
in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-7.
1222. Nutrition and Your Health: Dietary Guidelines
for Americans. Fourth Edition. US Department of Agriculture. US
Department of Health and Human Services, Washington, DC, 1995.
1223.
Winniford MD, Jansen DE, Reynolds GA, Apprill P, Black WH, Hillis
LD. Cigarette smoking-induced coronary vasoconstriction in atherosclerotic
coronary artery disease and prevention by calcium antagonists and
nitroglycerin. Am J Cardiol 1987; 59:203-7.
1224.
Deanfield J, Wright C, Krikler S, Ribeiro P, Fox K. Cigarette smoking
and the treatment of angina with propranolol, atenolol, and nifedipine.
N Engl J Med 1984;310:951-4.
1225.
Barry J, Mead K, Nabel EG, et al. Effect of smoking on the activity
of ischemic heart disease. JAMA 1989;261:398-402.
1226.
Burling TA, Singleton EG, Bigelow GE, Baile WF, Gottlieb SH. Smoking
following myocardial infarction: a critical review of the literature.
Health Psychol 1984;3:83-96.
1227.
Good Information For Smokers: You Can Quit Smoking. Consumer booklet.
U.S. Public Health Service. http://www.surgeongeneral. gov/tobacco/lowlit.htm,
September 2002. Accessed December 16, 2002.
1228.
Treating Tobacco Use and Dependence. Quick Reference Guide for Clinicians.
U.S. Public Health Service. http://www.surgeongeneral. gov/tobacco/tobaqrg.htm,
October 2000. Accessed December 16, 2002.
1229.
Houston-Miller N. Smoking cessation. In: Houston-Miller N, Taylor
CB, eds. Lifestyle Management for Patients with Coronary Heart Disease.
Champaigne, IL: Human Kinetics; 1995:85-104.
1230. Glover ED, Glover PN, Payne TJ. Treating
nicotine dependence. Am J Med Sci 2003;326:183-6.
1231.
Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the
nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940-7.
1232.
Gourlay SG, McNeil JJ. Antismoking products. Med J Aust 1990;153:699-707.
1233. Kimmel SE, Berlin JA, Miles C, Jaskowiak
J, Carson JL, Strom BL. Risk of acute first myocardial infarction
and use of nicotine patches in a general population. J Am Coll Cardiol
2001; 37:1297-302.
1234.
Working Group for the Study of Transdermal Nicotine in Patients
with Coronary Artery Disease. Nicotine replacement therapy for patients
with coronary artery disease. Arch Intern bMed
1994;154:989-95.
1235.
Sønderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine
patches in smoking cessation: a randomized trial among over-the-counter
customers in Denmark. Am J Epidemiol 1997;145:309-18.
1236. Joseph AM, Norman SM, Ferry LH, et al.
The safety of transdermal nicotine as an aid to smoking cessation
in patients with cardiac disease. N Engl J Med 1996;335:1792-8.
1237.
Mahmarian JJ, Moyé LA, Nasser GA, et al. Nicotine patch therapy
in smoking cessation reduces the extent of exercise-induced myocardial
ischemia. J Am Coll Cardiol 1997;30:125-30.
1238.
Covey LS, Glassman AH. A meta-analysis of double-blind placebo-
controlled trials of clonidine for smoking cessation. Br J Addict
1991;86:991-8.
1239.
Bernstein DA. Modification of smoking behavior: an evaluative review.
Psychol Bull 1969;71:418-40.
1240.
Davison GC, Rosen RC. Lobeline and reduction of cigarette smoking.
Psychol Rep 1972;31:443-56.
1241.
Ford S, Ederer F. Breaking the cigarette habit. JAMA 1965;194:139-42.
1242.
Bouvy ML, Buurma H, Egberts AC. Determinants for successful smoking
cessation with bupropion in daily practice. Pharm World Sci 2003;25:207-11.
1243.
Swan GE, McAfee T, Curry SJ, et al K. Effectiveness of bupropion
sustained release for smoking cessation in a health care setting:
a randomized trial. Arch Intern Med 2003;163:2337-44.
1244.
Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustainedrelease
bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.
1245.
Gutstein DE, Fuster V. Pathophysiologic bases for adjunctive therapies
in the treatment and secondary prevention of acute myocardial infarction.
Clin Cardiol 1998;21:161-8.
1246. Hennekens CH, Dyken ML, Fuster V. Aspirin
as a therapeutic agent in cardiovascular disease: a statement for
healthcare professionals from the American Heart Association. Circulation
1997;96:2751-3.
1247.
Hurlen M, Smith P, Arnesen H. Effects of warfarin, aspirin and the
two combined, on mortality and thromboembolic morbidity after myocardial
infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design.
Scand Cardiovasc J 2000;34:168- 71.
1248.
van Es RF, Jonker JJ,Verheugt FW, Deckers JW, Grobbee DE for the
Antithrombotics in the Secondary Prevention of Events in Coronary
Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after
acute coronary syndromes (the ASPECT-2 study): a randomised controlled
trial. Lancet 2002; 360:109-13.
1249.
Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus
coumarin versus aspirin alone in the prevention of reocclusion after
fibrinolysis for acute myocardial infarction: results of the Antithrombotics
in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2
Trial. Circulation 2002;106:659-65.
1250.
Steering Committee of the Physicians’ Health Study Research
Group. Final report on the aspirin component of the ongoing Physicians’
Health Study. N Engl J Med 1989;321:129-35.
1251.
Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic
daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-6.
1252.
Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclo-oxygenase inhibitors
and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
1253.
MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect
of aspirin. Lancet 2003;361:573-4.
1254.
Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits
of aspirin on first myocardial infarction by nonsteroidal antiinflammatory
drugs. Circulation 2003;108:1191-5.
1255.
Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental
myocardial infarction: beneficial effects of longterm therapy with
captopril. Circulation 1985;72:406-12.
1256.
Pfeffer MA, Braunwald E, Moyé LA, Basta L, et al, for the
SAVE Investigators. Effect of captopril on mortality and morbidity
in patients with left ventricular dysfunction after myocardial infarction:
results of the survival and ventricular enlargement trial. N Engl
J Med 1992;327:669-77.
1257.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
Effect of ramipril on mortality and morbidity of survivors of acute
myocardial infarction with clinical evidence of heart failure. Lancet
1993;342:821-8.
1258.
Køber L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril
Cardiac Evaluation (TRACE) Study Group. A clinical trial of the
angiotensin-converting-enzyme inhibitor trandolapril in patients
with left ventricular dysfunction after myocardial infarction. N
Engl J Med 1995;333:1670-6.
1259.
Johnstone D, Limacher M, Rousseau M, et al. Clinical characteristics
of patients in studies of left ventricular dysfunction (SOLVD).
Am J Cardiol 1992;70:894-900.
1260.
The SOLVD Investigators. Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced
left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
1261.
Rutherford JD, Pfeffer MA, Moyé LA, et al, for the SAVE Investigators.
Effects of captopril on ischemic events after myocardial infarction:
results of the Survival and Ventricular Enlargement trial. Circulation
1994;90:1731-8.
1262. Fox KM for the EURopean trial On reduction
of cardiac events with Perindopril in stable coronary Artery disease
Investigators. Efficacy of perindopril in reduction of cardiovascular
events among patients with stable coronary artery disease: randomised,
double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003;362:782-8.
1263. Granger CB, McMurray JJ, Yusuf S, et al,
for the CHARM Investigators and Committees. Effects of candesartan
in patients with chronic heart failure and reduced left-ventricular
systolic function intolerant to angiotensin-converting-enzyme inhibitors:
the CHARM-Alternative trial. Lancet 2003;362:772-6.
1264.
McMurray JJ, Ostergren J, Swedberg K, et al, for the CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and reduced left-ventricular systolic function taking
angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet 2003;362:767-71.
1265.
Yusuf S, Pfeffer MA, Swedberg K, et al, for the CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and preserved left-ventricular ejection fraction:
the CHARM-Preserved Trial. Lancet 2003;362:777- 81.
1266.
The Beta-Blocker Pooling Project Research Group. The Beta- Blocker
Pooling Project (BBPP): subgroup findings from randomized trials
in post infarction patients. Eur Heart J 1988;9:8- 16.
1267.
Barron HV, Viskin S, Lundstrom RJ, Wong CC, Swain BE, Truman AF,
Selby JV. Effect of beta-adrenergic blocking agents on mortality
rate in patients not revascularized after myocardial infarction:
data from a large HMO. Am Heart J 1997;134:608- 13.
1268.
Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic
heart failure. Circulation 2003;107:1570-5.
1269.
Chen J, Radford MJ,Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers
effective in elderly patients who undergo coronary revascularization
after acute myocardial infarction? Arch Intern Med 2000;160:947-52.
1270.
Krumholz HM, Radford MJ,Wang Y, Chen J, Heiat A, Marciniak TA. National
use and effectiveness of beta-blockers for the treatment of elderly
patients after acute myocardial infarction: National Cooperative
Cardiovascular Project. JAMA 1998;280:623-9.
1271.
Hochman JS, Califf RM. Acute myocardial infarction. In: Antman EA,
Colucci WS, Gotto AM, Josephson ME, Loscalzo J, Oparil S, Popma
JJ, eds. Cardiovascular therapeutics: a companion to Braunwald’s
heart disease. 2nd ed. Philadelphia, PA: WB Saunders Co Ltd; 2002:235-91.
1272. Marciniak TA, Ellerbeck EF, Radford MJ,
et al. Improving the quality of care for Medicare patients with
acute myocardial infarction: results from the Cooperative Cardiovascular
Project. JAMA 1998;279:1351-7.
1273.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality
among high-risk and low-risk patients after myocardial infarction.
N Engl J Med 1998;339:489-97.
1274.
Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Costs and
effectiveness of routine therapy with long-term betaadrenergic antagonists
after acute myocardial infarction. N Engl J Med 1988;319:152-7.
1275.
Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists’
practices compared with practice guidelines: use of beta-blockade
after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-6.
1276.
Seventh report of the Joint National Committee on the Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC
7): resetting the hypertension sails. Hypertension 2003;41:1178-9.
1277.
ALLHAT Officers and Coordinators for the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research
Group. Major outcomes in high-risk hypertensive patients randomized
to angiotensin-converting enzyme inhibitor or calcium channel blocker
vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981- 97.
1278. Salpeter S, Ormiston T, Salpeter E . Cardioselective
beta-blockers for reversible airway disease. Cochrane Database of
Systematic Reviews (4):CD002992, 2002.
1279.
Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive
drug therapy of acute myocardial infarction: evidence from clinical
trials. N Engl J Med 1996;335:1660-7.
1280.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998;352:837-53.
1281.
Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart
failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
1282.
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid
retention, and congestive heart failure: a consensus statement from
the American Heart Association and American Diabetes Association.
Circulation 2003;108:2941-8.
1283. Stevenson JC, Crook D, Godsland IF, Collins
P, Whitehead MI. Hormone replacement therapy and the cardiovascular
system: nonlipid effects. Drugs 1994;47:35-41.
1284.
Kafonek SD. Postmenopausal hormone replacement therapy and cardiovascular
risk reduction: a review. Drugs 1994;47:16-24.
1285.
Petitti DB. Coronary heart disease and estrogen replacement therapy:
can compliance bias explain the results of observational studies?
Ann Epidemiol 1994;4:115-8.
1286.
Whitehead M. Progestins and androgens. Fertil Steril 1994; 62:161S-167S.
1287.
Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestin
Replacement Study (HERS) Research Group. Randomized trial of estrogen
plus progestin for secondary prevention of coronary heart disease
in postmenopausal women. JAMA 1998;280:605-13.
1288.
Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone
replacement therapy and increased plasma concentration of C-reactive
protein. Circulation 1999;100:713-6.
1289.
Stanford JL,Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA.
Combined estrogen and progestin hormone replacement therapy in relation
to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
1290.
Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens
and progestins and the risk of breast cancer in postmenopausal women.
N Engl J Med 1995;332:1589-93.
1291.
Gorsky RD, Koplan JP, Peterson HB, Thacker SB. Relative risks and
benefits of long-term estrogen replacement therapy: a decision analysis.
Obstet Gynecol 1994;83:161-6.
1292.
Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen
replacement on the progression of coronary-artery atherosclerosis.
N Engl J Med 2000;343:522-9.
1293.
Grady D, Herrington D, Bittner V, et al, for the HERS Research Group.
Cardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
JAMA 2002;288:49-57.
1294.
Becker LB, Han BH, Meyer PM, et al. Racial differences in the incidence
of cardiac arrest and subsequent survival: the CPR Chicago Project.
N Engl J Med 1993;329:600-6.
1295.
van Daele ME, McNeill AJ, Fioretti PM, et al. Prognostic value of
dipyridamole sestamibi single-photon emission computed tomography
and dipyridamole stress echocardiography for new cardiac events
after an uncomplicated myocardial infarction. J Am Soc Echocardiogr
1994;7:370-80.
1296.
Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis.
N Engl J Med 2001;344:1222-31.
1297.
Rossouw JE, Anderson GL, Prentice RL, et al, for the Writing Group
for the Women’s Health Initiative Investigators. Risks and
benefits of estrogen plus progestin in healthy postmenopausal women:
principal results from the Women’s Health Initiative randomized
controlled trial. JAMA 2002;288:321-33.
1298.
Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement
therapy and antioxidant vitamin supplements on coronary atherosclerosis
in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
1299.
Hodis HN, Mack WJ, Azen SP, et al, for the Women’s Estrogen-
Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial
Research Group. Hormone therapy and the progression of coronary-artery
atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-45.
1300.
Barrett-Connor E, Grady D, Sashegyi A, et al, for the MORE Investigators
(Multiple Outcomes of Raloxifene Evaluation). Raloxifene and cardiovascular
events in osteoporotic postmenopausal women: four-year results from
the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized
trial. JAMA 2002;287:847-57.
1301.
Cherry N, Gilmour K, Hannaford P, et al, for the ESPRIT team. Oestrogen
therapy for prevention of reinfarction in postmenopausal women:
a randomised placebo controlled trial. Lancet 2002;360:2001-8.
1302.
Cairns JA, Markham BA. Economics and efficacy in choosing oral anticoagulants
or aspirin after myocardial infarction. JAMA 1995;273:965-7.
1303.
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin,
aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
1304.
Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P, for
the Combination Hemotherapy and Mortality Prevention (CHAMP) Study
Group. Department of Veterans Affairs Cooperative Studies Program
Clinical Trial comparing combined warfarin and aspirin with aspirin
alone in survivors of acute myocardial infarction: primary results
of the CHAMP study. Circulation 2002;105:557-63.
1305.
O’Connor CM, Gattis WA, Hellkamp AS, et al. Comparison of
two aspirin doses on ischemic stroke in post-myocardial infarction
patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS).
Am J Cardiol 2001;88:541-6.
1306. Coumadin Aspirin Reinfarction Study (CARS)
Investigators. Randomised double-blind trial of fixed low-dose warfarin
with aspirin after myocardial infarction. Lancet 1997;350:389-96.
1307. Herlitz J, Holm J, Peterson M, et al, for
the LoWASA Study Group. Effect of fixed low-dose warfarin added
to aspirin in the long term after acute myocardial infarction: the
LoWASA Study. Eur Heart J 2004;25:232-9.
1308.
Anticoagulants in the Secondary Prevention of Events in Coronary
Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant
treatment on mortality and cardiovascular morbidity after myocardial
infarction. Lancet 1994;343:499-503.
1309.
Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin,
clopidogrel, and warfarin after coronary stent placement in patients
with an indication for anticoagulation. Am Heart J 2004;147:463-7.
1310.
Spencer FA, Becker RC. When guidelines collide... Am Heart J 2004;147:395-7.
1311.
Vaitkus PT, Barnathan ES. Embolic potential, prevention and management
of mural thrombus complicating anterior myocardial infarction: a
meta-analysis. J Am Coll Cardiol 1993; 22:1004-9.
1312.
Keating EC, Gross SA, Schlamowitz RA, et al. Mural thrombi in myocardial
infarctions: prospective evaluation by two-dimensional echocardiography.
Am J Med 1983;74:989-95.
1313.
Cregler LL. Antithrombotic therapy in left ventricular thrombosis
and systemic embolism. Am Heart J 1992;123:1110-4.
1314.
Reeder GS, Lengyel M, Tajik AJ, Seward JB, Smith HC, Danielson GK.
Mural thrombus in left ventricular aneurysm: incidence, role of
angiography, and relation between anticoagulation and embolization.
Mayo Clin Proc 1981;56:77-81.
1315.
Lip GY. Intracardiac thrombus formation in cardiac impairment: the
role of anticoagulant therapy. Postgrad Med J 1996;72:731- 8.
1316. Sherman DG, Dyken ML, Fisher M, Harrison
MJ, Hart RG. Antithrombotic therapy for cerebrovascular disorders.
Chest 1989;95:140S-155S.
1317.
Weintraub WS, Ba’albaki HA. Decision analysis concerning the
application of echocardiography to the diagnosis and treatment of
mural thrombi after anterior wall acute myocardial infarction. Am
J Cardiol 1989;64:708-16.
1318.
Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA.
Warfarin anticoagulation and survival: a cohort analysis from the
Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;31:749-53.
1319.
Lip GY, Gibbs CR. Anticoagulation for heart failure in sinus rhythm:
a Cochrane systematic review. QJM 2002;95:451-9.
1320. US Department of Health and Human Services.
Physical Activity Fundamental to Preventing Disease. Office of the
Assistant Secretary for Planning and Evaluation. http://aspe.hhs.gov/health/reports/physicalactivity/,
June 2002. Accessed December 16, 2002.
1321. Deleted in press.
1322.
Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits
and recommendations for physical activity programs for all Americans:
a statement for health professionals by the Committee on Exercise
and Cardiac Rehabilitation of the Council on Clinical Cardiology,
American Heart Association. Circulation 1996;94:857-62.
1323.
Pate RR, Pratt M, Blair SN, et al. Physical activity and public
health: a recommendation from the Centers for Disease Control and
Prevention and the American College of Sports Medicine. JAMA 1995;273:402-7.
1324.
Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity
in the prevention and treatment of atherosclerotic cardiovascular
disease: a statement from the Council on Clinical Cardiology (Subcommittee
on Exercise, Rehabilitation, and Prevention) and the Council on
Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical
Activity). Circulation 2003;107:3109-16.
1325. Pollock ML, Franklin BA, Balady GJ, et
al. AHA science advisory: resistance exercise in individuals with
and without cardiovascular disease: benefits, rationale, safety,
and prescription: an advisory from the Committee on Exercise, Rehabilitation,
and Prevention, Council on Clinical Cardiology, American Heart Association;
Position paper endorsed by the American College of Sports Medicine.
Circulation 2000;101:828-33.
1326. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci
E, Colditz GA, Willett WC. Vitamin E consumption and the risk of
coronary heart disease in men. N Engl J Med 1993;328:1450-6.
1327.
Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B,Willett
WC. Vitamin E consumption and the risk of coronary disease in women.
N Engl J Med 1993;328:1444-9.
1328. Gey KF, Puska P, Jordan P, Moser UK. Inverse
correlation between plasma vitamin E and mortality from ischemic
heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991;53:326S-334S.
1329.
Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson
MJ. Randomised controlled trial of vitamin E in patients with coronary
disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
1330.
Kushi LH, Folsom AR, Prineas RJ, Mink PJ,Wu Y, Bostick RM. Dietary
antioxidant vitamins and death from coronary heart disease in postmenopausal
women. N Engl J Med 1996;334:1156- 62.
1331.
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
miocardico. Dietary supplementation with n-3 polyunsaturated fatty
acids and vitamin E after myocardial infarction: results of the
GISSI-Prevenzione trial. Lancet 1999;354:447-55.
1332. The Alpha-Tocopherol, Beta Carotene Cancer
Prevention Study Group. The effect of vitamin E and beta carotene
on the incidence
of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
1333.
Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination
of beta carotene and vitamin A on lung cancer and cardiovascular
disease. N Engl J Med 1996;334:1150-5.
1334. Hennekens CH, Buring JE, Manson JE, et
al. Lack of effect of long-term supplementation with beta carotene
on the incidence of malignant neoplasms and cardiovascular disease.
N Engl J Med 1996;334:1145-9.
1335.
Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among
a sample of the United States population. Epidemiology 1992;3:194-202.
1336.
Flaherty JT, Pitt B, Gruber JW, et al. Recombinant human superoxide
dismutase (h-SOD) fails to improve recovery of ventricular function
in patients undergoing coronary angioplasty for acute myocardial
infarction. Circulation 1994;89:1982-91.
1337. DeMaio SJ, King SB, Lembo NJ, et al. Vitamin
E supplementation, plasma lipids and incidence of restenosis after
percutaneous transluminal coronary angioplasty (PTCA). J Am Coll
Nutr 1992;11:68-73.
1338.
Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis
after coronary angioplasty? Circulation 1994;90: 2248-57.
1338a.
Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witzman
JL. Antioxidant vitamin supplements and cardiovascular disease.
Circulation. In press.
1339.
ENRICHD Investigators. Enhancing Recovery in Coronary Heart Disease
(ENRICHD) study intervention: rationale and design. Psychosom Med
2001;63:747-55.
1340.
Bush DE, Ziegelstein RC, Tayback M, et al. Even minimal symptoms
of depression increase mortality risk after acute myocardial infarction.
Am J Cardiol 2001;88:337-41.
1341.
Frasure-Smith N, Lespérance F, Gravel G, et al. Depression
and health-care costs during the first year following myocardial
infarction. J Psychosom Res 2000;48:471-8.
1342.
Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial
factors for prognosis after myocardial infarction. J Intern Med
2000;247:629-39.
1343.
Irvine J, Basinski A, Baker B, et al. Depression and risk of sudden
cardiac death after acute myocardial infarction: testing for the
confounding effects of fatigue. Psychosom Med 1999;61:729-37.
1344. Barefoot JC, Schroll M. Symptoms of depression,
acute myocardial infarction, and total mortality in a community
sample. Circulation 1996;93:1976-80.
1345.
Ladwig KH, Lehmacher W, Roth R, Breithardt G, Budde T, Borggrefe
M. Factors which provoke post-infarction depression: results from
the post-infarction late potential study (PILP). J Psychosom Res
1992;36:723-9.
1346. Lane D, Carroll D, Ring C, Beevers DG,
Lip GY. Mortality and quality of life 12 months after myocardial
infarction: effects of depression and anxiety. Psychosom Med 2001;63:221-30.
1347.
Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, Neil A.
Depression and anxiety as predictors of outcome after myocardial
infarction. Psychosom Med 2000;62:212-9.
1348. Carney RM, Blumenthal JA, Catellier D,
et al. Depression as a risk factor for mortality after acute myocardial
infarction. Am J Cardiol 2003;92:1277-81.
1349. Crilley JG, Farrer M. Impact of first myocardial
infarction on self-perceived health status. QJM 2001;94:13-8.
1350.
Swenson JR, O'Connor CM, Barton D, et al, for the Sertraline Antidepressant
Heart Attack Randomized Trial (SADHART) Group.
Influence of depression and effect of treatment with sertraline
on quality of life after hospitalization for acute coronary syndrome.
Am J Cardiol 2003;92:1271-6.
1351. Friedman S. Cardiac disease, anxiety, and
sexual functioning. Am J Cardiol 2000;86:46F-50F.
1352.
Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP,
Bush DE. Patients with depression are less likely to follow recommendations
to reduce cardiac risk during recovery from a myocardial infarction.
Arch Intern Med 2000;160:1818-23.
1353.
Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Predictors of attendance
at cardiac rehabilitation after myocardial infarction. J Psychosom
Res 2001;51:497-501.
1354. Sertraline treatment of major depression
in patients with acute MI or unstable angina. JAMA 2002;288:701-9.
1355.
Berkman LF, Blumenthal J, Burg M, et al, for Writing Committee for
the ENRICHD Investigators. Effects of treating depression and low
perceived social support on clinical events after myocardial infarction:
the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD)
Randomized Trial. JAMA 2003;289:3106-16.
1356.
Alonzo AA. Acute myocardial infarction and posttraumatic stress
disorder: the consequences of cumulative adversity. J Cardiovasc
Nurs 1999;13:33-45.
1357.
Berkman LF, Syme SL. Social networks, host resistance, and mortality:
a nine-year follow-up study of Alameda County residents. Am J Epidemiol
1979;109:186-204.
1358.
Case RB, Moss AJ, Case N, McDermott M, Eberly S. Living alone after
myocardial infarction: impact on prognosis. JAMA 1992;267:515-9.
1359.
Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. Psychosocial
influences on mortality after myocardial infarction. N Engl J Med
1984;311:552-9.
1360.
Frasure-Smith N, Lespérance F, Gravel G, et al. Social support,
depression, and mortality during the first year after myocardial
infarction. Circulation 2000;101:1919-24.
1361. Deleted in press.
1362.
Coppotelli HC, Orleans CT. Partner support and other determinants
of smoking cessation maintenance among women. J Consult Clin Psychol
1985;53:455-60.
1363.
Suls J, Green P, Rose G, Lounsbury P, Gordon E. Hiding worries from
one’s spouse: associations between coping via protective buffering
and distress in male post-myocardial infarction patients and their
wives. J Behav Med 1997;20:333-49.
1364. Clarke DE, Walker JR, Cuddy TE. The role
of perceived overprotectiveness in recovery 3 months after myocardial
infarction. J Cardiopulm Rehabil 1996;16:372-7.
1365.
Education, communication, and methods of intervention. In: Houston-Miller
N, Taylor CB. Lifestyle Management for Patients with Coronary Heart
Disease (Current Issues in Cardiac Rehabilitation, Monograph no.
2). Champaigne, IL: Human Kinetics; 1995:21-30.
1366.
Crowe JM, Runions J, Ebbesen LS, Oldridge NB, Streiner DL. Anxiety
and depression after acute myocardial infarction. Heart Lung 1996;25:98-107.
1367.
Cossette S, Frasure-Smith N, Lespérance F. Clinical implications
of a reduction in psychological distress on cardiac prognosis in
patients participating in a psychosocial intervention program. Psychosom
Med 2001;63:257-66.
1368.
Jones DA, West RR. Psychological rehabilitation after myocardial
infarction: multicentre randomised controlled trial. BMJ 1996;313:1517-21.
1369. Linden W. Psychological treatments in cardiac
rehabilitation: review of rationales and outcomes. J Psychosom Res
2000; 48:443-54.
1370. Linden W, Stossel C, Maurice J. Psychosocial
interventions for patients with coronary artery disease: a meta-analysis.
Arch Intern Med 1996;156:745-52.
1371.
Feigenbaum E, Carter E. Health Technology Assessment Report No.
6. US Department of Health and Human Services. Public Health Service.
National Center for Health Services, Research, and Health Care Technology
Assessment. Publication No. PHS 883427, 1988.
1372.
Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac
rehabilitation/secondary prevention programs: a statement for healthcare
professionals from the American Heart Association and the American
Association of Cardiovascular and Pulmonary Rehabilitation Writing
Group. Circulation 2000;102:1069-73.
1373.
Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim
S. Exercise-based rehabilitation for coronary heart disease. Cochrane
Database Syst Rev 2001 CD001800.
1374.
DeBusk RF, Miller NH, Superko HR, et al. A case-management system
for coronary risk factor modification after acute myocardial infarction.
Ann Intern Med 1994;120:721-9.
1375. Barber K, Stommel M, Kroll J, Holmes-Rovner
M, McIntosh B. Cardiac rehabilitation for community-based patients
with myocardial infarction: factors predicting discharge recommendation
and participation. J Clin Epidemiol 2001;54:1025-30.
1376.
Spencer FA, Salami B, Yarzebski J, Lessard D, Gore JM, Goldberg
RJ. Temporal trends and associated factors of inpatient cardiac
rehabilitation in patients with acute myocardial infarction: a community-wide
perspective. J Cardiopulm Rehabil 2001;21:377-84.
1377.
Frasure-Smith N, Lespérance F, Talajic M. Depression and
18- month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
1378.
O’Connor GT, Buring JE,Yusuf S, Goldhaber SZ, Olmstead EM,
Paffenbarger RS, Hennekens CH. An overview of randomized trials
of rehabilitation with exercise after myocardial infarction. Circulation
1989;80:234-44.
1379.
Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise
training programs in patients greater than or equal to 75 years
of age. Am J Cardiol 1996;78:675-7.
1380.
Ziegelstein RC. Depression in patients recovering from a myocardial
infarction. JAMA 2001;286:1621-7.
1381. Rost K, Smith GR. Return to work after
an initial myocardial infarction and subsequent emotional distress.
Arch Intern Med 1992;152:381-5.
1382.
Froelicher ES, Kee LL, Newton KM, Lindskog B, Livingston M. Return
to work, sexual activity, and other activities after acute myocardial
infarction. Heart Lung 1994;23:423-35.
1383.
Lewin R. Return to work after MI, the roles of depression, health
beliefs and rehabilitation. Int J Cardiol 1999;72:49-51.
1384. Brodie B, Grines CL, Spain M, et al. A
prospective, randomized trial evaluating early discharge (day 3)
without non-invasive risk stratification in low risk patients with
acute myocardial infarction: PAMI-2. J Am Coll Cardiol 1995;25:5A.
1385. Petrie KJ, Cameron LD, Ellis CJ, Buick
D, Weinman J. Changing illness perceptions after myocardial infarction:
an early intervention randomized controlled trial. Psychosom Med
2002;64:580-6.
1386.
Ostir GV, Goodwin JS, Markides KS, Ottenbacher KJ, Balfour J, Guralnik
JM. Differential effects of premorbid physical and emotional health
on recovery from acute events. J Am Geriatr Soc 2002;50:713-8.
1387.
Sansone GR, Alba A, Frengley JD. Analysis of FIM instrument scores
for patients admitted to an inpatient cardiac rehabilitation program.
Arch Phys Med Rehabil 2002;83:506-12.
1388. Froom P, Cohen C, Rashcupkin J, et al.
Referral to occupational medicine clinics and resumption of employment
after myocardial infarction. J Occup Environ Med 1999;41:943-7.
1389.
Boudrez H, De Backer G. Recent findings on return to work after
an acute myocardial infarction or coronary artery bypass grafting.
Acta Cardiol 2000;55:341-9.
1390. Mittag O, Kolenda KD, Nordman KJ, Bernien
J, Maurischat C. Return to work after myocardial infarction/coronary
artery bypass grafting: patients’ and physicians’ initial
viewpoints and outcome 12 months later. Soc Sci Med 2001;52:1441-50.
1391.
Kavanagh T, Matosevic V, Thacker L, Belliard R, Shephard RJ. On-site
evaluation of bus drivers with coronary heart disease. J Cardiopulm
Rehabil 1998;18:209-15.
1392.
Covinsky KE, Chren MM, Harper DL, Way LE, Rosenthal GE. Differences
in patient-reported processes and outcomes between men and women
with myocardial infarction. J Gen Intern Med 2000;15:169-74.
1393.
Haskell WL. Rehabilitation of the coronary patient. In: Wenger NK,
Hellerstein HK, eds. Design and implementation of cardiac conditioning
program. New York, NY: Churchill Livingstone, 1978:147.
1394.
Usher MC, Dennis CA, Schwartz RG, Ahn DK, DeBusk RF. Physician influences
on timing of return to work after myocardial infarction. Circulation
1986;74:II-490.
1395.
US Department of Transportation. Status of Medical Review in Driver
Licensing: Policies, Programs and Standards, 1992.
1396.
Code of Federal Regulation 14CFR 121. Pg 427, Section 25.841. Published
by the office of Federal Register, January 1, 2002.
1397.
Deleted in press.
1398.
Code of Federal Regulation 14 CFR 121. Appendix A:555-7. Published
by the office of the Federal Register, January 1, 2002.
|
